Oligosaccharide complexes and uses
Cationic and ionizable oligosaccharide conjugates with surfactants and additives improve nucleic acid delivery, addressing stability and safety issues in existing systems, enhancing targeted expression and reducing adverse effects.
Patent Information
- Application Number
- JP2024524378
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-09-29
- Filing Date
- 2022-10-21
- Publication Date
- 2024-11-22
AI Technical Summary
Existing nucleic acid delivery systems face challenges due to instability, poor membrane penetration, manufacturing difficulties, high polydispersity, and safety/efficacy issues, particularly with lipid- or polymer-based systems.
Conjugates containing cationic and/or ionizable oligosaccharides, combined with surfactants and additives, are developed for targeted delivery of biological agents like small molecules and nucleic acids, offering improved properties over previous compositions.
These conjugates enhance delivery efficiency, reduce adverse events, and allow for lower doses, providing safer and more effective targeted expression of RNA and other therapeutic agents.
Smart Images

Figure 2024543721000214 
Figure 2024543721000215 
Figure 2024543721000216
Abstract
Description
[Background technology]
[0001] explanation Targeted delivery and expression of therapeutic and / or prophylactic agents such as nucleic acids presents certain challenges due to the instability of nucleic acids and their inability to penetrate cell membranes.Certain approaches, including the use of lipid or polymer-based systems, are promising, but suffer from drawbacks related to manufacturing difficulties, poor structural definition, and high polydispersity.In addition, many of these compositions lack sufficient safety and efficacy for use in the delivery of therapeutic agents. Summary of the Invention
[0002] The present disclosure provides, inter alia, the surprising and unexpected insight that complexes comprising cationic and / or ionizable oligosaccharides are useful for targeted delivery of biological agents, including small molecules and nucleic acids. For example, in some embodiments, the present disclosure encompasses the insight that such complexes are surprisingly useful for delivering RNA. Furthermore, the complexes of the present disclosure avoid problems associated with other delivery systems, for example, by allowing for lower doses and further by avoiding certain adverse events associated with alternative and previous delivery systems (e.g., increased inflammatory activity manifested as pain, swelling, etc.).
[0003] In some embodiments, the present disclosure encompasses the insight that compositions comprising cationic oligosaccharides in combination with surfactants and one or more additives, for example, in the specific molar ratios described herein, provide complexes that exhibit improved properties compared to conventional lipid-based complexes or previously reported oligosaccharide compositions.
[0004] Previous research on cationic oligosaccharides has focused on their use with DNA. In particular, Carbajo-Gordillo et al. reported the use of certain oligosaccharides in DNA nanocomplexation and isolation (i.e., without the addition of surfactants or other additives) for delivery. See Carbajo-Gordillo, et al., Chem. Comm., 55:8227-8230 (2019). However, the oligosaccharide-DNA complexes reported by Carbajo-Gordillo et al., particularly when complexed with RNA, exhibit surprisingly different properties than complexes containing cationic oligosaccharides such as those reported in this application. For example, the complexes reported herein, in some embodiments, exhibit different in vivo behavior, such as targeting different systems in the body (i.e., triggering RNA expression in the body), and can be prepared with significantly reduced oligosaccharide-to-nucleic acid ratios. For at least these reasons, the complexes reported here exhibit unexpected advantages over previously reported complexes.
[0005] In some embodiments, the present disclosure provides a complex comprising, inter alia: i) a cationic oligosaccharide comprising one or more cationic moieties attached to a trehalose, sucrose, or gluco-n-oligosaccharide moiety, wherein n is 2-6; ii) a surfactant; and iii) one or more additives selected from a sterol, a helper lipid, an immunomodulator, and a targeting molecule.
[0006] In some embodiments, the present disclosure provides an oligosaccharide of formula I: [ka] or a pharmaceutically acceptable salt thereof, wherein: A is A 1 , A 2 , or A 3 and [ka] Each R 1 and R 2Independently, in each case, H, R a , and -C(O)-R a Selected from R 1 or R 2 At least one instance of is not H, Each R a But independently, C1-C 20 Aliphatic, C3-C 20 cycloaliphatic, C5-C6 aryl, 3- to 12-membered heterocyclyl containing 1 to 3 heteroatoms selected from N, O, and S; a But there is one or more R b optionally replaced by Each R b are independently halogen, -N3, -R c , -OR c , -SR c , -NHR c , -C(O)-R c , -OC(O)R c , -NHC(O)R c , -C(O)NHR c , and -NHC(O)NHR c is selected from Each R c are independently optionally substituted C-C 20 Aliphatic, optionally substituted C3-C 20 selected from cycloaliphatic, optionally substituted C5-C6 aryl, optionally substituted 3- to 12-membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, and optionally substituted 4- to 12-membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S; X 1 and X 2 are each independently selected from -S-, -SS-, and -NH-; Y 1 and Y 2 each independently represents an optionally substituted C 1-30 an aliphatic group in which one or more carbons are optionally and independently selected from -Cy-, -NH-, -NR Y C(O)-, -C(O)NR Y -, -NR Y C(O)O-, -OC(O)NRY -, -NR Y C(O)NR Y -, -NR Y (S)NR Y -, -C(S)NR Y - -C(O)NR Y SO2-, -SO2NR Y C(O)-, -OC(O)O-, -O-, -C(O)-, -OC(O)-, -C(O)O-, -SO-, or -SO 2- is replaced by Each R Y is independently selected from H and optionally substituted C1-C6 aliphatic; each Cy independently represents an optionally substituted C3-C 14 an optionally substituted 5- to 14-membered heterocyclyl ring having 1 to 3 heteroatoms selected from cycloaliphatic, N, O, and S; or an optionally substituted 5- to 14-membered heteroaryl ring having 1 to 3 heteroatoms selected from N, O, and S; Z 1 and Z 2 each independently represents an optionally substituted 5- to 14-membered heterocyclyl ring having 1 to 3 heteroatoms selected from N, O, and S; an optionally substituted 5- to 14-membered heteroaryl ring having 1 to 3 heteroatoms selected from N, O, and S; -N + (M)3, [ka] is a cationic or ionizable group selected from Each M is independently -C0-C6 aliphatic -R z , or -C0-C6 aliphatic -N + (R z )3, Each R z are independently H, optionally substituted C1-C6 aliphatic, optionally substituted C3-C 20selected from cycloaliphatic, optionally substituted C5-C6 aryl, optionally substituted 3-12 membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, and optionally substituted 4-12 membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S; or Two or more R's z can be taken together with the atom to which they are attached to form an optionally substituted 3- to 12-membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, or an optionally substituted 4- to 12-membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S; p is an integer selected from 1, 2, 3, 4, or 5.
[0007] In some embodiments, the present disclosure provides a method of increasing or causing an increase in expression of RNA in a target in a subject, comprising administering to the subject a complex described herein.
[0008] In some embodiments, the present disclosure provides methods of treating and / or preventing a disease, disorder, or condition in a subject, comprising administering to the subject a conjugate described herein. [Brief explanation of the drawings]
[0009] [Figure 1A] 1 is a bar graph showing the hydrodynamic diameter of complexes formulated with modRNA and different cationic oligosaccharides at N / P6 ratios. [Figure 1B] 1 is a bar graph showing bioluminescence quantified over the experimental period and normalized to the JLF41-modRNA group. [Figure 2A] 1 is a plot showing the hydrodynamic diameter of complexes formulated in N / P6 but with different surfactants and within surfactant:JLF99 ratios between about 0:1 and about 0.5:1. [Figure 2B]FIG. 1 is a plot showing the hydrodynamic diameter of complexes formulated with either Tween 20 (T20) or Tween 40 (T40) and N / P6, and within surfactant:JLF99 ratios between about 0:1 and about 0.5:1. [Figure 2C] A plot showing the expression of luciferase-encoding modRNA 24 hours after transfection of C2C12 cells with 100 ng of RNA / well of either modRNA formulated in N / P6, Tween 20, or Tween 40 at different ratios of JLF. [Figure 2D] Plot showing expression of luciferase-encoding modRNA 24 hours after transfection of HepG2 cells at 100 ng of RNA / well with modRNA formulated in N / P6, Tween 20, or Tween 40 at different detergent and JLF99 ratios. Data here represent three independent experiments (n=3) that were technically repeated three times. [Figure 2E] 1 is a bar graph showing the hydrodynamic diameter of complexes formulated at different ratios of JLF99 to surfactant. [Figure 2F] 1 is a bar graph showing quantified bioluminescence over the course of the experiment expressed as area under the curve. [Figure 2G] 1 is a plot showing quantified dorsal bioluminescence over approximately 6 days. [Figure 2H] 10 shows images showing bioluminescence in the ventral axis 6 hours after injection of modRNA in each group of mice. [Figure 3A] 1 is a plot showing the hydrodynamic diameter of exemplary complexes. [Figure 3B] 1 is a bar graph showing expression of luciferase-encoding modRNA 24 hours after transfection into either C2C12, HepG2, or RAW264.7 cells at 100 ng of RNA / well. Data here represent two independent experiments (n=2) that were technically repeated three times. [Figure 4A]1 is a bar graph showing the hydrodynamic diameter of complexes formed with either the combination of JLF99+Tween20+cholesterol or JLF99+Tween20+β-sitosterol. [Figure 4B] 1 is a bar graph showing normalized expression of luciferase-encoding modRNA relative to the JLF99 benchmark in either C2C12, HepG2, or RAW264.7 cells at 100 ng of RNA / well in complexes formed with either the JLF99 + Tween 20 + cholesterol or JLF99 + Tween 20 + β-sitosterol combinations after 24 hours. [Figure 4C] 1 is a bar graph showing the hydrodynamic diameter of complexes formed by combining JLF99+Tween20+β-sitosterol+helper lipid in a molar ratio of 1:0.5:0.5:0.5 with either DOPE, DOPC, DOPS, DSPC, or DSPE. [Figure 4D] A bar graph showing the normalized expression of luciferase-encoding modRNA relative to the JLF99 benchmark 24 hours after transfection of either C2C12, HepG2, or RAW264.7 cells with 100 ng of RNA / well of a complex formed with either DOPE, DOPC, DOPS, DSPC, or DSPE at a molar ratio of JLF99 + Tween 20 + β-sitosterol + helper lipid of 1:0.5:0.5:0.5. [Figure 4E] 1 is a bar graph showing the hydrodynamic diameter of complexes formed by combining JLF99+Tween20+sterol+DSPC with either β-sitosterol, stigmasterol, or acetate-α-tocopherol in a molar ratio of 1:0.5:0.5:0.5. [Figure 4F]1 is a bar graph showing the normalized expression of luciferase-encoding modRNA relative to the JLF99 benchmark 24 hours after transfection of either C2C12, HepG2, or RAW264.7 cells with 100 ng of RNA / well of a complex formed at a 1:0.5:0.5:0.5 molar ratio of JLF99 + Tween 20 + sterol + DSPC, where the sterol is either β-sitosterol, stigmasterol, or acetate-α-tocopherol. [Figure 4G] FIG. 1 is a scatter plot showing the hydrodynamic diameter of complexes formed by combining different molar ratios of JLF99+Tween20+β-sitosterol+helper lipid with either DMPC or DSPC. [Figure 4H] This is a scatter plot showing the expression of luciferase-encoding modRNA 24 hours after transfection of C2C12 cells with 100 ng of RNA / well of complexes formed at different molar ratios of JLF99 + Tween 20 + β-sitosterol + helper lipids using either DMPC or DSPC. [Figure 4I] This is a plot showing the expression of luciferase-encoding modRNA 24 hours after transfection of HepG2 with 100 ng of RNA / well of complexes formed at different molar ratios of JLF99 + Tween 20 + β-sitosterol + helper lipids using either DMPC or DSPC. [Figure 4J] This is a plot showing the expression of luciferase-encoding modRNA 24 hours after transfection of RAW647.7 cells with 100 ng of RNA / well of complexes formed at different molar ratios of JLF99 + Tween 20 + β-sitosterol + helper lipids using either DMPC or DSPC. [Figure 5A] 1 is a bar graph showing the hydrodynamic diameter of complexes formulated with different N / P6. [Figure 5B] 1 is a bar graph showing quantified bioluminescence over the course of the experiment expressed as area under the curve. [Figure 5C]1 is a plot showing quantified dorsal bioluminescence over the course of the experiment. [Figure 5D] 10 is an image of ventral bioluminescence measured 6 hours after injection in mice. [Figure 6A] 1 is a bar graph showing the hydrodynamic diameter of complexes formulated with different N / P6. [Figure 6B] 1 is a bar graph showing quantified dorsal bioluminescence in the region of interest (muscle) 6 hours after injection. [Figure 6C] 1 is a bar graph showing quantified ventral bioluminescence in the region of interest (liver) 6 hours after injection. [Figure 6D] 10 is an image of ventral bioluminescence measured 6 hours after injection in mice. [Figure 7A] 1 is a bar graph showing the hydrodynamic diameter of complexes formulated with different N / P6. [Figure 7B] 1A and 1B are plots and bar graphs, respectively, showing quantified dorsal bioluminescence in the region of interest (muscle) over the duration of the experiment as area under the curve. [Figure 7C] 1A and 1B are plots and bar graphs, respectively, showing quantified dorsal bioluminescence in the region of interest (muscle) over the duration of the experiment as area under the curve. [Figure 7D] 1 is a bar graph showing the quantified spot numbers in the ELISpot readout, reflecting T cell responses to luciferase peptide or an irrelevant peptide (AH1). [Figure 8A] 8A-10I are scatter plots showing quantified IL-6 secretion in hPBMCs upon exposure to different doses of test formulations. As used herein with reference to FIGS. 8A-10I, "T40" refers to Tween 40, "TAK" refers to TAK-242, and "dex" or "dexa" refers to dexamethasone. [Figure 8B] FIG. 1 is a scatter plot showing quantified TNF-α secretion in hPBMCs upon exposure to different doses of test formulations. [Figure 8C]FIG. 1 is a scatter plot showing quantified IL-1β secretion in hPBMCs upon exposure to different doses of test formulations. [Figure 8D] FIG. 1 is a scatter plot showing quantified IFN-γ secretion in hPBMCs upon exposure to different doses of test formulations. [Figure 9A] 1 is a bar graph showing the hydrodynamic diameter of different complexes formulated with N / P6. [Figure 9B] FIG. 1 is a scatter plot showing serological levels of specific IgG to HA at different time points over the course of the experiment (days 0, 14, 28, and 49). [Figure 9C] FIG. 1 is a plot showing the quantified spot numbers in the IFN-ELISPOT readout, reflecting the CD4 / CD8 T cell response to HA peptide pools. [Figure 10A] FIG. 1 is a scatter plot showing quantified IL-6 secretion in hPBMCs upon exposure to different doses of test formulations. [Figure 10B] FIG. 1 is a scatter plot showing quantified TNF-α secretion in hPBMCs upon exposure to different doses of test formulations. [Figure 10C] FIG. 1 is a scatter plot showing quantified IL-1β secretion in hPBMCs upon exposure to different doses of test formulations. [Figure 10D] FIG. 1 is a scatter plot showing quantified IFN-γ secretion in hPBMCs upon exposure to different doses of test formulations. [Figure 10E] FIG. 1 is a scatter plot showing quantified MCP-1 secretion in hPBMCs upon exposure to different doses of test formulations. [Figure 10F] FIG. 1 is a scatter plot showing quantified MIP-1β secretion in hPBMCs upon exposure to different doses of test formulations. [Figure 10G] FIG. 1 is a scatter plot showing quantified IP-10 secretion in hPBMCs upon exposure to different doses of test formulations. [Figure 10H]1 is a bar graph showing cumulative luciferase expression in the dose range of 0.01 to 1 μg for both test groups over the course of 6 days post-transfection. [Figure 10I] 1 is a bar graph showing cumulative luciferase expression in the dose range of 0.01 to 1 μg for all test groups at different time points over the course of the experiment (24 h, 48 h, 144 h). [Figure 11A] 1 is a plot showing serological levels of specific IgG to HA over the course of the experiment. [Figure 11B] 1 is a plot showing the endpoint titration of serological levels of specific IgG to HA. [Figure 11C] 1 is a bar graph showing T cell responses to HA peptides. [Figure 12A] 1 is a plot showing IL-6 secretion in human PBMCs (hPMBCs) for different doses of test formulations. [Figure 12B] 1 is a plot showing TNFα secretion by hPBMCs for different doses of test formulations. [Figure 12C] 1 is a plot showing IL1b secretion from hPBMCs for different doses of test formulations. [Figure 12D] 1 is a plot showing IFNg secretion from hPBMCs for different doses of test formulations. [Figure 12E] 1 is a plot showing MCP-1 secretion from hPBMCs for different doses of test formulations. [Figure 12F] 1 is a plot showing MIP-1b secretion from hPBMCs for different doses of test formulations. [Figure 12G] 1 is a plot showing IP-10 secretion from hPBMCs for different doses of test formulations. [Figure 12H] 1 is a plot showing cell viability of hPBMCs transfected at a dose range of 0.01 to 3 μg for test groups after 24 hours.
[0010] Detailed Description of Specific Embodiments The present disclosure provides, among other things, complexes comprising cationic oligosaccharides that efficiently deliver therapies (e.g., nucleic acid therapies) to target tissues or cells in a patient. The complexes of the present disclosure avoid problems associated with other delivery systems, for example, by allowing for lower doses and further by avoiding certain adverse events associated with alternative and previous delivery systems (e.g., increased inflammatory activity manifested as pain, swelling, etc.). In some embodiments, the present disclosure provides, among other things, complexes comprising: i) a cationic oligosaccharide comprising one or more cationic moieties attached to a trehalose, sucrose, or gluco-n-oligosaccharide moiety, where n is 2 to 6; ii) a surfactant; and iii) one or more additives selected from a sterol, a helper lipid, an immunomodulator, and a targeting molecule.
[0011] definition The compounds of the present disclosure generally include those described above and are further exemplified by the classes, subclasses, and species disclosed herein. As used herein, the following definitions shall apply unless otherwise specified. For the purposes of this disclosure, chemical elements are identified according to the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 75th Edition. Furthermore, the general principles of organic chemistry are described in "Organic Chemistry", Thomas Sorrell, University Science Books, Sausalito: 1999, and "March's Advanced Organic Chemistry", 5th Edition: Smith, MB and March, J., John Wiley & Sons, New York: 2001, the entire contents of which are incorporated herein by reference.
[0012] Unless otherwise indicated, structures depicted herein are intended to include all stereoisomeric (e.g., enantiomeric or diastereomeric) forms of the structure, as well as all geometric or conformational isomeric forms of the structure. For example, both the R and S configurations of each stereocenter are contemplated as part of this disclosure. Thus, single stereochemical isomers as well as enantiomeric, diastereomeric, and geometric (or conformational) mixtures of the provided compounds are within the scope of this disclosure. For example, in some cases, Tables 1 and 2 depict one or more stereoisomers of a compound, and unless otherwise specified, each stereoisomer is represented alone and / or as a mixture. Unless otherwise specified, all tautomeric forms of the provided compounds are within the scope of this disclosure.
[0013] Unless otherwise stated, structures depicted herein are meant to include compounds that differ only in the presence of one or more isotopically enriched atoms, for example, the replacement of a hydrogen by deuterium or tritium, or 13 C or 14 Compounds having this structure including the replacement of a carbon with a C-rich carbon are within the scope of this disclosure.
[0014] About or Approximately: As used herein, the term "about" or "approximately," when applied to one or more values of interest, refers to a value similar to a stated reference value. Generally, a person skilled in the art familiar with the context will fully understand the relevant degree of difference encompassed by "about" or "approximately" in that context. For example, in some embodiments, the term "about" or "approximately" can encompass a range of values within (i.e., ±) 25%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, or less of the reference value.
[0015] Administration: As used herein, the term "administering" or "administration" typically refers to administration of a composition to a subject to achieve delivery of the composition or agent contained therein to a target site or site to be treated. Those of skill in the art will recognize various routes available for administration to a subject, e.g., a human, under appropriate circumstances. For example, in some embodiments, administration may be ocular, oral, parenteral, topical, etc. In some specific embodiments, administration may be bronchial (e.g., by bronchial instillation), buccal, transdermal (e.g., may be or include one or more of topical cutaneous, intradermal, interdermal, transdermal, etc.), enteral, intraarterial, intradermal, intragastric, intramedullary, intramuscular, intranasal, intraperitoneal, intrathecal, intravenous, intraventricular, intraorgan (e.g., intrahepatic), mucosal, nasal, oral, rectal, subcutaneous, sublingual, topical, tracheal (e.g., by intratracheal instillation), vaginal, intravitreal, etc. In some embodiments, administration may be parenteral. In some embodiments, administration may be oral. In some specific embodiments, administration may be intravenous. In some specific embodiments, administration may be subcutaneous. In some embodiments, administration may involve only a single dose. In some embodiments, administration may involve the application of a set number of doses. In some embodiments, administration may involve administration that is intermittent (e.g., multiple doses separated in time) and / or periodic (e.g., individual doses separated by a common period of time) administration. In some embodiments, administration may involve continuous administration (e.g., perfusion) for at least a selected period of time. In some embodiments, administration may involve a prime-and-boost protocol. A prime-and-boost protocol may include administration of a first dose of a pharmaceutical composition (e.g., an immunogenic composition, e.g., a vaccine), followed, after a set interval of time, by administration of a second or subsequent dose of a pharmaceutical composition (e.g., an immunogenic composition, e.g., a vaccine). In the case of an immunogenic composition, a prime-and-boost protocol may result in an increased immune response in a patient.
[0016] Aliphatic: The term "aliphatic" refers to a linear (i.e., unbranched) or branched, substituted or unsubstituted hydrocarbon chain that is fully saturated or contains one or more unsaturated units, or a monocyclic or bicyclic hydrocarbon that is fully saturated or contains one or more unsaturated units, but is not aromatic (also referred to herein as "cycloaliphatic"), and has a single or multiple points of attachment to the remainder of the molecule. Unless otherwise specified, an aliphatic group contains 1 to 12 aliphatic carbon atoms. As used herein, it is understood that aliphatic groups can also be divalent (e.g., encompassing divalent hydrocarbon chains that are saturated or contain one or more unsaturated units, e.g., -CH2-, -CH2-CH2-, -CH2-CH2-CH2-, etc.). In some embodiments, an aliphatic group contains 1 to 6 aliphatic carbon atoms (e.g., C 1-6 In some embodiments, aliphatic groups contain 1-5 aliphatic carbon atoms (e.g., C 1-5 In other embodiments, aliphatic groups contain 1-4 aliphatic carbon atoms (e.g., C 1-4 In still other embodiments, aliphatic groups contain 1-3 aliphatic carbon atoms (e.g., C 1-3 ), and in still other embodiments, aliphatic groups contain 1-2 aliphatic carbon atoms (e.g., C 1-2 In some embodiments, "cycloaliphatic" refers to a monocyclic C group that is fully saturated or contains one or more units of unsaturation, but is not aromatic and has a single or multiple points of attachment to the rest of the molecule. 3-8 Hydrocarbon or bicyclic C 7-10 "Aliphatic groups" refers to hydrocarbons. Suitable aliphatic groups include, but are not limited to, linear or branched, substituted or unsubstituted alkyl, alkenyl, or alkynyl groups, and hybrids thereof. Preferred aliphatic groups are C 1-6 It is alkyl.
[0017] Alkyl: The term “alkyl” used alone or as part of a larger moiety refers to an alkyl group having 1 to 12, 1 to 10, 1 to 8, 1 to 6, 1 to 4, 1 to 3, or 1 to 2 carbon atoms (unless otherwise specified) (e.g., C1-12 , C 1-10 , C 1-8 , C 1-6 , C 1-4 , C 1-3 , or C 1-2 ), means a saturated, optionally substituted, straight or branched chain hydrocarbon group. Exemplary alkyl groups include methyl, ethyl, propyl, butyl, pentyl, hexyl, and heptyl.
[0018] Alkenyl: The term “alkenyl,” used alone or as part of a larger moiety, refers to an alkyl group having at least one double bond and having 2 to 12, 2 to 10, 2 to 8, 2 to 6, 2 to 4, or 2 to 3 carbon atoms (unless otherwise specified) (e.g., C 2-12 , C 2-10 , C 2-8 , C 2-6 ,C 2-4 , or C 2-3 ), an optionally substituted straight-chain, branched-chain, or cyclic hydrocarbon group. Exemplary alkenyl groups include ethenyl, propenyl, butenyl, pentenyl, hexenyl, and heptenyl. The term "cycloalkenyl" refers to an optionally substituted non-aromatic monocyclic or multicyclic ring system containing at least one carbon-carbon double bond and having from about 3 to about 10 carbon atoms. Exemplary monocyclic cycloalkenyl rings include cyclopentenyl, cyclohexenyl, and cycloheptenyl.
[0019] Alkynyl: The term “alkynyl,” used alone or as part of a larger moiety, refers to an alkyl group having at least one triple bond and having 2 to 12, 2 to 10, 2 to 8, 2 to 6, 2 to 4, or 2 to 3 carbon atoms (unless otherwise specified) (e.g., C 2-12 , C 2-10 , C 2-8 , C 2-6 , C 2-4 , or C 2-3), an optionally substituted straight or branched chain hydrocarbon group. Exemplary alkynyl groups include ethynyl, propynyl, butynyl, pentynyl, hexynyl, and heptynyl.
[0020] Analog: As used herein, the term "analog" refers to a substance that shares one or more particular structural features, elements, components, or moieties with a reference substance. Typically, an "analog" exhibits significant structural similarity to the reference substance, e.g., sharing a core or consensus structure, but also differs in certain distinct ways. In some embodiments, an analog is a substance that can be produced from a reference substance, e.g., by chemical manipulation of the reference substance. In some embodiments, an analog is a substance that can be produced through the implementation of a synthetic process that is substantially similar (e.g., shares multiple steps) with the synthetic process that produces the reference substance. In some embodiments, an analog is produced, or can be produced, by the implementation of a synthetic process that is different from the synthetic process used to produce the reference substance.
[0021] Aryl: The term "aryl" refers to an alkyl group having a total of 5 to 14 ring members (e.g., C5-C 14 ) refers to monocyclic and bicyclic ring systems in which at least one ring in the system is aromatic and each ring in the system contains 3 to 7 ring members. In some embodiments, an "aryl" group refers to a ring system containing 6 to 12 total ring members (e.g., C6-C 12 ). The term "aryl" may be used interchangeably with the term "aryl ring." In certain embodiments of the present invention, "aryl" refers to an aromatic ring system, including phenyl, biphenyl, naphthyl, anthracyl, and the like, which may bear one or more substituents. Unless otherwise specified, an "aryl" group is a hydrocarbon. In some embodiments, an "aryl" ring system is an aromatic ring (e.g., phenyl) fused to a non-aromatic ring (e.g., cycloalkyl). Examples of fused aryl rings include: [ka] Examples include:
[0022] Associated: As used herein, two events or entities are "associated" with one another when the presence, level, and / or form of one correlates with that of the other. For example, a particular entity (e.g., a polypeptide, gene signature, metabolite, microorganism, etc.) is considered associated with a particular disease, disorder, or condition if its presence, level, and / or state correlates with the occurrence and / or susceptibility of the disease, disorder, or condition (e.g., across a relevant population). In some embodiments, two or more entities are physically "associated" with one another when they interact directly or indirectly to be in physical proximity and / or remain in close proximity to one another. In some embodiments, two or more entities that are physically associated with one another are covalently linked to one another. In some embodiments, two or more entities that are physically associated with one another are not covalently linked to one another, but are non-covalently associated, for example, by hydrogen bonding, van der Waals interactions, hydrophobic interactions, magnetism, and combinations thereof.
[0023] Biological sample: As used herein, the term "biological sample" typically refers to a sample obtained or derived from a biological source of interest (e.g., a tissue or organism or cell culture) as described herein. In some embodiments, the source of interest comprises an organism such as an animal or a human. In some embodiments, the biological sample is or comprises a biological tissue or fluid. In some embodiments, a biological sample can be or include bone marrow, blood, blood cells, ascites, tissue or fine needle biopsy samples, cell-containing bodily fluids, suspended nucleic acids, sputum, saliva, urine, cerebrospinal fluid, peritoneal fluid, pleural effusion, feces, lymph, gynecological fluids, skin swabs, vaginal swabs, oral swabs, nasal swabs, washings or lavage fluids such as ductal lavage or bronchoalveolar lavage, aspirates, scrapings, bone marrow specimens, tissue biopsy specimens, surgical specimens, feces, other bodily fluids (e.g., sperm, sweat, tears), secretions, and / or excretions, and / or cells therefrom, etc. In some embodiments, a biological sample is or includes cells obtained from an individual. In some embodiments, the obtained cells are or include cells from the individual from whom the sample is obtained. In some embodiments, a sample is a "primary sample" obtained directly from a source of interest by any suitable means. For example, in some embodiments, the primary biological sample is obtained by a method selected from the group consisting of biopsy (e.g., fine needle aspiration or tissue biopsy), surgery, collection of bodily fluids (e.g., blood, lymph, stool, etc.), and the like. In some embodiments, as will be clear from the context, the term "sample" refers to a preparation obtained by processing the primary sample (e.g., by removing one or more components and / or adding one or more agents), e.g., filtration using a semi-permeable membrane. Such a "processed sample" can include, for example, nucleic acids or proteins extracted from the sample or obtained by subjecting the primary sample to techniques such as amplification or reverse transcription of mRNA, isolation and / or purification of specific components, etc.
[0024] Carrier: As used herein, the term "carrier" refers to a diluent, adjuvant, excipient, or vehicle used in administering a composition. In some exemplary embodiments, a carrier can comprise sterile liquids such as, for example, water and oils, including those of petroleum, animal, vegetable, or synthetic origin, such as, for example, peanut oil, soybean oil, mineral oil, sesame oil, etc. In some embodiments, a carrier is or comprises one or more solid ingredients.
[0025] Combination therapy: As used herein, the term "combination therapy" refers to a situation in which a subject is exposed to two or more therapeutic regimens (e.g., two or more therapeutic agents or modalities) simultaneously. In some embodiments, the two or more regimens may be administered simultaneously. In some embodiments, the regimens may be administered sequentially (e.g., all "doses" of a first regimen are administered before any doses of a second regimen are administered). In some embodiments, the agents are administered in overlapping dosing regimens. In some embodiments, "administration" of a combination therapy may include administering one or more agent(s) or modality(s) in combination to a subject receiving other agent(s) or modality(s). For clarity, combination therapy does not require that the individual agents be administered together in a single composition (or even necessarily simultaneously), although in some embodiments, two or more agents or their active portions may be administered together in a combined composition or even a combined compound (e.g., as part of a single chemical complex or covalent conjugate).
[0026] Comparable: As used herein, the term "comparable" refers to two or more agents, substances, circumstances, sets of conditions, etc. that are not necessarily identical to one another, but are sufficiently similar to permit a comparison between them, where one of skill in the art would understand that conclusions can be reasonably drawn based on the observed differences or similarities. In some embodiments, comparable sets of conditions, circumstances, individuals, or populations are characterized by multiple substantially identical characteristics and one or a few different characteristics. One of skill in the art will understand the degree of identity required for two or more such agents, substances, circumstances, sets of conditions, etc. to be considered comparable in any given situation in context. For example, one of skill in the art will understand that sets of circumstances, individuals, or populations are comparable to one another when they are characterized by a sufficient number and type of substantially identical characteristics to warrant a reasonable conclusion that differences in results obtained or phenomena observed under or with different sets of circumstances, individuals, or populations are caused by, or indicate, variations in those characteristics.
[0027] Composition: Those skilled in the art will understand that the term "composition" can be used to refer to a separate physical entity that includes one or more defined components. Generally, unless otherwise specified, a composition can be in any form, e.g., gas, gel, liquid, solid, etc.
[0028] Cycloaliphatic: As used herein, "cycloaliphatic" refers to a monocyclic C ring that is fully saturated or contains one or more units of unsaturation, but is not aromatic, and has single or multiple points of attachment to the rest of the molecule. 3-8 Hydrocarbon or bicyclic C 7-10 Refers to hydrocarbons.
[0029] Cycloalkyl: As used herein, the term "cycloalkyl" refers to an optionally substituted saturated monocyclic or multicyclic ring system of about 3 to about 10 ring carbon atoms. Exemplary monocyclic cycloalkyl rings include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl.
[0030] Dosage form or unit dosage form: Those of skill in the art will understand that the term "dosage form" can be used to refer to a physically discrete unit of an active agent (e.g., a therapeutic or diagnostic agent) for administration to a subject. Typically, each such unit contains a predetermined amount of the active agent. In some embodiments, such amount is a unit dosage (or all of it) appropriate for administration according to a dosing regimen (i.e., a therapeutic dosing regimen) that has been determined to correlate with a desired or beneficial outcome when administered to a relevant population. Those of skill in the art will understand that the total amount of a therapeutic composition or agent to be administered to a particular subject is determined by one or more attending physicians and may involve the administration of multiple dosage forms.
[0031] Dosing regimen or treatment regimen: Those skilled in the art will understand that the terms "dosing regimen" and "treatment regimen" can be used to refer to a set of unit doses (typically more than one) typically administered to a subject separately over time periods. In some embodiments, a given therapeutic agent has a recommended dosing regimen, which can include one or more doses. In some embodiments, a dosing regimen includes multiple doses, each spaced in time from the other doses. In some embodiments, the individual doses are separated from each other by equidistant periods. In some embodiments, a dosing regimen includes multiple doses, and the individual doses are separated by two different periods. In some embodiments, all doses within a dosing regimen are of the same unit dose. In some embodiments, different doses within a dosing regimen are of different amounts. In some embodiments, a dosing regimen includes a first dosing at a first dosage amount, followed by one or more additional doses at a second dosage amount different from the first dosage amount. In some embodiments, the dosing regimen comprises a first dosing at a first dosage amount, followed by one or more additional dosings at a second dosage amount that is the same as the first dosage amount. In some embodiments, the dosing regimen correlates with a desired or beneficial outcome when administered within a relevant population (i.e., is a therapeutic dosing regimen).
[0032] Excipient: As used herein, the term "excipient" refers to a non-therapeutic agent that may be included in a pharmaceutical composition, for example, to provide or contribute to a desired consistency or stabilizing effect. Suitable pharmaceutical excipients include, for example, starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol, and the like.
[0033] Heteroaliphatic: As used herein, the term "heteroaliphatic" or "heteroaliphatic group" refers to an optionally substituted hydrocarbon moiety having, in addition to carbon atoms, 1 to 5 heteroatoms, which may be straight-chained (i.e., unbranched), branched, or cyclic ("heterocyclic"), fully saturated, or may contain one or more units of unsaturation, but is not aromatic. The term "heteroatom" means nitrogen, oxygen, or sulfur, and includes any oxidized form of nitrogen or sulfur and any quaternized form of basic nitrogen. The term "nitrogen" also includes substituted nitrogen. Unless otherwise specified, heteroaliphatic groups contain 1 to 10 carbon atoms, in which 1 to 3 carbon atoms are optionally and independently replaced with heteroatoms selected from oxygen, nitrogen, and sulfur. In some embodiments, heteroaliphatic groups contain 1 to 4 carbon atoms, in which 1 to 2 carbon atoms are optionally and independently replaced with heteroatoms selected from oxygen, nitrogen, and sulfur. In yet other embodiments, heteroaliphatic groups contain 1 to 3 carbon atoms, with one carbon atom optionally and independently replaced with a heteroatom selected from oxygen, nitrogen, and sulfur. Suitable heteroaliphatic groups include, but are not limited to, linear or branched heteroalkyl, heteroalkenyl, and heteroalkynyl groups. For example, heteroaliphatic groups of 1 to 10 atoms include exemplary groups such as -O-CH, -CH-O-CH, and -O-CH-CH-O-CH-CH-O-CH.
[0034] Heteroaryl: The terms "heteroaryl" and "heteroar-" are used alone or as part of a larger moiety, e.g., "heteroaralkyl" or "heteroaralkoxy" refer to a monocyclic or bicyclic ring group (e.g., a 5- or 6-membered monocyclic heteroaryl or a 9- or 12-membered bicyclic heteroaryl) having 5 to 12 ring atoms, 6, 10, or 14 pi electrons shared in the cyclic arrangement, and having 1 to 5 heteroatoms in addition to carbon atoms. The term "heteroatom" means nitrogen, oxygen, or sulfur, and includes any oxidized form of nitrogen or sulfur and any quaternized form of a basic nitrogen. Heteroaryl groups include, but are not limited to, thienyl, furanyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, indolizinyl, purinyl, naphthyridinyl, pteridinyl, imidazo[1,2-a]pyrimidinyl, imidazo[1,2-a]pyridyl, imidazo[4,5-b]pyridyl, imidazo[4,5-c]pyridyl, pyrrolopyridyl, pyrrolopyrazinyl, thienopyrimidinyl, triazolopyridyl, and benzisoxazolyl. As used herein, the terms "heteroaryl" and "heteroara-" also include groups in which a heteroaromatic ring is fused to one or more aryl, cycloaliphatic, or heterocyclyl rings, and the radical or point of attachment is on the heteroaromatic ring (i.e., a bicyclic heteroaryl ring having 1 to 3 heteroatoms). Non-limiting examples include indolyl, isoindolyl, benzothienyl, benzofuranyl, dibenzofuranyl, indazolyl, benzimidazolyl, benzotriazolyl, benzothiazolyl, benzothiadiazolyl, benzoxazolyl, quinolyl, isoquinolyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, 4H-quinolizinyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl, phenoxazinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, pyrido[2,3-b]-1,4-oxazin-3(4H)-one, 4H-thieno[3,2-b]pyrrole, and benzisoxazolyl.Heteroaryl groups can be monocyclic or bicyclic. The term "heteroaryl" can be used interchangeably with the terms "heteroaryl ring," "heteroaryl group," or "heteroaromatic," all of which include rings that are optionally substituted. The term "heteroaralkyl" refers to an alkyl group substituted by a heteroaryl, where the alkyl and heteroaryl portions independently are optionally substituted.
[0035] Heteroatom: As used herein, the term "heteroatom" means nitrogen, oxygen, or sulfur, and includes any oxidized form of nitrogen or sulfur, and any quaternized form of a basic nitrogen.
[0036] Heterocycle: As used herein, the terms "heterocycle," "heterocyclyl," "heterocyclic radical," and "heterocyclic ring" are used interchangeably and refer to a stable 3- to 8-membered monocyclic, 7- to 12-membered bicyclic, or 10- to 16-membered polycyclic heterocyclic moiety that is either saturated or partially unsaturated and has, in addition to carbon atoms, one or more, preferably one to four, heteroatoms as defined above. When used in reference to a ring atom of a heterocycle, the term "nitrogen" includes substituted nitrogen. As an example, in a saturated or partially unsaturated ring having 0-3 heteroatoms selected from oxygen, sulfur, or nitrogen, the nitrogen may be N (as in 3,4-dihydro-2H-pyrrolyl), NH (as in pyrrolidinyl), or NR +(such as N-substituted pyrrolidinyl). A heterocyclic ring can be attached to its pendant group at any heteroatom or carbon atom that results in a stable structure, and any of the ring atoms can be optionally substituted. Examples of such saturated or partially unsaturated heterocyclic radicals include, but are not limited to, azetidinyl, oxetanyl, tetrahydrofuranyl, tetrahydrothienyl, pyrrolidinyl, piperidinyl, decahydroquinolinyl, oxazolidinyl, piperazinyl, dioxanyl, dioxolanyl, diazepinyl, oxazepinyl, thiazepinyl, morpholinyl, and thiamorpholinyl. A heterocyclyl group can be monocyclic, bicyclic, tricyclic, or polycyclic, preferably monocyclic, bicyclic, or tricyclic, more preferably monocyclic or bicyclic. The term "heterocyclylalkyl" refers to an alkyl group substituted by a heterocyclyl, wherein the alkyl and heterocyclyl portions are independently optionally substituted. Bicyclic heterocyclic rings also include groups in which a heterocyclic ring is fused to one or more aryl rings. Exemplary bicyclic heterocyclic groups include indolinyl, isoindolinyl, benzodioxolyl, 1,3-dihydroisobenzofuranyl, 2,3-dihydrobenzofuranyl, tetrahydroquinolinyl, [ka] The bicyclic heterocyclic ring may be a spirocyclic ring system (e.g., a 7- to 11-membered spirocyclic fused heterocyclic ring having, in addition to carbon atoms, one or more heteroatoms (e.g., 1, 2, 3, or 4 heteroatoms) as defined above). The bicyclic heterocyclic ring may also be a bridged ring system (e.g., a 7- to 11-membered bridged heterocyclic ring having 1, 2, or 3 bridging atoms).
[0037] Immunomodulator: As used herein, the term "immunomodulator" refers to an agent (e.g., small molecule, protein, nucleic acid, etc.) that acts as an immunostimulator or immunosuppressant. An immunostimulator refers to an agent that stimulates the immune system by inducing activation or increasing the activity of any of its components. An immunosuppressant refers to an agent that inhibits or prevents the activity of the immune system.
[0038] Nucleic Acid / Polynucleotide: As used herein, the term "nucleic acid" refers to a polymer of at least 10 or more nucleotides. In some embodiments, a nucleic acid is or comprises DNA. In some embodiments, a nucleic acid is or comprises RNA. In some embodiments, a nucleic acid is or comprises peptide nucleic acid (PNA). In some embodiments, a nucleic acid is or comprises single-stranded nucleic acid. In some embodiments, a nucleic acid is or comprises double-stranded nucleic acid. In some embodiments, a nucleic acid comprises both single-stranded and double-stranded portions. In some embodiments, a nucleic acid comprises a backbone comprising one or more phosphodiester bonds. In some embodiments, a nucleic acid comprises a backbone comprising both phosphodiester and non-phosphodiester bonds. For example, in some embodiments, a nucleic acid can comprise a backbone comprising one or more phosphorothioate or 5'-N-phosphoramidite bonds and / or one or more peptide bonds, e.g., "peptide nucleic acids." In some embodiments, a nucleic acid comprises one or more, or all, naturally occurring residues (e.g., adenine, cytosine, deoxyadenosine, deoxycytidine, deoxyguanosine, deoxythymidine, guanine, thymine, uracil). In some embodiments, a nucleic acid comprises one or more, or all, non-naturally occurring residues. In some embodiments, the non-natural residue comprises a nucleoside analog (e.g., 2-aminoadenosine, 2-thiothymidine, inosine, pyrrolo-pyrimidine, 3-methyladenosine, 5-methylcytidine, C-5 propynyl-cytidine, C-5 propynyl-uridine, 2-aminoadenosine, C5-bromouridine, C5-fluorouridine, C5-iodouridine, C5-propynyl-uridine, C5-propynyl-cytidine, C5-methylcytidine, 2-aminoadenosine, 7-deazaadenosine, 7-deazaguanosine, 8-oxoadenosine, 8-oxoguanosine, 6-O-methylguanine, 2-thiocytidine, methylated bases, intercalating bases, and combinations thereof).In some embodiments, the non-natural residue comprises one or more modified sugars (e.g., 2'-fluororibose, ribose, 2'-deoxyribose, arabinose, and hexose) compared to that of the natural residue. In some embodiments, the nucleic acid has a nucleotide sequence that encodes a functional gene product, such as an RNA or a polypeptide. In some embodiments, the nucleic acid has a nucleotide sequence that includes one or more introns. In some embodiments, nucleic acids can be prepared by isolation from natural sources, enzymatic synthesis (e.g., polymerization based on a complementary template in vivo or in vitro, replication in a recombinant cell or system, or chemical synthesis. In some embodiments, nucleic acids are at least 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 20, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500, 600, 700, 800, 900, 1000, 1500, 2000, 2500, 3000, 3500, 4000, 4500, 5000, 5500, 6000, 6500, 7000, 7500, 8000, 8500, 9000, 9500, 10,000, 10,500, 11,000, 11,500, 12,000, 12 1,500, 13,000, 13,500, 14,000, 14,500, 15,000, 15,500, 16,000, 16,500, 17,000, 17,500, 18,000, 18,500, 19,000, 19,500, or 20,000 or more residues or nucleotides in length.
[0039] Nucleic acid particles: "Nucleic acid particles" can be used to deliver nucleic acids to a desired target site (e.g., a cell, tissue, organ, etc.). Nucleic acid particles can be formed from at least one cationic lipid or cationically ionizable lipid or lipid-like material, at least one cationic polymer such as protamine, or a mixture thereof, and nucleic acid. Nucleic acid particles include lipid nanoparticle (LNP)-based and lipoplex (LPX)-based formulations.
[0040] Nucleotide: As used herein, the term "nucleotide" refers to its art-recognized meaning. When a number of nucleotides is used, for example, as an indicator of the size of a polynucleotide, a specific number of nucleotides refers to the number of nucleotides on a single strand, for example, a polynucleotide.
[0041] Oral: As used herein, the phrases "oral administration" and "orally administered" have their art-understood meanings, meaning administration of a compound or composition by mouth.
[0042] Parenteral: As used herein, the terms "parenteral administration" and "parenterally administered" have their art-understood meanings and refer to modes of administration other than enteral and topical administration, usually by injection, and include, but are not limited to, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal, and intrasternal injection and infusion.
[0043] Partially unsaturated: As used herein, the term "partially unsaturated" refers to a ring moiety that includes at least one double or triple bond between ring atoms. The term "partially unsaturated" is intended to encompass rings with multiple sites of unsaturation, but is not intended to include aromatic (e.g., aryl or heteroaryl) moieties as defined herein.
[0044] Patient or Subject: As used herein, the term "patient" or "subject" refers to any organism to which a provided composition is or can be administered, for example, for experimental, diagnostic, prophylactic, cosmetic, and / or therapeutic purposes. Typical patients or subjects include animals (e.g., mammals such as mice, rats, rabbits, non-human primates, and / or humans). In some embodiments, the patient is human. In some embodiments, the patient or subject suffers from or is prone to one or more disorders or conditions. In some embodiments, the patient or subject exhibits one or more symptoms of a disorder or condition. In some embodiments, the patient or subject has been diagnosed with one or more disorders or conditions. In some embodiments, the patient or subject is undergoing or has undergone a particular therapy to diagnose and / or treat a disease, disorder, or condition.
[0045] Pharmaceutical composition: As used herein, the term "pharmaceutical composition" refers to an active agent formulated with one or more pharmaceutically acceptable carriers. In some embodiments, the active agent is present in a unit dose suitable for administration in a treatment or dosing regimen that exhibits a statistically significant probability of achieving a predetermined therapeutic effect when administered to a relevant population. In some embodiments, the pharmaceutical composition may be specially formulated for administration in solid or liquid form, including oral administration, e.g., drenches (aqueous or non-aqueous solutions or suspensions), tablets, e.g., buccal, sublingual, and those targeted for systemic absorption, boluses, powders, granules, pastes for application to the tongue; parenteral administration, e.g., by subcutaneous, intramuscular, intravenous, or epidural injection, e.g., as a sterile solution or suspension, or sustained-release formulation; topical application, e.g., as a cream, ointment, or controlled-release patch or spray applied to the skin, lungs, or oral cavity; vaginal or rectal administration, e.g., as a pessary, cream, or foam; sublingual; ophthalmic; transdermal; or compatible with the nose, lungs, and other mucosal surfaces.
[0046] Pharmaceutically acceptable: As used herein, the phrase "pharmaceutically acceptable" means compounds, materials, compositions, and / or dosage forms that, within the scope of sound medical judgment, are suitable for use in contact with the tissues of human beings and animals without undue toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit / risk ratio.
[0047] Pharmaceutically acceptable carrier: As used herein, the term "pharmaceutically acceptable carrier" means a pharmaceutically acceptable material, composition, or vehicle, such as a liquid or organ filler, diluent, excipient, or solvent encapsulating material, that is involved in carrying or transporting a compound of interest from one organ or body part to another. Each carrier must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient. Some examples of materials that can serve as pharmaceutically acceptable carriers include sugars such as lactose, glucose, and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives, for example, sodium carboxymethylcellulose, ethylcellulose, and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients such as cocoa butter and suppository waxes; oils such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil, and soybean oil; glycols such as propylene glycol; polyols such as glycerin, sorbitol, mannitol, and polyethylene glycol; esters such as ethyl oleate and ethyl laurate; agar; buffers such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethyl alcohol; pH buffer solutions; polyesters, polycarbonates, and / or polyanhydrides; and other non-toxic, compatible substances used in pharmaceutical formulations.
[0048] Pharmaceutically acceptable salt: As used herein, the term "pharmaceutically acceptable salt" means a salt of a compound that is suitable for use in a pharmaceutical context, i.e., a salt that, within the scope of sound medical judgment, is suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response, and the like, commensurate with a reasonable benefit / risk ratio. Pharmaceutically acceptable salts are well known in the art. For example, S. M. Berge et al. describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 66:1-19 (1977). In some embodiments, pharmaceutically acceptable salts include, but are not limited to, non-toxic acid addition salts of amino groups formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, and perchloric acid, or organic acids such as acetic acid, maleic acid, tartaric acid, citric acid, succinic acid, or malonic acid, or formed by using other methods used in the art, such as ion exchange. In some embodiments, pharmaceutically acceptable salts include, but are not limited to, adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecyl sulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxybenzoate, benzoic acid, benzoates ... Examples of suitable salts include dimethylsulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerate, etc. Representative alkali metal or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, etc.In some embodiments, pharmaceutically acceptable salts include non-toxic ammonium, quaternary ammonium, and amine cations formed, where appropriate, using counterions such as halides, hydroxides, carboxylates, sulfates, phosphates, nitrates, alkyls having 1 to 6 carbon atoms, sulfonates, and arylsulfonates.
[0049] Polycyclic: As used herein, the term "polycyclic" refers to a saturated or unsaturated ring system having two or more rings (e.g., heterocyclyl, heteroaryl, cycloalkyl, or aryl rings) with 7 to 20 atoms, in which one or more carbon atoms are common to two adjacent rings. For example, in some embodiments, a polycyclic ring system refers to a saturated or unsaturated ring system having three or more rings (e.g., heterocyclyl, heteroaryl, cycloalkyl, or aryl rings) with 14 to 20 atoms, in which one or more carbon atoms are common to two adjacent rings. The rings in a polycyclic ring system may be fused (i.e., bicyclic or tricyclic), spirocyclic, or a combination thereof. Exemplary polycyclic rings are steroids.
[0050] Polypeptide: As used herein, the term "polypeptide" typically has its art-recognized meaning of a polymer of at least three or more amino acids. Those of skill in the art will understand that the term "polypeptide" is intended to be sufficiently general to encompass not only polypeptides having the complete sequences described herein, but also polypeptides that represent functional, biologically active, or characteristic fragments, portions, or domains of such complete polypeptides (e.g., fragments, portions, or domains that retain at least one activity). In some embodiments, polypeptides may contain L-amino acids, D-amino acids, or both, and / or may contain any of a variety of amino acid modifications or analogs known in the art. Useful modifications include, for example, terminal acetylation, amidation, methylation, and the like. In some embodiments, polypeptides may contain (e.g., be or include) natural amino acids, unnatural amino acids, synthetic amino acids, and combinations thereof (e.g., may be peptidomimetics).
[0051] Prevention or prophylaxis: As used herein, the terms "prevention" or "prophylaxis," when used in connection with the occurrence of a disease, disorder, and / or condition, refer to a reduction in the risk of the disease, disorder, and / or condition occurring and / or a delay in the onset of one or more characteristics or symptoms of the disease, disorder, or condition. Prevention may be considered complete if the onset of the disease, disorder, or condition has been delayed for a predefined period of time.
[0052] Reference: As used herein, describes a standard or control against which a comparison is made. For example, in some embodiments, an agent, animal, individual, population, sample, sequence, or value of interest is compared to a reference or control agent, animal, individual, population, sample, sequence, or value. In some embodiments, the reference or control is tested and / or determined substantially contemporaneously with the test or determination of interest. In some embodiments, the reference or control is a historical reference or control, optionally embodied in a tangible medium. Typically, as will be understood by those of skill in the art, a reference or control is determined or characterized under conditions or circumstances comparable to those being evaluated. Those of skill in the art will understand when there is sufficient similarity to justify reliance on and / or comparison to a particular reference or control considered.
[0053] Ribonucleotide: As used herein, the term "ribonucleotide" encompasses unmodified ribonucleotides and modified ribonucleotides. For example, unmodified ribonucleotides include the purine bases adenine (A) and guanine (G) and the pyrimidine bases cytosine (C) and uracil (U). Modified ribonucleotides can include one or more modifications, including, but not limited to, (a) terminal modifications, such as 5'-terminal modifications (e.g., phosphorylation, dephosphorylation, conjugation, inverted linkages, etc.), 3'-terminal modifications (e.g., conjugation, inverted linkages, etc.), (b) base modifications, such as substitution with a modified base, a stabilized base, a destabilized base, or a base that base pairs with an expanded repertoire of partners, or a conjugated base, (c) sugar modifications (e.g., at the 2' or 4' position) or sugar substitutions, and (d) internucleoside linkage modifications, including modifications or substitutions of phosphodiester bonds. The term "ribonucleotide" also encompasses ribonucleotide triphosphates, including modified and unmodified ribonucleotide triphosphates.
[0054] Ribonucleic acid (RNA): As used herein, the term "RNA" refers to a polymer of ribonucleotides. In some embodiments, the RNA is single-stranded. In some embodiments, the RNA is double-stranded. In some embodiments, the RNA includes both single-stranded and double-stranded portions. In some embodiments, the RNA can include a backbone structure as described in the definition of "nucleic acid / polynucleotide" above. The RNA can be a regulatory RNA (e.g., siRNA, microRNA, etc.) or a messenger RNA (mRNA). In some embodiments, the RNA is an mRNA. In some embodiments, the RNA is an mRNA, and the RNA typically includes a poly(A) region at its 3' end. In some embodiments, the RNA is an mRNA, and the RNA typically includes an art-recognized cap structure at its 5' end, for example, for recognition and binding of the mRNA to a ribosome to initiate translation. In some embodiments, the RNA is synthetic RNA. Synthetic RNA includes RNA synthesized in vitro (e.g., by enzymatic and / or chemical synthesis).
[0055] Sample: As used herein, the term "sample" typically refers to an aliquot of material obtained from or derived from a source of interest. In some embodiments, the source of interest is a biological or environmental source. In some embodiments, the source of interest can be or include a cell, tissue, or organism, such as a microorganism, a plant, or an animal (e.g., a human). In some embodiments, the source of interest is or includes a biological tissue or fluid. In some embodiments, the source of interest can be or include a preparation generated in a production process. In some embodiments, a sample is a "primary sample" obtained directly from the source of interest by any suitable means. In some embodiments, as will be clear from the context, the term "sample" refers to a preparation obtained by processing a primary sample (e.g., by removing one or more components and / or adding one or more agents).
[0056] Substituted or optionally substituted: As described herein, compounds of the invention can contain "optionally substituted" moieties. In general, the term "substituted," whether preceded by the term "optionally," means that one or more hydrogens of the specified moiety are replaced with a suitable substituent. "Substituted" applies to one or more hydrogens that are either explicit or implicit from the structure (e.g., [ka] At least [ka] refers to, [ka] At least [ka] (refers to "optionally substituted"). Unless otherwise specified, an "optionally substituted" group can have a suitable substituent at each substitutable position of the group, and when more than one position in any given structure can be substituted with more than one substituent selected from a specified group, the substituents can be the same or different at all positions. Combinations of substituents envisioned by the present invention are preferably those that result in the formation of stable or chemically feasible compounds. As used herein, the term "stable" refers to a compound that remains substantially unchanged when subjected to conditions that permit the compound's production, detection, and, in certain embodiments, its recovery, purification, and use for one or more of the purposes provided herein. Groups described as "substituted" preferably have 1 to 4 substituents, more preferably 1 or 2 substituents. Groups described as "optionally substituted" can be unsubstituted or "substituted" as described above.
[0057] Suitable monovalent substituents on a substitutable carbon atom of an "optionally substituted" group are independently halogen, -(CH) 0-4 R°, -(CH2) 0-4 OR°, -O(CH2) 0-4 R o , -O-(CH2) 0-4 C(O)OR°, -(CH2) 0-4 CH(OR°)2, -(CH2) 0-4 SR°, R° may be substituted -(CH2) 0-4 Ph, R° may be substituted -(CH2) 0-4 O(CH2) 0-1 Ph, may be substituted with R° -CH=CHPh, may be substituted with R° -(CH 0-4 O(CH2) 0-1 -Pyridyl, -NO2, -CN, -N3, (CH2) 0-4 N(R°)2, -(CH2) 0-4 N(R°)C(O)R°, -N(R°)C(S)R°, -(CH2) 0-4 N(R°)C(O)NR°2, N(R°)C(S)NR°2, -(CH2) 0-4 N(R°)C(O)OR°, -N(R°)N(R°)C(O)R°, N(R°)N(R°)C(O)NR°2, N(R°)N(R°)C(O)OR°, -(CH2) 0-4 C(O)R°, C(S)R°, -(CH2) 0-4 C(O)OR°, -(CH2) 0-4 C(O)SR°, (CH2) 0-4 C(O)OSiR°3, -(CH2) 0-4 OC(O)R°, -OC(O)(CH2) 0-4 SR°, -(CH2) 0-4 SC(O)R°, -(CH2) 0-4 C(O)NR°2, -C(S)NR°2, -C(S)SR°, -SC(S)SR°, (CH2) 0-4 OC(O)NR°2, C(O)N(OR°)R°, -C(O)C(O)R°, -C(O)CH2C(O)R°, -C(NOR°)R°, (CH2) 0-4 SSR°, -(CH2) 0-4 S(O)2R°, -(CH2) 0-4 S(O)2OR°, -(CH2) 0-4OS(O)2R°, -S(O)2NR°2, (CH2) 0-4 S(O)R°, N(R°)S(O)2NR°2, -N(R°)S(O)2R°, -N(OR°)R°, -C(NH)NR°2, -P(O)2R°, P(O)R°2, OP(O)R°2, -OP(O)(OR°)2, SiR°3, -(C 1-4 linear or branched alkylene)ON(R°)2, or -(C 1-4 linear or branched alkylene)C(O)ON(R°), where each R° can be substituted as defined below and is independently hydrogen, C 1-6 Aliphatic, -CH2Ph, -O(CH2) 0-1 Ph, -CH2- (a 5- to 6-membered heteroaryl ring), or a 3- to 6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or, notwithstanding the above definitions, two independent occurrences of R°, taken together with their intervening atom(s), form a 3- to 12-membered saturated, partially unsaturated, or aryl mono- or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, which may be substituted as defined below.
[0058] Suitable monovalent substituents on R° (or the ring formed by two independent occurrences of R° and their intervening atoms) are independently halogen, —(CH) 0-2 R ● , -(haloR ● ), -(CH2) 0-2 OH, -(CH2) 0-2 OR ● , -(CH2) 0-2 CH(OR ● )2, O(haloR ● ), -CN, -N3, -(CH2) 0-2 C(O)R ● , -(CH2) 0-2 C(O)OH, -(CH2) 0-2 C(O)OR ● , -(CH2) 0-2 SR ● , -(CH2) 0-2 SH, -(CH2)0-2 NH2, -(CH2) 0-2 NHR ● , -(CH2) 0-2 NR ● 2, -NO2, -SiR ● 3. -OSiR ● 3. C(O)SR ● , -(C 1-4 Linear or branched alkylene)C(O)OR ● , or -SSR ● and each R ● is unsubstituted or, if preceded by "halo", substituted only with one or more halogens, and independently, C 1-4 Aliphatic, -CH2Ph, -O(CH2) 0-1 Ph is selected from a 3- to 6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. Suitable divalent substituents on a saturated carbon atom of R° include =0 and =S.
[0059] Suitable divalent substituents on a saturated carbon atom of an "optionally substituted" group include ═O ("oxo"), ═S, ═NNR * 2, =NNHC(O)R * , =NNHC(O)OR * , =NNHS(O)2R * , =NR * , =NOR * , -O(C(R * 2)) 2-3 O-, or -S(C(R * 2)) 2-3 S- is mentioned, R * Each independent occurrence of may be substituted as defined below with hydrogen, C 1-6 aliphatic or unsubstituted 5-6 membered saturated, partially unsaturated, or aryl rings having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. Suitable divalent substituents attached to adjacent substitutable carbons of an "optionally substituted" group include -O(CR * 2) 2-3 O- and R * Each independent occurrence of may be substituted as defined below with hydrogen, C1-6 Selected from aliphatic or unsubstituted 5-6 membered saturated, partially unsaturated, or aryl rings having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
[0060] R * Suitable substituents on the aliphatic group include halogen, -R ● , (Halo R ● ), OH, -OR ● , -O(HaloR ● ), -CN, -C(O)OH, -C(O)OR ● , -NH2, -NHR ● , -NR ● 2, or -NO2, and each R ● is unsubstituted or, if preceded by "halo", substituted only with one or more halogens, and independently, C 1-4 Aliphatic, -CH2Ph, -O(CH2) 0-1 Ph, or a 5-6 membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
[0061] Suitable substituents on a substitutable nitrogen of an "optionally substituted" group include -R † , -NR † 2. -C(O)R † , -C(O)OR † , -C(O)C(O)R † , -C(O)CHC(O)R † , S(O)2R † , S(O)NR † 2. -C(S)NR † 2. -C(NH)NR † 2, or -N(R † )S(O)2R † are listed, and each R † are independently hydrogen, C which may be substituted as defined below 1-6 an aliphatic, unsubstituted -OPh, or unsubstituted 3-6 membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or, regardless of the above definitions, R† two independent occurrences of together with their intervening atom(s) form an unsubstituted 3-12 membered saturated, partially unsaturated, or mono- or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
[0062] R † Suitable substituents on the aliphatic group are independently halogen, —R ● , (Halo R ● ), -OH, -OR ● , -O(HaloR ● ), -CN, -C(O)OH, -C(O)OR ● , -NH2, -NHR ● , -NR ● 2, or NO2, and each R ● is unsubstituted or, if preceded by "halo", substituted only with one or more halogens, and independently, C 1-4 Aliphatic, -CH2Ph, -O(CH2) 0-1 Ph, or a 3-6 membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
[0063] Small molecule: As used herein, the term "small molecule" refers to a low molecular weight organic and / or inorganic compound. Generally, a "small molecule" is a molecule that is less than about 5 kilodaltons (kD) in size. In some embodiments, a small molecule is less than about 4 kD, 3 kD, 2 kD, or 1 kD. In some embodiments, a small molecule is less than about 800 daltons (D), 600 D, 500 D, 400 D, 300 D, 200 D, or 100 D. In some embodiments, a small molecule is less than about 2000 g / mol, less than about 1500 g / mol, less than about 1000 g / mol, less than about 800 g / mol, or less than about 500 g / mol. In some embodiments, a small molecule is not a polymer.
[0064] Those skilled in the art will understand, upon reading this disclosure, that certain small molecule compounds described herein, including, for example, the oligosaccharide compounds described herein, may be provided and / or utilized in any of a variety of forms, such as, for example, crystalline forms (e.g., polymorphs, solvates, etc.), salt forms, protected forms, prodrug forms, ester forms, isomeric forms (e.g., optical and / or structural isomers), isotopic forms, etc.
[0065] Those skilled in the art will appreciate that certain small molecule compounds (e.g., the oligosaccharide compounds described herein) have structures that can exist in one or more stereoisomeric forms. In some embodiments, such small molecules may be utilized in accordance with the present disclosure in the form of individual enantiomers, diastereomers, or geometric isomers, or in the form of a mixture of stereoisomers; in some embodiments, such small molecules may be utilized in accordance with the present disclosure in the form of a racemic mixture.
[0066] Those skilled in the art will appreciate that certain small molecule compounds (e.g., the oligosaccharide compounds described herein) have structures that can exist in one or more tautomeric forms. In some embodiments, such small molecules may be utilized in accordance with the present disclosure in the form of individual tautomers or in forms that interconvert between tautomers.
[0067] Those skilled in the art will recognize that a particular small molecule compound (e.g., an oligosaccharide compound described herein) has a structure that allows for isotopic substitution (e.g., in the case of H, 2 H or 3 H, 12 In the case of C 11 C. 13 C, or 14 C. 14 In the case of N 13 N or 15 N, 16 In the case of O 17 O or 18 O. 35 Cl or 37 In the case of Cl 36 Cl, 19 In the case of F 18 F,127 In the case of I 131 It will be understood that such small molecules have one or more isotopically modified forms, or mixtures thereof, in accordance with the present disclosure.
[0068] In some embodiments, a reference to a particular small molecule compound (e.g., an oligosaccharide compound described herein) may refer to a particular form of that compound. In some embodiments, a particular small molecule compound may be provided and / or utilized in the form of a salt (e.g., an acid addition or base addition salt, depending on the compound), and in some such embodiments, the salt form may be a pharmaceutically acceptable salt form.
[0069] In some embodiments, if a small molecule compound is a naturally occurring or naturally found compound, the compound may be provided and / or utilized in accordance with the present disclosure in a form that differs from that in which it naturally occurs or is found in nature. One skilled in the art will understand that in some embodiments, the absolute or relative amount of a compound, or a preparation of a particular small molecule compound (e.g., an oligosaccharide compound described herein) containing a particular form thereof, will differ from the compound present in a reference preparation or source (e.g., a primary sample from a source of interest, such as a biological or environmental source) in terms of the absolute or relative amount of the compound or form present (e.g., with respect to other components of the preparation that contain other forms of the compound). Thus, in some embodiments, for example, a preparation of a single stereoisomer of a small molecule compound may be considered to be a distinct form from a racemic mixture of the compound, a particular salt of a small molecule compound may be considered to be a distinct form from another salt form of the compound, a preparation that includes only forms of the compound that contain one stereoisomer of the double bond ((Z) or (E)) may be considered to be a distinct form from forms of the compound that contain the other stereoisomer of the double bond (E) or (Z), and a preparation in which one or more atoms are isotopes different from those present in a reference preparation may be considered to be a distinct form.
[0070] Those skilled in the art will recognize that in small molecule structures, the symbols [ka] It will further be understood to refer to the point of attachment between two atoms.
[0071] Therapeutic Agent: As used herein, the term "therapeutic agent" generally refers to any agent that induces a desired pharmacological effect when administered to an organism. In some embodiments, an agent is considered to be a therapeutic agent if it exhibits a statistically significant effect in an appropriate population. In some embodiments, the appropriate population may be a population of model organisms. In some embodiments, the appropriate population may be defined by various criteria, such as a particular age group, sex, genetic background, pre-existing clinical condition, etc. In some embodiments, a therapeutic agent is any substance that can be used to alleviate, ameliorate, relieve, inhibit, prevent, delay the onset, reduce the severity, and / or reduce the incidence of one or more symptoms or characteristics of a disease, disorder, and / or condition. In some embodiments, a "therapeutic agent" is a drug that has been, or needs to be, approved by a government agency before it can be commercially available for administration to humans. In some embodiments, a "therapeutic agent" is an agent that requires a medical prescription for administration to humans.
[0072] Treat: As used herein, the terms "treat," "treatment," or "treating" refer to any method used to partially or completely alleviate, ameliorate, relieve, inhibit, prevent, delay the onset of, reduce the severity of, and / or reduce the incidence of one or more symptoms or characteristics of a disease, disorder, and / or condition. Treatment may be administered to subjects who do not exhibit signs of the disease, disorder, and / or condition. In some embodiments, treatment may be administered to subjects who exhibit only early signs of the disease, disorder, and / or condition, for example, to reduce the risk of developing conditions associated with the disease, disorder, and / or condition.
[0073] Complexes and Compositions The compositions described herein exhibit unexpectedly improved properties compared to previously described complexes containing oligosaccharides or lipid-based complexes. Furthermore, the present disclosure encompasses the insight that cationic and / or ionizable oligosaccharides are surprisingly useful for the delivery and targeted expression of certain therapeutic agents, such as nucleic acids and RNA. In some embodiments, the present disclosure provides a complex comprising: i) a cationic oligosaccharide comprising one or more cationic moieties linked to a trehalose, sucrose, or gluco-n-oligosaccharide moiety, where n is 2-6; ii) a surfactant; and iii) one or more additives selected from a sterol, a helper lipid, an immunomodulator, and a targeting molecule.
[0074] The present disclosure further encompasses the insight that, inter alia, specific combinations and molar ratios of cationic oligosaccharides, surfactants, and one or more additives provide complexes that exhibit properties suitable for delivery of cargo (e.g., small molecule drugs or nucleic acids).
[0075] Polycationic Oligosaccharides The conjugates described herein comprise cationic oligosaccharides comprising multiple cationic moieties linked to trehalose, sucrose, or gluco-n-oligosaccharide moieties, where n is 2 to 6. In some embodiments, the trehalose moiety has the following structure: [ka] In the formula, each G 1 The moieties are independently cationic moieties optionally linked to trehalose moieties via linker groups, and each G 2 are independently H or C1-C 60 It is an aliphatic group.
[0076] In some embodiments, the sucrose moiety has the structure: [ka] In the formula, each G 1The moieties are independently cationic moieties optionally linked to trehalose moieties via linker groups, and each G 2 are independently H or C1-C 60 It is an aliphatic group.
[0077] In some embodiments, the gluco-n-oligosaccharide moiety has the structure: [ka] In the formula, each G 1 The moieties are independently cationic moieties optionally linked to trehalose moieties via linker groups, and each G 2 are independently H or C1-C 60 It is an aliphatic group, and n is from 2 to 6 (e.g., 2, 3, 4, 5, or 6). In some embodiments, n is from 2 to 5. In some embodiments, n is from 3 to 6.
[0078] In some embodiments, each linker group independently is an optionally substituted C 1-30 an aliphatic group, wherein one or more carbons are optionally and independently -Cy-, -NR Y -, -NR Y C(O)-, -C(O)NR Y -, -NR Y C(O)O-, -OC(O)NR Y -, -NR Y C(O)NR Y -, -NR Y C(S)NR Y -, -C(S)NR Y - -C(O)NR Y SO2-, -SO2NR Y is substituted by C(O)-, -OC(O)O-, -O-, -C(O)-, -OC(O)-, -C(O)O, -SO-, or -SO2-, and each R Y are independently H or an optionally substituted C1-C6 aliphatic, and each Cy is independently an optionally substituted C3-C 14an optionally substituted 5- to 14-membered heterocyclyl ring having 1 to 3 heteroatoms selected from N, O, and S; an optionally substituted 5- to 14-membered heteroaryl ring having 1 to 3 heteroatoms selected from N, O, and S.
[0079] As used herein, a "cationic" moiety is a group that has a net positive charge. As used herein, an "ionizable" moiety is a group that may have a neutral charge at a particular pH but may become charged (e.g., cationic) at a different pH. For example, in some embodiments, the ionizable moiety becomes cationic (i.e., positively charged) at physiological pH (e.g., a pH of about 7.4). Exemplary cationic moieties include, but are not limited to, ammonium, guanidinium, isothioronium, amidinium, piperazinium, piperidinium, morpholinium, pyrrolidinium, imidazolium, pyrazolium, oxazolium, thiazolium, triazolium, and the like. Those of skill in the art will also understand that the oligosaccharides described herein comprise multiple (i.e., one or more) cationic moieties. Those of skill in the art will also understand that the cationic moieties described herein can also exist as salts (e.g., pharmaceutically acceptable salts) comprising the cationic moiety and one or more suitable counterions. For example, in some embodiments, the cationic group described herein comprises ammonium chloride. Suitable counterions include halogens (e.g., Br - , Cl - , I - , F - ), acetate (e.g., C(O)O - ) and the like. For additional examples, see the definition of pharmaceutically acceptable salts provided herein. Reference to a particular counterion, e.g., a counterion shown in Table 1, is intended to encompass a single charged moiety as well as all chemically feasible counterions.
[0080] In some embodiments, the cationic oligosaccharide is a compound of formula I: [ka] or a pharmaceutically acceptable salt thereof, wherein: A is A 1 , A 2 , or A 3 and [ka] R 1 and R 2 each independently, in each instance, H, R a , and -C(O)-R a Selected from R 1 or R 2 At least one instance of is not H, Each R a But independently, C1-C 20 Aliphatic, C3-C 20 cycloaliphatic, C5-C6 aryl, 3- to 12-membered heterocyclyl containing 1 to 3 heteroatoms selected from N, O, and S; a But there is one or more R b optionally replaced by Each R b are independently halogen, -N3, -R c , -OR c , -SR c , -NHR c , -C(O)-R c , -OC(O)R c , -NHC(O)R c , -C(O)NHR c , and -NHC(O)NHR c is selected from Each R c are independently optionally substituted C-C 20 Aliphatic, optionally substituted C3-C 20 selected from cycloaliphatic, optionally substituted C5-C6 aryl, optionally substituted 3- to 12-membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, and optionally substituted 4- to 12-membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S; X 1 and X 2are each independently selected from -S-, -SS-, and -NH-; Y 1 and Y 2 each independently represents an optionally substituted C 1-30 an aliphatic group, wherein one or more carbons are optionally and independently selected from Cy-, -NR Y -, -NR Y C(O)-, -C(O)NR Y -, -NR Y C(O)O-, -OC(O)NR Y -, -NR Y C(O)NR Y -, -NR Y C(S)NR Y -, -C(S)NR Y -, -C(O)NR Y SO2-, -SO2NR Y substituted by -C(O)-, -OC(O)O-, -O-, -C(O)-, -OC(O)-, -C(O)O-, -SO-, or -SO2-; Each R Y are independently H or an optionally substituted C1-C6 aliphatic; each Cy independently represents an optionally substituted C3-C 14 an optionally substituted 5- to 14-membered heterocyclyl ring having 1 to 3 heteroatoms selected from cycloaliphatic, N, O, and S, or an optionally substituted 5- to 14-membered heteroaryl ring having 1 to 3 heteroatoms selected from N, O, and S; Z 1 and Z 2 each independently represents an optionally substituted 5- to 14-membered heterocyclyl ring having 1 to 3 heteroatoms selected from N, O, and S; a 5- to 14-membered heteroaryl ring having 1 to 3 heteroatoms selected from N, O, and S; -N + (M)3, [ka] is a cationic or ionizable group selected from Each M is independently -C0-C6 aliphatic -R z , or -C0-C6 aliphatic -N + (Rz )3, Each R z are independently H, optionally substituted C1-C6 aliphatic, optionally substituted C3-C 20 selected from cycloaliphatic, optionally substituted C5-C6 aryl, optionally substituted 3-12 membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, and optionally substituted 4-12 membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S; or Two or more R's z can be taken together with the atom to which they are attached to form an optionally substituted 3- to 12-membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, or an optionally substituted 4- to 12-membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S; p is an integer selected from 1, 2, 3, 4, or 5.
[0081] As described herein, A is A 1 , A 2 , or A 3 is: [ka]
[0082] In some embodiments, A is A 1 or A 2 In some embodiments, A is A 1 In some embodiments, A is A 2 In some embodiments, A is A 3 In some embodiments, A is A 1 and the oligosaccharide is a compound of formula Ia, [ka] or a pharmaceutically acceptable salt thereof, wherein R 1 , R 2 , X 1 , X 2 , Y1 , Y 2 , Z 1 , and Z 2 are as described in classes and subclasses herein, both alone and in combination.
[0083] In some embodiments, the oligosaccharide is a compound of formula Ia: [ka] or a pharmaceutically acceptable salt thereof, wherein: R 1 and R 2 each independently, in each instance, H, R a , and -C(O)-R a Selected from R 1 or R 2 At least one instance of is not H, Each R a But independently, C1-C 20 Aliphatic, C3-C 20 cycloaliphatic, C5-C6 aryl, 3- to 12-membered heterocyclyl containing 1 to 3 heteroatoms selected from N, O, and S; a But there is one or more R b optionally replaced by Each R b are independently halogen, -N3, -R c , -OR c , -SR c , -NHR c , -C(O)-R c , -OC(O)R c , -NHC(O)R c , -C(O)NHR c , and -NHC(O)NHR c is selected from Each R c are independently optionally substituted C-C 20 Aliphatic, optionally substituted C3-C 20selected from cycloaliphatic, optionally substituted C5-C6 aryl, optionally substituted 3- to 12-membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, and optionally substituted 4- to 12-membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S; X 1 and X 2 are each independently selected from -S-, -SS-, and -NH-; Y 1 and Y 2 each independently represents an optionally substituted C 1-30 an aliphatic group, wherein one or more carbons are optionally and independently selected from Cy-, -NR Y -, -NR Y C(O)-, -C(O)NR Y -, -NR Y C(O)O-, -OC(O)NR Y -, -NR Y C(O)NR Y -, -NR Y C(S)NR Y -, -C(S)NR Y -, -C(O)NR Y SO2-, -SO2NR Y substituted by -C(O)-, -OC(O)O-, -O-, -C(O)-, -OC(O)-, -C(O)O-, -SO-, or -SO2-; Each R Y are independently H or an optionally substituted C1-C6 aliphatic; each Cy independently represents an optionally substituted C3-C 14 an optionally substituted 5- to 14-membered heterocyclyl ring having 1 to 3 heteroatoms selected from cycloaliphatic, N, O, and S, or an optionally substituted 5- to 14-membered heteroaryl ring having 1 to 3 heteroatoms selected from N, O, and S; Z 1 and Z 2 each independently represents an optionally substituted 5- to 14-membered heterocyclyl ring having 1 to 3 heteroatoms selected from N, O, and S; a 5- to 14-membered heteroaryl ring having 1 to 3 heteroatoms selected from N, O, and S; -N +(M)3, [ka] is a cationic or ionizable group selected from Each M is independently -C0-C6 aliphatic -R z , or -C0-C6 aliphatic -N + (R z )3, Each R z are independently H, optionally substituted C1-C6 aliphatic, optionally substituted C3-C 20 selected from cycloaliphatic, optionally substituted C5-C6 aryl, optionally substituted 3-12 membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, and optionally substituted 4-12 membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S; or Two or more R's z can be taken together with the atoms to which they are attached to form an optionally substituted 3- to 12-membered heterocyclyl containing 1 to 3 heteroatoms selected from N, O, and S, or an optionally substituted 4- to 12-membered heteroaryl containing 1 to 3 heteroatoms selected from N, O, and S.
[0084] In some embodiments, A is A 2 and the oligosaccharide is a compound of formula Ib [ka] or a pharmaceutically acceptable salt thereof, wherein R 1 , R 2 , X 1 , X 2 , Y 1 , Y 2 , Z 1 , and Z 2 are as described in classes and subclasses herein, both alone and in combination.
[0085] In some embodiments, the oligosaccharide is a compound of formula Ib [ka] or a pharmaceutically acceptable salt thereof, wherein: R 1 and R 2 each independently, in each instance, H, R a , and -C(O)-R a Selected from R 1 or R 2 At least one instance of is not H, Each R a But independently, C1-C 20 Aliphatic, C3-C 20 cycloaliphatic, C5-C6 aryl, 3- to 12-membered heterocyclyl containing 1 to 3 heteroatoms selected from N, O, and S; a But there is one or more R b optionally replaced by Each R b are independently halogen, -N3, -R c , -OR c , -SR c , -NHR c , -C(O)-R c , -OC(O)R c , -NHC(O)R c , -C(O)NHR c , and -NHC(O)NHR c is selected from Each R c are independently optionally substituted C-C 20 Aliphatic, optionally substituted C3-C 20 selected from cycloaliphatic, optionally substituted C5-C6 aryl, optionally substituted 3- to 12-membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, and optionally substituted 4- to 12-membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S; X 1 and X 2 are each independently selected from -S-, -SS-, and -NH-; Y 1 and Y 2 each independently represents an optionally substituted C 1-30an aliphatic group, wherein one or more carbons are optionally and independently selected from Cy-, -NR Y -, -NR Y C(O)-, -C(O)NR Y -, -NR Y C(O)O-, -OC(O)NR Y -, -NR Y C(O)NR Y -, -NR Y C(S)NR Y -, -C(S)NR Y -, -C(O)NR Y SO2-, -SO2NR Y substituted by -C(O)-, -OC(O)O-, -O-, -C(O)-, -OC(O)-, -C(O)O-, -SO-, or -SO2-; Each R Y are independently H or an optionally substituted C1-C6 aliphatic; each Cy independently represents an optionally substituted C3-C 14 an optionally substituted 5- to 14-membered heterocyclyl ring having 1 to 3 heteroatoms selected from cycloaliphatic, N, O, and S, or an optionally substituted 5- to 14-membered heteroaryl ring having 1 to 3 heteroatoms selected from N, O, and S; Z 1 and Z 2 each independently represents an optionally substituted 5- to 14-membered heterocyclyl ring having 1 to 3 heteroatoms selected from N, O, and S; a 5- to 14-membered heteroaryl ring having 1 to 3 heteroatoms selected from N, O, and S; -N + (M)3, [ka] is a cationic or ionizable group selected from Each M is independently -C0-C6 aliphatic -R z , or -C0-C6 aliphatic -N + (R z )3, Each R z are independently H, optionally substituted C1-C6 aliphatic, optionally substituted C3-C 20selected from cycloaliphatic, optionally substituted C5-C6 aryl, optionally substituted 3-12 membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, and optionally substituted 4-12 membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S; or Two or more R's z can be taken together with the atoms to which they are attached to form an optionally substituted 3- to 12-membered heterocyclyl containing 1 to 3 heteroatoms selected from N, O, and S, or an optionally substituted 4- to 12-membered heteroaryl containing 1 to 3 heteroatoms selected from N, O, and S.
[0086] In some embodiments, A is A 3 and the oligosaccharide is a compound of formula Ic, [ka] or a pharmaceutically acceptable salt thereof, wherein p, R 1 , R 2 , X 1 , X 2 , Y 1 , Y 2 , Z 1 , and Z 2 are as described in classes and subclasses herein, both alone and in combination.
[0087] In some embodiments, the oligosaccharide is a compound of formula Ic [ka] or a pharmaceutically acceptable salt thereof, wherein: R 1 and R 2 each independently, in each instance, H, R a , and -C(O)-R a Selected from R 1 or R 2 At least one instance of is not H, Each R a But independently, C1-C20 Aliphatic, C3-C 20 cycloaliphatic, C5-C6 aryl, 3- to 12-membered heterocyclyl containing 1 to 3 heteroatoms selected from N, O, and S; a But there is one or more R b optionally replaced by Each R b are independently halogen, -N3, -R c , -OR c , -SR c , -NHR c , -C(O)-R c , -OC(O)R c , -NHC(O)R c , -C(O)NHR c , and -NHC(O)NHR c is selected from Each R c are independently optionally substituted C-C 20 Aliphatic, optionally substituted C3-C 20 selected from cycloaliphatic, optionally substituted C5-C6 aryl, optionally substituted 3- to 12-membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, and optionally substituted 4- to 12-membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S; X 1 and X 2 are each independently selected from -S-, -SS-, and -NH-; Y 1 and Y 2 each independently represents an optionally substituted C 1-30 an aliphatic group, wherein one or more carbons are optionally and independently selected from Cy-, -NR Y -, -NR Y C(O)-, -C(O)NR Y -, -NR Y C(O)O-, -OC(O)NR Y -, -NR Y C(O)NR Y -, -NR Y C(S)NR Y -, -C(S)NR Y -, -C(O)NR YSO2-, -SO2NR Y substituted by -C(O)-, -OC(O)O-, -O-, -C(O)-, -OC(O)-, -C(O)O-, -SO-, or -SO2-; Each R Y are independently H or an optionally substituted C1-C6 aliphatic; each Cy independently represents an optionally substituted C3-C 14 an optionally substituted 5- to 14-membered heterocyclyl ring having 1 to 3 heteroatoms selected from cycloaliphatic, N, O, and S, or an optionally substituted 5- to 14-membered heteroaryl ring having 1 to 3 heteroatoms selected from N, O, and S; Z 1 and Z 2 each independently represents an optionally substituted 5- to 14-membered heterocyclyl ring having 1 to 3 heteroatoms selected from N, O, and S; a 5- to 14-membered heteroaryl ring having 1 to 3 heteroatoms selected from N, O, and S; -N + (M)3, [ka] is a cationic or ionizable group selected from Each M is independently -C0-C6 aliphatic -R z , or -C0-C6 aliphatic -N + (R z )3, Each R z are independently H, optionally substituted C1-C6 aliphatic, optionally substituted C3-C 20 selected from cycloaliphatic, optionally substituted C5-C6 aryl, optionally substituted 3-12 membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, and optionally substituted 4-12 membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S; or Two or more R's zcan be taken together with the atom to which they are attached to form an optionally substituted 3- to 12-membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, or an optionally substituted 4- to 12-membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S; p is an integer selected from 1, 2, 3, 4, or 5.
[0088] In some embodiments, p is 1 and the oligosaccharide is a compound of formula Ic-i [ka] or a pharmaceutically acceptable salt thereof, wherein R 1 , R 2 , X 1 , X 2 , Y 1 , Y 2 , Z 1 , and Z 2 are as described in classes and subclasses herein, both alone and in combination.
[0089] In some embodiments, p is 2 and the oligosaccharide is a compound of formula Ic-ii [ka] or a pharmaceutically acceptable salt thereof, wherein R 1 , R 2 , X 1 , X 2 , Y 1 , Y 2 , Z 1 , and Z 2 are as described in classes and subclasses herein, both alone and in combination.
[0090] In some embodiments, p is 3 and the oligosaccharide is a compound of formula Ic-iii: [ka] or a pharmaceutically acceptable salt thereof, wherein R1 , R 2 , X 1 , X 2 , Y 1 , Y 2 , Z 1 , and Z 2 are as described in classes and subclasses herein, both alone and in combination.
[0091] In some embodiments, p is 4 and the oligosaccharide is a compound of formula Ic-iv [ka] or a pharmaceutically acceptable salt thereof, wherein R 1 , R 2 , X 1 , X 2 , Y 1 , Y 2 , Z 1 , and Z 2 are as described in classes and subclasses herein, both alone and in combination.
[0092] In some embodiments, p is 5 and the oligosaccharide is a compound of formula Ic-v: [ka] or a pharmaceutically acceptable salt thereof, wherein R 1 , R 2 , X 1 , X 2 , Y 1 , Y 2 , Z 1 , and Z 2 are as described in classes and subclasses herein, both alone and in combination.
[0093] Generally, as described herein, R 1 and R 2 each independently, in each instance, H, R a , and -C(O)-R a Selected from R 1 or R2 At least one instance of is not H. In some embodiments, R 1 and R 2 are each independently R a , and -C(O)-R a In some embodiments, R 1 and R 2 is R a In some embodiments, R 1 and R 2 is R a and each R a are independently C1-C 20 Aliphatic, C3-C 20 cycloaliphatic, C5-C6 aryl, 3- to 12-membered heterocyclyl containing 1 to 3 heteroatoms selected from N, O, and S; a is one or more R b is optionally replaced by
[0094] In some embodiments, R 1 and R 2 Each of R a and each R a may independently be one or more R b C1-C optionally substituted with 20 In some embodiments, R 1 and R 2 Each of R a and each R a may independently be one or more R b C1-C optionally substituted with 14 In some embodiments, R 1 and R 2 Each of R a and each R a may independently be one or more R b C1-C optionally substituted with 10 In some embodiments, R 1 and R 2 Each of R a and each R a may independently be one or more R bC5-C optionally substituted with 10 In some embodiments, R 1 and R 2 Each of R a and each R a may independently be one or more R b C5-C optionally substituted with 10 In some embodiments, R 1 and R 2 Each of R a and each R a independently, C5-C 10 In some embodiments, R 1 and R 2 Each of R a and each R a is independently selected from methyl, ethyl, n-propyl, n-butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, and n-nonyl. 1 and R 2 is R a and each R a is, independently, [ka] is selected from.
[0095] In some embodiments, R 1 and R 2 Each of R a and each R a may independently be one or more R b C3-C optionally substituted with 20 In some embodiments, R 1 and R 2 Each of R a and each R a may independently be one or more R b In some embodiments, R 1 and R 2 Each of R a and each Ra is independently selected from cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
[0096] In some embodiments, R 1 and R 2 Each of R a and each R a may independently be one or more R b In some embodiments, R 1 and R 2 Each of R a and R a is phenyl.
[0097] In some embodiments, R 1 and R 2 Each of R a and R a is one or more R b In some embodiments, R is a 3- to 12-membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, optionally substituted with 1 and R 2 Each of R a and R a is one or more R b and optionally substituted with 3 to 6-membered heterocyclyl containing 1 to 3 heteroatoms selected from N, O, and S.
[0098] In some embodiments, R 1 and R 2 Each of the groups is -C(O)-R a and each R a are independently C1-C 20 Aliphatic, C3-C 20 cycloaliphatic, C5-C6 aryl, 3- to 12-membered heterocyclyl containing 1 to 3 heteroatoms selected from N, O, and S; a is one or more R b is optionally replaced by
[0099] In some embodiments, R1 and R 2 Each of the groups is -C(O)-R a In some embodiments, R 1 and R 2 Each of the groups is -C(O)-R a and R a is one or more R b C1-C optionally substituted with 20 In some embodiments, R 1 and R 2 Each of the groups is -C(O)-R a and R a is one or more R b C1-C optionally substituted with 14 In some embodiments, R 1 and R 2 Each of the groups is -C(O)-R a and R a is one or more R b C1-C optionally substituted with 10 In some embodiments, R 1 and R 2 Each of the groups is -C(O)-R a and R a is one or more R b C5-C optionally substituted with 10 In some embodiments, R 1 and R 2 Each of the groups is -C(O)-R a and R a is one or more R b C5-C optionally substituted with 10 In some embodiments, R 1 and R 2 Each of the groups is -C(O)-R a and R a is C5-C 10 In some embodiments, R 1 and R 2 Each of the groups is -C(O)-R a and R ais methyl, ethyl, n-propyl, n-butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, or n-nonyl. 1 and R 2 Each of the groups is -C(O)-R a and each R a is, independently, [ka] is selected from.
[0100] In some embodiments, R 1 and R 2 Each of the groups is -C(O)-R a and R a is one or more R b C3-C optionally substituted with 20 In some embodiments, R 1 and R 2 Each of the groups is -C(O)-R a and R a is one or more R b In some embodiments, R 1 and R 2 Each of the groups is -C(O)-R a and each R a is independently selected from cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl. 1 and R 2 Each of the groups is -C(O)-R a and R a is one or more R b Polycyclic C optionally substituted with 10 -C 20 In some embodiments, R 1 and R 2 Each of the [ka] is.
[0101] In some embodiments, R 1 and R 2 Each of the groups is -C(O)-R a and each R a may independently be one or more R b In some embodiments, R 1 and R 2 Each of the groups is -C(O)-R a and each R a is independently phenyl.
[0102] In some embodiments, R 1 and R 2 Each of the groups is -C(O)-R a and each R a may independently be one or more R b In some embodiments, R is a 3- to 12-membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, optionally substituted with 1 and R 2 Each of the groups is -C(O)-R a and each R a may independently be one or more R b and optionally substituted with 3 to 6-membered heterocyclyl containing 1 to 3 heteroatoms selected from N, O, and S.
[0103] In some embodiments, R 1 and R 2 each of which independently [ka] is selected from.
[0104] As described herein, each R b are independently halogen, -N3, -R c , -OR c , -SR c , -NHR c , -C(O)-R c , -OC(O)R c , -NHC(O)R c , -C(O)NHRc , and -NHC(O)NHR c In some embodiments, R b is halogen. In some embodiments, R b is -N3. In some embodiments, R b is R c In some embodiments, R b -OR c In some embodiments, R b -SR c In some embodiments, R b -NHR c In some embodiments, R b is -C(O)-R c In some embodiments, R b is -OC(O)R c In some embodiments, R b is -NHC(O)R c In some embodiments, R b is -C(O)NHR c In some embodiments, R b is -NHC(O)NHR c is.
[0105] As described herein, each R c are independently optionally substituted C-C 20 Aliphatic, C3-C 20 In some embodiments, R is selected from cycloaliphatic, C5-C6 aryl, 3- to 12-membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, and 4- to 12-membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S. c is an optionally substituted C1-C 20 In some embodiments, R c is an optionally substituted C3-C 20 In some embodiments, R c is an optionally substituted C5-C6 aryl. In some embodiments, R cis an optionally substituted 3-12 membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S. In some embodiments, R c is an optionally substituted 4-12 membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S.
[0106] As described herein, X 1 and X 2 are each independently selected from -S-, -SS-, and -NH-. 1 is -S-. In some embodiments, X 1 is -SS-. In some embodiments, X 1 is -NH-. In some embodiments, X 2 is -S-. In some embodiments, X 2 is -SS-. In some embodiments, X 2 is -NH-. In some embodiments, X 1 and X 2 are each -S-. In some embodiments, X 1 and X 2 are each -SS-. In some embodiments, X 1 and X 2 are each —NH—. In some embodiments, X 1 is -S- and X 2 is -NH-. In some embodiments, X 1 is -NH- and X 2 is -S-.
[0107] As described herein, Y 1 and Y 2 each independently represents an optionally substituted C 1-30 is an aliphatic group, and Y 1 and / or Y 2 One or more carbons of the group may optionally and independently be selected from the group consisting of Cy-, -NR Y -, -NR Y C(O)-, -C(O)NR Y -, -NRY C(O)O-, -OC(O)NR Y -, -NR Y C(O)NR Y -, -NR Y C(S)NR Y -, -C(S)NR Y -, -C(O)NR Y SO2-, -SO2NR Y In some embodiments, Y is substituted with -C(O)-, -OC(O)O-, -O-, -C(O)-, -OC(O)-, -C(O)O-, -SO-, or -SO2-. 1 and Y 2 each independently represents an optionally substituted C 1-30 is an aliphatic group, and Y 1 and / or Y 2 One or more carbons of the group are optionally and independently substituted with -Cy-, -NH-, -NHC(O)-, -C(O)NH-, -NHC(O)O-, -OC(O)NH-, -NHC(O)NH-, -NHC(S)NH-, -C(S)NH-, -C(O)NHSO-, -SONHC(O)-, -OC(O)O-, -O-, -C(O)-, -OC(O)-, -C(O)O-, -SO-, or -SO-. As described herein, Y 1 and Y 2 is a divalent moiety with one end X 1 or X 2 The other end is bonded to the Z group. 1 or Z 2 It is understood that the bond is to a group.
[0108] As described herein, each R Y is independently selected from H and optionally substituted C-C aliphatic. In some embodiments, each R Y is independently selected from H and C1-C3 alkyl. In some embodiments, each R Y is independently selected from H, and CH3.
[0109] In some embodiments, Y 1 and Y 2 are each independently C1-C 10Aliphatic, C0-C4-aliphatic-NHC(O)NH-C0-C4aliphatic, C0-C4-aliphatic-NHC(S)NH-C0-C4aliphatic, C0-C4-aliphatic-C(O)NH-C0-C4aliphatic, C0-C4-aliphatic-C( S) selected from NH-C0-C4 aliphatic, C0-C4-aliphatic-NHC(O)-C0-C4 aliphatic, C0-C4-aliphatic-NHSO2-C0-C4 aliphatic, and C0-C4-aliphatic-C(O)-C0-C4 aliphatic.
[0110] In some embodiments, Y 1 and Y 2 are C1-C 10 In some embodiments, Y is aliphatic. 1 and Y 2 are each methylene, ethylene, propylene, or butylene. 1 and Y 2 are each -CH2-CH2-.
[0111] In some embodiments, Y 1 and Y 2 are each C-C-aliphatic-NHC(O)NH-C-C-aliphatic. In some embodiments, Y 1 and Y 2 are each C1-C4-aliphatic-NHC(O)NH-C1-C4 aliphatic. In some embodiments, Y 1 and Y 2 are each —CH—CH—NHC(O)NH—CH—CH—
[0112] In some embodiments, Y 1 and Y 2 are each C-C-aliphatic-NHC(S)NH-C-C-aliphatic. In some embodiments, Y 1 and Y 2 are each C1-C4-aliphatic-NHC(S)NH-C1-C4 aliphatic. In some embodiments, Y 1 and Y 2 are each —CH—CH—NHC(S)NH—CH—CH—
[0113] In some embodiments, Y 1 and Y 2 are each C-C-aliphatic-C(O)NH-C-C-aliphatic. In some embodiments, Y 1 and Y 2 are each C1-C4-aliphatic-C(O)NH-C1-C4 aliphatic. In some embodiments, Y 1 and Y 2 are each —CH—CH—C(O)NH—CH—CH—
[0114] In some embodiments, Y 1 and Y 2 are each C-C-aliphatic-NHC(O)-C-C-aliphatic. In some embodiments, Y 1 and Y 2 are each C0-C4-aliphatic-NHC(O)-C1-C4 aliphatic. In some embodiments, Y 1 and Y 2 are each —CH—CH—NHC(O)—CH—CH—.
[0115] In some embodiments, Y 1 and Y 2 are each C-C-aliphatic-NHSO-C-C-aliphatic. 1 and Y 2 are each C1-C4-aliphatic-NHSO2-C1-C4 aliphatic. In some embodiments, Y 1 and Y 2 are respectively -CH2-CH2-NHSO2-CH2-CH2.
[0116] In some embodiments, Y 1 is C1-C 10Aliphatic, C0-C4-aliphatic-NHC(O)NH-C0-C4aliphatic, C0-C4-aliphatic-NHC(S)NH-C0-C4aliphatic, C0-C4-aliphatic-C(O)NH-C0-C4aliphatic, C0-C4-aliphatic- selected from C(S)NH-C0-C4 aliphatic, C0-C4-aliphatic-C(O)NH-C0-C4 aliphatic, C0-C4-aliphatic-NHSO2-C0-C4 aliphatic, and C0-C4-aliphatic-C(O)-C0-C4.
[0117] In some embodiments, Y 1 is C1-C 10 In some embodiments, Y is aliphatic. 1 is methylene, ethylene, propylene, or butylene. In some embodiments, Y 1 is -CH2-CH2-.
[0118] In some embodiments, Y 1 is C-C-aliphatic-NHC(O)NH-C-C-aliphatic. In some embodiments, Y 1 is C1-C4-aliphatic-NHC(O)NH-C1-C4 aliphatic. In some embodiments, Y 1 is -CH2-CH2-NHC(O)NH-CH2-CH2-.
[0119] In some embodiments, Y 1 is C-C-aliphatic-NHC(S)NH-C-C-aliphatic. In some embodiments, Y 1 is C1-C4-aliphatic-NHC(S)NH-C1-C4 aliphatic. In some embodiments, Y 1 is -CH2-CH2-NHC(S)NH-CH2-CH2-.
[0120] In some embodiments, Y 1 is C-C-aliphatic-C(O)NH-C-C-aliphatic. In some embodiments, Y 1 is C1-C4-aliphatic-C(O)NH-C1-C4 aliphatic. In some embodiments, Y 1is -CH2-CH2-C(O)NH-CH2-CH2-.
[0121] In some embodiments, Y 1 is C-C-aliphatic-NHC(O)-C-C-aliphatic. In some embodiments, Y 1 is C1-C4-aliphatic-NHC(O)-C1-C4 aliphatic. In some embodiments, Y 1 is -CH2-CH2-NHC(O)-CH2-CH2-.
[0122] In some embodiments, Y 1 is C-C-aliphatic-NHSO-C-C-aliphatic. In some embodiments, Y 1 is C1-C4-aliphatic-NHSO2-C1-C4 aliphatic. In some embodiments, Y 1 is -CH2-CH2-NHSO2-CH2-CH2-.
[0123] In some embodiments, Y 2 is C1-C 10 Aliphatic, C0-C4-aliphatic-NHC(O)NH-C0-C4aliphatic, C0-C4-aliphatic-NHC(S)NH-C0-C4aliphatic, C0-C4-aliphatic-C(O)NH-C0-C4aliphatic, C0-C4-aliphatic- selected from C(S)NH-C0-C4 aliphatic, C0-C4-aliphatic-C(O)NH-C0-C4 aliphatic, C0-C4-aliphatic-NHSO2-C0-C4 aliphatic, and C0-C4-aliphatic-C(O)-C0-C4.
[0124] In some embodiments, Y 2 is C1-C 10 In some embodiments, Y is aliphatic. 2 is methylene, ethylene, propylene, or butylene. In some embodiments, Y 2 is -CH2-CH2-.
[0125] In some embodiments, Y 2is C-C-aliphatic-NHC(O)NH-C-C-aliphatic. In some embodiments, Y 2 is C1-C4-aliphatic-NHC(O)NH-C1-C4 aliphatic. In some embodiments, Y 2 is -CH2-CH2-NHC(O)NH-CH2-CH2-.
[0126] In some embodiments, Y 2 is C-C-aliphatic-NHC(S)NH-C-C-aliphatic. In some embodiments, Y 2 is C1-C4-aliphatic-NHC(S)NH-C1-C4 aliphatic. In some embodiments, Y 2 is -CH2-CH2-NHC(S)NH-CH2-CH2-.
[0127] In some embodiments, Y 2 is C-C-aliphatic-C(O)NH-C-C-aliphatic. In some embodiments, Y 2 is C1-C4-aliphatic-C(O)NH-C1-C4 aliphatic. In some embodiments, Y 2 is -CH2-CH2-C(O)NH-CH2-CH2-.
[0128] In some embodiments, Y 2 is C-C-aliphatic-NHC(O)-C-C-aliphatic. In some embodiments, Y 2 is C1-C4-aliphatic-NHC(O)-C1-C4 aliphatic. In some embodiments, Y 2 is -CH2-CH2-NHC(O)-CH2-CH2-.
[0129] In some embodiments, Y 2 is C-C-aliphatic-NHSO-C-C-aliphatic. In some embodiments, Y 2 is C1-C4-aliphatic-NHSO2-C1-C4 aliphatic. In some embodiments, Y 2 is -CH2-CH2-NHSO2-CH2-CH2-.
[0130] Generally, as described herein, each Cy independently represents an optionally substituted C3-C 14 It is a cyclic aliphatic ring, a 5- to 14-membered heterocyclyl ring having 1 to 3 heteroatoms selected from N, O, and S, and a 5- to 14-membered heteroaryl ring having 1 to 3 heteroatoms selected from N, O, and S.
[0131] In some embodiments, the moiety X 1 -Y 1 -Z 1 teeth, [ka] is.
[0132] In some embodiments, the moiety X 2 -Y 2 -Z 2 teeth, [ka] is.
[0133] Generally, as described herein, Z 1 and Z 2 each independently represents an optionally substituted 5- to 14-membered heterocyclyl ring having 1 to 3 heteroatoms selected from N, O, and S; a 5- to 14-membered heteroaryl ring having 1 to 3 heteroatoms selected from N, O, and S; -N + (M)3, [ka] is a cationic or ionizable group selected from:
[0134] In some embodiments, Z 1 and Z 2each independently represents an optionally substituted 5- to 14-membered heterocyclyl ring having 1 to 3 heteroatoms selected from N, O, and S; an optionally substituted 5- to 14-membered heteroaryl ring having 1 to 3 heteroatoms selected from N, O, and S; -N + (M)3, [ka] is a cationic or ionizable group selected from:
[0135] In some embodiments, Z 1 and Z 2 are each an optionally substituted 5-14 membered heterocyclyl ring having 1-3 heteroatoms selected from N, O, and S. In some embodiments, Z 1 and Z 2 are each an optionally substituted 5-6 membered heterocyclyl ring having 1-3 heteroatoms selected from N, O, and S. In some embodiments, Z 1 and Z 2 are each an optionally substituted 6-membered heterocyclyl ring having 1 to 3 heteroatoms selected from N, O, and S. In some embodiments, Z 1 and Z 2 are each selected from optionally substituted piperidinyl, piperazinyl, and morpholinyl.
[0136] In some embodiments, Z 1 and Z 2 are each an optionally substituted 5-14 membered heteroaryl ring having 1-3 heteroatoms selected from N, O, and S.
[0137] In some embodiments, Z 1 and Z 2 are each independently [ka] is selected from.
[0138] In some embodiments, Z1 and Z 2 are each independently [ka] is selected from.
[0139] In some embodiments, Z 1 and Z 2 are respectively: [ka]
[0140] In some embodiments, Z 1 and Z 2 are respectively -N + (M)3. In some embodiments, Z 1 and Z 2 are respectively -N + (C0-C6 aliphatic-R z )3. In some embodiments, Z 1 and Z 2 are respectively -N + (R z )3. In some embodiments, Z 1 and Z 2 are respectively -N + H3. In some embodiments, Z 1 and Z 2 are respectively -N + H(R z )2. In some embodiments, Z 1 and Z 2 are respectively -N + H(C1-C6 aliphatic)2. In some embodiments, Z 1 and Z 2 are respectively -N + (H)2CH3. In some embodiments, Z 1 and Z 2 are respectively -N + H(CH3)2. In some embodiments, Z 1 and Z 2 are respectively -N +(CH3)3.
[0141] In some embodiments, Z 1 and Z 2 are respectively -N + (R z )2-C1-C6 aliphatic-N + (R z )3. In some embodiments, Z 1 and Z 2 are respectively -N + (R z )(C1-C6 aliphatic-N + (R z ) 3) 2. In some embodiments, Z 1 and Z 2 are respectively: [ka]
[0142] In some embodiments, Z 1 and Z 2 are respectively: [ka]
[0143] In some embodiments, Z 1 and Z 2 are, respectively, [ka] is.
[0144] In some embodiments, Z 1 and Z 2 are, respectively, [ka] is.
[0145] In some embodiments, Z 1 and Z 2 are, respectively, [ka] is.
[0146] In some embodiments, Z 1 and Z 2 are, respectively, [ka] is.
[0147] In some embodiments, Z 1 is an optionally substituted 5-14 membered heterocyclyl ring having 1-3 heteroatoms selected from N, O, and S. In some embodiments, Z 1 are each an optionally substituted 5-6 membered heterocyclyl ring having 1-3 heteroatoms selected from N, O, and S. In some embodiments, Z 1 is an optionally substituted 6-membered heterocyclyl ring having 1 to 3 heteroatoms selected from N, O, and S. In some embodiments, Z 1 is selected from optionally substituted piperidinyl, piperazinyl, and morpholinyl.
[0148] In some embodiments, Z 1 -N + (M)3. In some embodiments, Z 1 -N + (C0-C6 aliphatic-R z )3. In some embodiments, Z 1 -N + (R z )3. In some embodiments, Z 1 -N + H3. In some embodiments, Z 1 -N + H(R z )2. In some embodiments, Z 1 -N + H(C1-C6 aliphatic)2. In some embodiments, Z 1 -N+ (H)2CH3. In some embodiments, Z 1 -N + H(CH3)2. In some embodiments, Z 1 -N + (CH3)3.
[0149] In some embodiments, Z 1 -N + (R z )2-C1-C6 aliphatic-N + (R z )3. In some embodiments, Z 1 -N + (R z )(C1-C6 aliphatic-N + (R z ) 3) 2. In some embodiments, Z 1 is: [ka]
[0150] In some embodiments, Z 1 is: [ka]
[0151] In some embodiments, Z 1 is: [ka]
[0152] In some embodiments, Z 1 is: [ka]
[0153] In some embodiments, Z 1 is [ka]
[0154] In some embodiments, Z 1 is as follows: [ka]
[0155] In some embodiments, Z 2 is an optionally substituted 5-14 membered heterocyclyl ring having 1-3 heteroatoms selected from N, O, and S. In some embodiments, Z 2 are each an optionally substituted 5-6 membered heterocyclyl ring having 1-3 heteroatoms selected from N, O, and S. In some embodiments, Z 2 is an optionally substituted 6-membered heterocyclyl ring having 1 to 3 heteroatoms selected from N, O, and S. In some embodiments, Z 2 is selected from optionally substituted piperidinyl, piperazinyl, and morpholinyl.
[0156] In some embodiments, Z 2 -N + (M)3. In some embodiments, Z 2 -N + (C0-C6 aliphatic-R z )3. In some embodiments, Z 2 -N + (R z )3. In some embodiments, Z 2 -N + H3. In some embodiments, Z 2 -N + H(R z )2. In some embodiments, Z 2 -N + H(C1-C6 aliphatic)2. In some embodiments, Z 2 -N + (H)2CH3. In some embodiments, Z2 -N + H(CH3)2. In some embodiments, Z 2 -N + (CH3)3.
[0157] In some embodiments, Z 2 -N + (R z )2-C1-C6 aliphatic-N + (R z )3. In some embodiments, Z 2 -N + (R z )(C1-C6 aliphatic-N + (R z ) 3) 2. In some embodiments, Z 2 is: [ka]
[0158] In some embodiments, Z 2 is: [ka]
[0159] In some embodiments, Z 2 is: [ka]
[0160] In some embodiments, Z 2 is: [ka]
[0161] In some embodiments, Z 2 is [ka]
[0162] In some embodiments, Z 2 is as follows: [ka]
[0163] Generally, as described herein, each M is independently —C-C aliphatic —R z , or -C0-C6 aliphatic -N + (R z In some embodiments, each M is a C-C aliphatic -R z In some embodiments, each M is -C0-C6 aliphatic-N + (R z )3.
[0164] Generally, as described herein, each R z are independently H, optionally substituted C1-C6 aliphatic, optionally substituted C3-C 20 or two or more R selected from cycloaliphatic, optionally substituted C5-C6 aryl, optionally substituted 3- to 12-membered heterocyclyl containing 1 to 3 heteroatoms selected from N, O, and S, and optionally substituted 4- to 12-membered heteroaryl containing 1 to 3 heteroatoms selected from N, O, and S; z can be taken together with the atoms to which they are attached to form an optionally substituted 3- to 12-membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, or an optionally substituted 4- to 12-membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S.
[0165] In some embodiments, each R z is H. In some embodiments, each R z is an optionally substituted C-C aliphatic. In some embodiments, each R z is an optionally substituted C3-C 20In some embodiments, each R z is an optionally substituted C-C aryl. In some embodiments, each R z is an optionally substituted 3-12 membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S. In some embodiments, each R z is an optionally substituted 4-12 membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S.
[0166] In some embodiments, two or more R z can be taken together with the atoms to which they are attached to form an optionally substituted 3- to 12-membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S. In some embodiments, two or more R z can be taken together with the atom to which they are attached to form an optionally substituted 4-12 membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S.
[0167] In some embodiments, Z 1 R on the part z and Z 2 R on the part z can be taken together to form a 4- to 6-membered heterocycle having 1 to 3 heteroatoms selected from N, O, and S.
[0168] As used herein, a "cationic" moiety is a group that has a net positive charge. As used herein, an "ionizable" moiety is a group that may have a neutral charge at a particular pH, but may become charged (e.g., cationic) at a different pH. For example, in some embodiments, the ionizable moiety becomes cationic (i.e., positively charged) at physiological pH (e.g., a pH of about 7.4). Furthermore, in some embodiments, a cationic or ionizable moiety, Z, as described herein, 1 and Z 2 The moiety further comprises a counterion (e.g., an anion for each cationic or ionizable moiety). For example, in some embodiments, Z1 and Z 2 The moiety comprises a counterion that is a halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, alkyl having 1 to 6 carbon atoms, sulfonate, and arylsulfonate. 1 and Z 2 The part is acetate (CH3COO - ), chloride (Cl - ), iodide (I - ), bromide (Br - ), or Frodo (F - ) counterion.
[0169] In some embodiments, Z 1 and Z 2 are each independently [ka] [ka] is selected from.
[0170] In some embodiments, the compound of formula I is a compound of formula Id: [ka] or a pharmaceutically acceptable salt thereof, wherein n and m are each independently selected from 0, 1, 2, 3, 4, 5, or 6; a , Y 1 , Y 2 , Z 1 , and Z 2 are as described in classes and subclasses herein, both alone and in combination.
[0171] In some embodiments, the compound of formula Id is a compound of formula Id-i: [ka] or a pharmaceutically acceptable salt thereof, wherein n and m are each independently selected from 0, 1, 2, 3, 4, 5, or 6; a , Z 1 , and Z 2 are as described in classes and subclasses herein, both alone and in combination.
[0172] In some embodiments, the compound of formula I is selected from Table 1. [Table 1-1] [Table 1-2] [Table 1-3] [Table 1-4] [Table 1-5] [Table 1-6] [Table 1-7] [Table 1-8] [Table 1-9] [Table 1-10] [Table 1-11] [Table 1-12] [Table 1-13] Table 1-14 Table 1-15 Table 1-16 Table 1-17 Table 1-18 Table 1-19 Table 1-20 Table 1-21 Table 1-22 Table 1-23 Table 1-24 Table 1-25 Table 1-26 Table 1-27 Table 1-28 Table 1-29 Table 1-30 Table 1-31 Table 1-32 Table 1-33 Table 1-34 Table 1-35 Table 1-36 Table 1-37 Table 1-38 Table 1-39 Table 1-40 Table 1-41 Table 1-42 Table 1-43 Table 1-44 Table 1-45 Table 1-46 Table 1-47 Table 1-48 Table 1-49 Table 1-50 Table 1-51 Table 1-52 Table 1-53 Table 1-54 Table 1-55 Table 1-56 Table 1-57 Table 1-58 Table 1-59 Table 1-60 Table 1-61 Table 1-62 Table 1-63 Table 1-64 Table 1-65 Table 1-66 Table 1-67 Table 1-68
Table 1-69
[0173] In some embodiments, provided compounds are provided and / or utilized in the form of a salt (e.g., a pharmaceutically acceptable salt). Reference to a compound provided herein is understood to include a reference to the salt, unless otherwise indicated. Furthermore, reference to a particular salt herein, for example, in Table 1, is also intended to include a reference to the free base form of the compound.
[0174] The exemplary compounds in Table 1 may contain a counterion (e.g., Cl - , I - Although the present invention is presented as specific salts (e.g., chloride salts, iodide salts, etc.) including cationic nitrogen groups (e.g., chloride salts, iodide salts, etc.), one of skill in the art will understand that any suitable counterion can be used in combination with the cationic nitrogen groups of Table 1. Thus, Table 1 is intended to encompass any positively charged nitrogen group associated with any chemically feasible counterion. Thus, the specific counterions provided above are provided by way of example and are not intended to be limiting.
[0175] In some embodiments, the compound of Formula I is selected from Table 2: [Table 2-1] [Table 2-2] [Table 2-3] [Table 2-4] [Table 2-5] [Table 2-6] [Table 2-7] [Table 2-8] Table 2-9 Table 2-10 Table 2-11 Table 2-12 Table 2-13 Table 2-14 Table 2-15 Table 2-16 Table 2-17 Table 2-18 Table 2-19 Table 2-20 Table 2-21 Table 2-22 Table 2-23 Table 2-24
[0176] In some embodiments, provided compounds are provided and / or utilized in the form of a salt (e.g., a pharmaceutically acceptable salt). Reference to a compound provided herein is understood to include a reference to the salt, unless otherwise indicated. Furthermore, reference to a particular salt herein, for example, in Table 2, is also intended to include a reference to the free base form of the compound.
[0177] The exemplary compounds in Table 2 contain a counterion (e.g., Cl - , I - Although the present invention is presented as specific salts (e.g., chloride salts, iodide salts, etc.) including cationic nitrogen groups (e.g., chloride salts, iodide salts, etc.), one of skill in the art will understand that any suitable counterion can be used in combination with the cationic nitrogen groups of Table 2. Thus, Table 2 is intended to encompass any positively charged nitrogen group associated with any chemically feasible counterion. Thus, the specific counterions provided above are provided by way of example and are not intended to be limiting.
[0178] The polycationic oligosaccharide conjugates described herein can be prepared according to methods known to those skilled in the art. For example, the provided oligosaccharide conjugates can be prepared according to the methods provided in EP21382958.3, the entire contents of which are incorporated herein by reference.
[0179] In some embodiments, the present disclosure provides a conjugate comprising a compound selected from: [Table 3]
[0180] In some embodiments, the complexes described herein do not include JRL13 or JRL45.
[0181] surfactants In some embodiments, the complexes described herein further comprise a surfactant. In some embodiments, the surfactant is selected from compounds comprising an amphiphilic moiety selected from polysorbates (e.g., polysorbate 20 (Tween 20), polysorbate 40 (Tween 40), polysorbate 60 (Tween 60), and polysorbate 80 (Tween 80)), poloxamers, and / or polyalkylene glycols (e.g., polyethylene glycol), poly(2-oxazoline), poly(2-oxazine), polysarcosine, polyvinylpyrrolidone, and poly[N-(2-hydroxypropyl)methacrylamide], wherein the amphiphilic moiety comprises one or more C 12 -C 20 It is bonded to an aliphatic group.
[0182] In some embodiments, the surfactant is a polysorbate. In some embodiments, the polysorbate is polysorbate 20 (Tween 20), polysorbate 40 (Tween 40), polysorbate 60 (Tween 60), or polysorbate 80 (Tween 80). In some embodiments, the polysorbate is polysorbate 20. In some embodiments, the polysorbate is polysorbate 40. In some embodiments, the polysorbate is polysorbate 60. In some embodiments, the polysorbate is polysorbate 80.
[0183] In some embodiments, the molar ratio of oligosaccharide to surfactant is about 1:0.0075 to about 1:3. In some embodiments, the molar ratio of oligosaccharide to surfactant is about 1:0.0075 to about 1:1.5. In some embodiments, the molar ratio of oligosaccharide to surfactant is about 1:1. In some embodiments, the molar ratio of oligosaccharide to surfactant is about 1:0.0075, about 1:0.01, about 1:0.1, about 1:0.5, about 1:1, about 1:1.5, about 1:2, about 1:2.5, or about 1:3.
[0184] In some embodiments, the surfactant is a polysorbate. In some embodiments, the molar ratio of oligosaccharide to polysorbate is 1:0.0075 to 1:3. In some embodiments, the surfactant is a polysorbate. In some embodiments, the molar ratio of oligosaccharide to polysorbate is 1:0.0075 to 1:1.5. In some embodiments, the surfactant is a polysorbate. In some embodiments, the molar ratio of oligosaccharide to polysorbate is 1:0.0075 to 1:1. In some embodiments, the molar ratio of oligosaccharide to polysorbate is about 1:0.0075, about 1:0.01, about 1:0.1, about 1:0.5, about 1:1, about 1:1.5, about 1:2, about 1:2.5, or about 1:3.
[0185] In some embodiments, the present disclosure provides a complex comprising: i) a cationic oligosaccharide comprising one or more cationic moieties attached to a trehalose, sucrose, or gluco-n-oligosaccharide moiety, where n is 2 to 6; ii) a surfactant; and iii) one or more additives, wherein the molar ratio of cationic oligosaccharide to surfactant is about 1:0.0075 to about 1:3. In some embodiments, the molar ratio of cationic oligosaccharide to surfactant is about 1:0.0075, about 1:0.01, about 1:0.2, about 1:0.3, about 1:0.4, about 1:0.5, about 1:0.6, about 1:0.7, about 1:0.8, about 1:0.9, or about 1:1. In some embodiments, the molar ratio of cationic oligosaccharide to surfactant is about 1:0.5 to about 1:1 (e.g., about 1:0.5, about 1:0.75, or about 1:1). In some embodiments, the molar ratio of cationic oligosaccharide to surfactant is about 1:0.5.
[0186] additives As described herein, the present invention provides conjugates further comprising one or more additives, wherein the one or more additives are selected from a sterol, a helper lipid, an immunomodulatory agent, and a targeting moiety. It is understood that the conjugates described herein comprise at least one of a sterol, a helper lipid, an immunomodulatory agent, and a targeting moiety, alone or in any combination.
[0187] In some embodiments, the complexes described herein comprise: i) a cationic oligosaccharide comprising one or more cationic moieties attached to a trehalose, sucrose, or gluco-n-oligosaccharide moiety, where n is 2-6; ii) a surfactant; and iii) one or more additives that are or comprise a sterol. In some embodiments, the complexes described herein comprise: i) a cationic oligosaccharide comprising one or more cationic moieties attached to a trehalose, sucrose, or gluco-n-oligosaccharide moiety, where n is 2-6; ii) a surfactant; and iii) one or more additives that are or comprise a helper lipid. In some embodiments, the complexes described herein comprise: i) a cationic oligosaccharide comprising one or more cationic moieties attached to a trehalose, sucrose, or gluco-n-oligosaccharide moiety, where n is 2-6; ii) a surfactant; and iii) one or more additives that are or comprise an immunomodulatory agent. In some embodiments, the complexes described herein comprise: i) a cationic oligosaccharide comprising one or more cationic moieties linked to a trehalose, sucrose, or gluco-n-oligosaccharide moiety, where n is 2-6; ii) a surfactant; and iii) one or more additives that are or include a target molecule.
[0188] In some embodiments, the complexes described herein comprise: i) a cationic oligosaccharide comprising one or more cationic moieties attached to a trehalose, sucrose, or gluco-n-oligosaccharide moiety, where n is 2 to 6; ii) a surfactant; and iii) one or more additives that are or comprise a sterol and / or a helper lipid. In some embodiments, the complexes described herein comprise: i) a cationic oligosaccharide comprising one or more cationic moieties attached to a trehalose, sucrose, or gluco-n-oligosaccharide moiety, where n is 2 to 6; ii) a surfactant; and iii) one or more additives that are or comprise a sterol and / or an immunomodulatory agent. In some embodiments, the complexes described herein comprise: i) a cationic oligosaccharide comprising one or more cationic moieties attached to a trehalose, sucrose, or gluco-n-oligosaccharide moiety, where n is 2-6; ii) a surfactant; and iii) one or more additives that are or include a sterol and / or a targeting molecule.
[0189] In some embodiments, the complexes described herein comprise: i) a cationic oligosaccharide comprising one or more cationic moieties attached to a trehalose, sucrose, or gluco-n-oligosaccharide moiety, where n is 2 to 6; ii) a surfactant; and iii) one or more additives that are or comprise a helper lipid and / or an immunomodulatory agent. In some embodiments, the complexes described herein comprise: i) a cationic oligosaccharide comprising one or more cationic moieties attached to a trehalose, sucrose, or gluco-n-oligosaccharide moiety, where n is 2 to 6; ii) a surfactant; and iii) one or more additives that are or comprise a helper lipid and / or a targeting molecule.
[0190] In some embodiments, the complexes described herein comprise: i) a cationic oligosaccharide comprising one or more cationic moieties attached to a trehalose, sucrose, or gluco-n-oligosaccharide moiety, where n is 2-6; ii) a surfactant; and iii) one or more additives that are or include an immunomodulatory agent and / or a targeting molecule.
[0191] In some embodiments, the complexes described herein comprise: i) a cationic oligosaccharide comprising one or more cationic moieties attached to a trehalose, sucrose, or gluco-n-oligosaccharide moiety, where n is 2 to 6; ii) a surfactant; and iii) one or more additives that are or comprise a sterol and / or a helper lipid and / or an immunomodulatory agent. In some embodiments, the complexes described herein comprise: i) a cationic oligosaccharide comprising one or more cationic moieties attached to a trehalose, sucrose, or gluco-n-oligosaccharide moiety, where n is 2 to 6; ii) a surfactant; and iii) one or more additives that are or comprise a sterol and / or a helper lipid and / or a targeting molecule. In some embodiments, the complexes described herein comprise: i) cationic oligosaccharides comprising one or more cationic moieties attached to a trehalose, sucrose, or gluco-n-oligosaccharide moiety, where n is 2 to 6; ii) a surfactant; and iii) one or more additives that are or comprise a helper lipid and / or an immunomodulatory agent and / or a targeting molecule. In some embodiments, the complexes described herein comprise: i) cationic oligosaccharides comprising one or more cationic moieties attached to a trehalose, sucrose, or gluco-n-oligosaccharide moiety, where n is 2 to 6; ii) a surfactant; and iii) one or more additives that are or comprise a sterol and / or a helper lipid and / or a targeting molecule. In some embodiments, the complexes described herein comprise: i) a cationic oligosaccharide comprising one or more cationic moieties attached to a trehalose, sucrose, or gluco-n-oligosaccharide moiety, where n is 2-6; ii) a surfactant; and iii) one or more additives that are or include a helper lipid and / or an immunomodulatory agent and / or a targeting molecule.
[0192] In some embodiments, the complexes described herein comprise i) a cationic oligosaccharide comprising one or more cationic moieties attached to a trehalose moiety, ii) a surfactant, and iii) one or more additives that are or comprise a sterol and / or a helper lipid and / or an immunomodulatory agent. In some embodiments, the complexes described herein comprise i) a cationic oligosaccharide comprising one or more cationic moieties attached to a sucrose moiety, ii) a surfactant, and iii) one or more additives that are or comprise a sterol and / or a helper lipid and / or an immunomodulatory agent.
[0193] sterols In some embodiments, the sterol is or comprises β-sitosterol, stigmasterol, cholesterol, cholecalciferol, ergocalciferol, calcipotriol, botulin, lupeol, ursolic acid, oleanolic acid, cycloartenol, lanosterol, or α-tocopherol. In some embodiments, the sterol is an optionally substituted C1-C 30The sterol may be or include an analog of one or more of β-sitosterol, stigmasterol, cholesterol, cholecalciferol, ergocalciferol, calcipotriol, botulin, lupeol, ursolic acid, oleanolic acid, cycloartenol, lanosterol, or α-tocopherol bound to an aliphatic moiety. In some embodiments, the sterol is β-sitosterol. In some embodiments, the sterol is stigmasterol. In some embodiments, the sterol is cholesterol. In some embodiments, the sterol is cholecalciferol. In some embodiments, the sterol is ergocalciferol. In some embodiments, the sterol is calcipotriol. In some embodiments, the sterol is botulin. In some embodiments, the sterol is lupeol. In some embodiments, the sterol is ursolic acid. In some embodiments, the sterol is oleanolic acid. In some embodiments, the sterol is cycloartenol. In some embodiments, the sterol is lanosterol. In some embodiments, the sterol is α-tocopherol.
[0194] In some embodiments, the molar ratio of cationic oligosaccharide to sterol is about 1:0.25 to about 1:1. In some embodiments, the molar ratio of cationic oligosaccharide to sterol is about 1:0.25, about 1:0.5, or about 1:1. In some embodiments, the molar ratio of cationic oligosaccharide to sterol is about 1:0.5.
[0195] Helper lipids In some embodiments, the helper lipid is selected from the group consisting of phosphatidylcholine, phosphatidylethanolamine, phosphatidylglycerol, phosphatidic acid, phosphatidylserine, and sphingomyelin, more preferably distearoylphosphatidylcholine (DSPC), dioleoylphosphatidylcholine (DOPC), dimyristoylphosphatidylcholine (DMPC), dipentadecanoylphosphatidylcholine, dilauroylphosphatidylcholine, dipalmitoylphosphatidylcholine (DPPC), diarauroylphosphatidylcholine (DAP ... Dibenzoylphosphatidylcholine (DAPC), dibehenoylphosphatidylcholine (DBPC), ditricosanoylphosphatidylcholine (DTPC), dilignoceroylphosphatidylcholine (DLPC), palmitoyloleoylphosphatidylcholine (POPC), 1,2-di-O-octadecenyl-sn-glycero-3-phosphocholine (18:0 diether PC), 1-oleoyl-2-cholesterylhemisuccinoyl-sn-glycero-3-phosphocholine (OChemsPC), 1-hexadecyl-sn-glycero-3-phosphocholine (C16 Lyso PC), dioleoylphosphatidylethanolamine (DOPE), distearoyl-phosphatidylethanolamine (DSPE), dipalmitoyl-phosphatidylethanolamine (DPPE), dimyristoyl-phosphatidylethanolamine (DMPE), dilauroyl-phosphatidylethanolamine (DLPE), diphytanoyl-phosphatidylethanolamine (DPyPE), and combinations thereof.
[0196] In some embodiments, the helper lipid is DSPC and / or DMPC. In some embodiments, the helper lipid is DSPC. In some embodiments, the helper lipid is DMPC.
[0197] In some embodiments, the molar ratio of cationic oligosaccharide to helper lipid is about 1:0.25 to about 1:1. In some embodiments, the molar ratio of cationic oligosaccharide to helper lipid is about 1:0.25, about 1:0.5, or about 1:1. In some embodiments, the molar ratio of cationic oligosaccharide to helper lipid is about 1:0.5.
[0198] In some embodiments, the complexes described herein comprise a cationic oligosaccharide, a surfactant, a sterol, and a helper lipid, wherein the molar ratio of cationic oligosaccharide to sterol to helper lipid (i.e., cationic oligosaccharide:sterol:helper lipid) is about 1:0.25:0.25 to about 1:1:1. In some embodiments, the molar ratio of cationic oligosaccharide to sterol to helper lipid is about 1:0.5:0.5 to about 1:1:1. In some embodiments, the molar ratio of cationic oligosaccharide to sterol to helper lipid is about 1:0.25:025, about 1:0.5:0.25, about 1:0.75:0.25, about 1:1:0.25, about 1:0.25:0.5, about 1:0.25:0.75, about 1:0.25:1, about 1:0.5:0.5, about 1:0.75:0.5, about 1:1:0.5, about 1:0.5:0.75, about 1:0.5:1, about 1:0.75:0.75, about 1:1:0.75, about 1:0.75:1, or about 1:1:1. In some embodiments, the molar ratio of cationic oligosaccharide to sterol to helper lipid is about 1:0.5:0.5.
[0199] In some embodiments, the molar ratio of cationic oligosaccharide to surfactant to sterol to helper lipid is about 1:0.25:0.25:0.25 to about 1:1:1:1. In some embodiments, the molar ratio of cationic oligosaccharide to surfactant to sterol to helper lipid is approximately as follows: [Table 4]
[0200] In some embodiments, the molar ratio of cationic oligosaccharide to surfactant to sterol to helper lipid is about 1:0.5:0.5:0.5.
[0201] immunomodulators As described herein, the conjugates of the present disclosure include an immunomodulatory agent. In some embodiments, the immunomodulatory agent-containing conjugates deliver cargo to a patient target (e.g., a tissue or cell) without eliciting an inflammatory response, as seen with other delivery systems, such as lipid nanoparticles. The present disclosure encompasses, among other things, the insight that immunomodulatory agent-containing conjugates inhibit immune responses commonly seen, for example, in the delivery of nucleic acid therapeutics. Such immune responses are often associated with adverse effects, such as pain, fever, and swelling, and can inhibit or otherwise attenuate the therapeutic efficacy of the nucleic acid therapy. Advantages of immunomodulatory agent-containing conjugates are described in Examples 8, 9, and 10.
[0202] In some embodiments, the immunomodulatory agent is an immunosuppressant. In some embodiments, the immunomodulatory agent is an immunostimulatory agent. In some embodiments, the immunomodulatory factor is an agent (e.g., a small molecule) that is an agonist or antagonist of a toll-like receptor (e.g., TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, TLR10) or a pattern recognition receptor (PRR). In some embodiments, the immunomodulatory agent is a sp 2 In some embodiments, the immunomodulatory agent is: [Table 5-1] [Table 5-2] [Table 5-3] [Table 5-4] [Table 5-5] [Table 5-6] or a pharmaceutically acceptable salt thereof.
[0203] In some embodiments, the immunomodulatory agent is a small molecule downstream inhibitor of NF-κB. In some embodiments, the immunomodulatory agent is a sp 2 -iminoglycolipid.
[0204] In some embodiments, the immunomodulatory agent is a TLR inhibitor. In some embodiments, the TLR inhibitor is an inhibitor of TLR2, TLR4, and / or TLR6. In some embodiments, the TLR inhibitor is an inhibitor of TLR2. In some embodiments, the immunomodulatory agent is an inhibitor of TLR4. In some embodiments, the immunomodulatory agent is an inhibitor of TLR6. In some embodiments, the inhibitor of TLR4 is TAK-242: [ka] or a pharmaceutically acceptable salt thereof. In some embodiments, the inhibitor of TLR2 is TLC-C29: [ka] or a pharmaceutically acceptable salt thereof.
[0205] In some embodiments, the immunomodulatory agent is a terpenoid. In some embodiments, the terpenoid is a triterpene. In some embodiments, the terpenoid is a triterpenoid. In some embodiments, the triterpenoid is a synthetic or natural derivative of amylin, betulinic acid, oleanolic acid, sterol, squalene, or ursolic acid.
[0206] In some embodiments, the immunomodulatory agent is a sterol, squalene, oleanolic acid, ursolic acid, betulinic acid, or amylin.
[0207] In some embodiments, the immunomodulatory agent is a corticosteroid. In some embodiments, the corticosteroid is a glucocorticoid. In some embodiments, the glucocorticoid is selected from dexamethasone, prednisolone, fluticasone propionate, budesonide, or a pharmaceutically acceptable salt thereof. In some embodiments, the glucocorticoid is dexamethasone or a pharmaceutically acceptable salt thereof. In some embodiments, the glucocorticoid is prednisolone or a pharmaceutically acceptable salt thereof. In some embodiments, the glucocorticoid is fluticasone or a pharmaceutically acceptable salt thereof. In some embodiments, the glucocorticoid is propionate or a pharmaceutically acceptable salt thereof. In some embodiments, the glucocorticoid is budesonide or a pharmaceutically acceptable salt thereof.
[0208] In some embodiments, the conjugates described herein comprise more than one immunomodulatory agent. In some embodiments, the conjugates comprise an immunomodulatory agent and one or more additional immunomodulatory agents. In some embodiments, the conjugates comprise a terpenoid (e.g., a corticosteroid or glucocorticoid, e.g., dexamethasone, prednisolone, fluticasone propionate, or budesonide) and one or more additional immunomodulatory agents (e.g., another corticosteroid or glucocorticoid, e.g., dexamethasone, prednisolone, fluticasone propionate, or budesonide, or a TLR or PRR agonist or antagonist described herein). In some embodiments, the conjugates comprise an immunomodulatory agent that is a terpenoid (including any of the subclasses described herein) and a small molecule agonist or antagonist of a TLR or PRR (e.g., including any of the subclasses described herein, such as TAK-242).
[0209] In some embodiments, the molar ratio of cationic oligosaccharide to immunomodulatory agent is about 1:0.05 to about 1:1. In some embodiments, the molar ratio of cationic oligosaccharide to immunomodulatory agent is about 1:0.05 to about 1:0.5. In some embodiments, the molar ratio of cationic oligosaccharide to immunomodulatory agent is about 1:0.05, about 1:0.1, about 1:0.2, about 1:0.3, about 1:0.4, about 1:0.5, about 1:0.6, about 1:0.7, about 1:0.8, about 1:0.9, or about 1:1.
[0210] target molecule In some embodiments, the targeting molecule is an agent that has strong binding affinity for a specific cell marker on the target cell, thereby enhancing targeting and internalization of the complex and / or cargo. In some embodiments, the targeting molecule is or includes one or more of a small molecule, peptide, aptamer, or other nucleic acid sequence, or nanobody. In some embodiments, the small molecule targeting molecule is folic acid, phenylboronic acid, alendronate, telmisartan, glycyrrhetinic acid, adenosine, a vitamin, or a carbohydrate. In some embodiments, the vitamin is vitamin H (biotin) or vitamin B (flavin) mononucleotide. In some embodiments, the carbohydrate is a monosaccharide selected from glucose, mannose, galactose, fucose, sialic acid, mannose-6-phosphate, and lactobionic acid, or an oligosaccharide comprising one or more monosaccharides described herein. In some embodiments, the peptide is a cysteine-arginine-glutamic acid-lysine-alanine (CREKA) peptide, a K237 peptide, an F3 peptide, an A54 peptide, apamin, a hexapeptide ligand AE, an epidermal growth factor, an octreotide, an RGD (Arg-Gly-Asp) motif, an iRGD, an RGDF peptide, a cRGD, a U11 peptide, an HIV transactivating transcription factor (TAT) peptide, a Lyp-1 peptide, a rabies virus glycoprotein (RVG), a chlorotoxin (ClTx), an Aβ binding peptide (KLVFF), a TGNYKALHPHNG (TGN), a QSHYRHISPAQV (QSH), a Tet-1 peptide, a T7 peptide, an apolipoprotein, an E peptide (ApoE), a peptide motif B6, angiopep-2, a cell penetrating peptide (CPP), or a ferritin. In some embodiments, the aptamer is the nucleotide-targeting ADN aptamer AS1411, an anti-epidermal growth factor receptor aptamer, a mucin-1 aptamer, a prostate-specific membrane antigen (PSMA) aptamer A9g, or a PSMA A10. In some embodiments, the nanobody is an anti-HER2 nanobody 2Rb17c or an EGa1 nanobody.In some embodiments, the targeting molecule is a multivalent dendron moiety that contains several identical or different targeting motifs.
[0211] N / P ratio and complex size The complexes reported herein exhibit an improved ratio of cationic moieties, or ionizable cationic groups (on the oligosaccharide) to anionic moieties (on the nucleic acid). For example, as described herein, the complexes comprise a ratio of cationic groups to anionic groups, referred to as the "N / P ratio." As described herein, the N / P ratio refers to the molar ratio of cationic groups (or ionizable groups that can become cationic, referred to as the "N" in N / P) in a composition comprising a cationic oligosaccharide compound to anionic groups in a composition comprising mRNA (referred to as the "P" in N / P). The compositions reported herein exhibit a favorable ratio compared to previously reported complexes with DNA, thereby providing concentrated complexes for RNA delivery. For example, Carbajo-Gordillo's complex requires an N / P ratio of approximately 20:1 for effective targeting and delivery of pDNA. In contrast, the complexes of the present invention comprise an N / P ratio of less than 20:1. It is understood that the N / P ratio may also be expressed as a single digit, e.g., 5, and the numerical value set forth herein is referred to as a ratio of X:1. For example, an N / P of 5 is intended to refer to an N / P of 5:1. Similarly, an N / P of 10 is intended to refer to an N / P of 10:1, etc.
[0212] For example, in some embodiments, the N / P ratios of the complexes reported herein are less than 20:1. In some embodiments, the N / P ratios of the complexes reported herein are 15:1 or less. In some embodiments, the N / P ratios of the complexes reported herein are 12:1 or less. In some embodiments, the N / P ratios of the complexes reported herein are 10:1 or less. In some embodiments, the N / P ratios of the complexes reported herein are 5:1 or less. In some embodiments, the N / P ratios of the complexes reported herein are 2:1 or less. In some embodiments, the N / P ratios of the complexes reported herein are 1:1 or less. In some embodiments, the N / P ratios of the complexes reported herein are from about 1:1 to about 15:1. In some embodiments, the N / P ratios of the complexes reported herein are from about 1:1 to about 12:1. In some embodiments, the N / P ratios of the complexes reported herein are from about 1:1 to about 10:1. In some embodiments, the N / P ratio of the complexes reported herein is about 1:1, about 2:1, about 3:1, about 4:1, about 5:1, about 6:1, about 7:1, about 8:1, about 9:1, about 10:1, about 11:1, about 12:1, about 13:1, about 14:1, about 15:1, about 16:1, about 17:1, about 18:1, or about 19:1.
[0213] In some embodiments, the complexes described herein have a diameter of about 30 nm to about 300 nm. In some embodiments, the complexes described herein have a diameter of about 50 nm to about 200 nm. In some embodiments, the complexes described herein have a diameter of about 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, or 200 nm. In some embodiments, the complexes described herein have a diameter of about 30 nm to about 150 nm. In some embodiments, the complexes described herein have a diameter of about 30 nm to about 100 nm. In some embodiments, the complexes described herein have a diameter of less than 100 nm. In some embodiments, the complexes described herein have a diameter of about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 nm.
[0214] In some embodiments, a complex comprising an oligosaccharide and a pharmaceutically acceptable surfactant has a diameter of about 30 nm to about 150 nm. In some embodiments, a complex described herein has a diameter of about 30 nm to about 100 nm. In some embodiments, a complex comprising an oligosaccharide and a pharmaceutically acceptable surfactant has a diameter of less than 100 nm. In some embodiments, a complex comprising an oligosaccharide and a pharmaceutically acceptable surfactant has a diameter of about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 nm.
[0215] cargo In some embodiments, the conjugates described herein further comprise a cargo. In some embodiments, the cargo is a therapeutic agent, e.g., a small molecule, a peptide, a nucleic acid, or a combination thereof. In some embodiments, the cargo is a small molecule. In some embodiments, the cargo is a peptide. In some embodiments, the cargo is a nucleic acid.
[0216] nucleic acid In some embodiments, the complexes described herein comprise a nucleic acid. In some embodiments, the nucleic acid is RNA.
[0217] In some embodiments, the RNA applicable to the techniques described herein is single-stranded RNA. In some embodiments, the RNA disclosed herein is linear RNA. In some embodiments, the single-stranded RNA is non-coding RNA in that its nucleotide sequence does not contain an open reading frame (or its complementary strand). In some embodiments, the single-stranded RNA has a nucleotide sequence that encodes (or is the complementary strand of) a polypeptide or multiple polypeptides (e.g., epitopes) of the present disclosure.
[0218] In some embodiments, the RNA is or comprises siRNA, miRNA, or other non-coding RNA.
[0219] In many embodiments, the related RNAs comprise at least one open reading frame (ORF) (e.g., are mRNAs), in some embodiments, the related RNAs comprise a single ORF, and in some embodiments, the related RNAs comprise more than one ORF.
[0220] In some embodiments, the RNA comprises, for example, an ORF encoding a polypeptide of interest, or encoding multiple polypeptides of interest. In some embodiments, the RNA produced in accordance with the techniques provided herein comprises multiple ORFs (e.g., encoding multiple polypeptides). In some embodiments, the RNA produced in accordance with the techniques provided herein comprises a single ORF encoding multiple polypeptides. In some such embodiments, the polypeptide is or comprises an antigen or epitope (e.g., an associated antigen) thereof.
[0221] In some embodiments, an ORF for use in accordance with the present disclosure encodes a polypeptide that includes a signal sequence that is functional in mammalian cells, e.g., an endogenous signal sequence or a heterologous signal sequence. In some embodiments, the signal sequence directs secretion of the encoded polypeptide, and in some embodiments, the signal sequence directs transport of the encoded polypeptide to a defined cellular compartment, preferably the cell surface, the endoplasmic reticulum (ER), or an endosomal-lysosomal compartment.
[0222] In some embodiments, the ORF encodes a polypeptide that includes a multimerization element (e.g., a native or heterologous multimerization element). In some embodiments, an ORF that encodes a surface polypeptide (e.g., includes a signal sequence that directs surface localization) includes a multimerization element.
[0223] In some embodiments, the ORF encodes a polypeptide that includes a transmembrane element or domain.
[0224] In some embodiments, the ORF is codon-optimized for expression in a particular host, eg, a mammalian host, eg, a human cell.
[0225] In some embodiments, the RNA comprises unmodified uridine residues, and RNA comprising only unmodified uridine residues may be referred to as "uRNA." In some embodiments, the RNA comprises one or more modified uridine residues, and in some embodiments, such RNA (e.g., RNA comprising fully modified uridine residues) is referred to as "modRNA." In some embodiments, the RNA may be a self-amplifying RNA (saRNA). In some embodiments, the RNA may be a trans-amplifying RNA (taRNA) (see, e.g., WO2017 / 162461).
[0226] In some embodiments, the relevant RNA comprises a portion encoding a polypeptide or a portion encoding multiple polypeptides. In certain embodiments, such a portion or portions may encode a polypeptide or polypeptides that is or includes a biologically active polypeptide or portion thereof (e.g., an enzyme or cytokine, or a therapeutic protein such as a replacement protein or antibody or portion thereof). In certain embodiments, such a portion or portions may encode a polypeptide or polypeptides that is or includes an antigen (or epitope thereof), cytokine, enzyme, etc. In some embodiments, the encoded polypeptide or polypeptides may be or include one or more neoantigens or neoepitopes associated with a tumor. In some embodiments, the encoded polypeptide or polypeptides may be or include one or more antigens (or epitopes thereof) of an infectious agent (e.g., a bacterium, fungus, virus, etc.). In certain embodiments, the encoded polypeptide may be a variant of a wild-type polypeptide.
[0227] In some embodiments, the single-stranded RNA (e.g., mRNA) may include a region encoding a secretion signal (e.g., a region encoding a secretion signal that enables the encoded target entity or entities to be secreted upon translation by the cell). In some embodiments, such a region encoding a secretion signal may be or include a non-human secretion signal. In some embodiments, such a region encoding a secretion signal may be or include a human secretion signal.
[0228] In some embodiments, a single-stranded RNA (e.g., an mRNA) can include at least one non-coding element (e.g., to improve RNA stability and / or translation efficiency). Examples of non-coding elements include, but are not limited to, a 3' untranslated region (UTR), a 5' UTR, a cap structure (e.g., in some embodiments, an enzymatically added cap; in some embodiments, a co-transcriptional cap), a polyadenine (polyA) tail (e.g., in some embodiments, can be or include 100 or more A residues, and / or in some embodiments can include one or more "interrupt" [i.e., non-A] sequence elements), and any combination thereof. Exemplary embodiments of such non-coding elements can be found, for example, in WO2011015347, WO2017053297, US10519189, US10494399, WO2007024708, WO2007036366, WO2017060314, WO2016005324, WO2005038030, WO2017036889, WO2017162266, and WO2017162461, each of which is incorporated herein by reference in its entirety.
[0229] At least four formats useful for RNA pharmaceutical compositions (e.g., immunogenic compositions or vaccines) have been developed: unmodified uridine containing mRNA (uRNA), nucleoside-depleted mRNA (modRNA), self-amplifying mRNA (saRNA), and trans-amplifying RNA.
[0230] Characteristics of the unmodified uridine platform may include, for example, one or more of inherent adjuvant effect, good tolerability and safety, and potent antibody and T cell responses.
[0231] The characteristics of the modified uridine (e.g., pseudouridine) platform may include reduced adjuvant effect, blunted immune sensor activation capacity, and thus increased antigen expression, good tolerability and safety, and strong antibody and CD4+ T cell responses. As described herein, the present disclosure provides insight that such strong antibody and CD4+ T cell responses may be particularly useful for vaccination.
[0232] Characteristics of a self-amplifying platform may include, for example, long-term polypeptide (eg, protein) expression, good tolerability and safety, and high potential for efficacy at very low vaccine doses.
[0233] In some embodiments, a self-amplifying platform (e.g., RNA) comprises two nucleic acid molecules, one nucleic acid molecule encoding a replicase (e.g., a viral replicase) and another nucleic acid molecule capable of being replicated by the replicase in trans (a trans-replication system) (e.g., a repcon). In some embodiments, a self-amplifying platform (e.g., RNA) comprises multiple nucleic acid molecules, the nucleic acids encoding multiple replicases and / or replicas.
[0234] In some embodiments, the trans-replication system comprises the presence of both nucleic acid molecules within a single host cell.
[0235] In some such embodiments, the nucleic acid encoding the replicase (e.g., a viral replicase) is unable to autonomously replicate in a target cell and / or target organism, hi some such embodiments, the nucleic acid encoding the replicase (e.g., a viral replicase) lacks at least one conserved sequence element important for (+)-strand template-based (-)-strand synthesis and / or (+)-strand template-based (-)-strand synthesis.
[0236] In some embodiments, the self-amplifying RNA comprises a 5'-cap, and in some trans-replication systems, at least the RNA encoding the replicase is capped. Without wishing to be bound by any one theory, it has been found that the 5'-cap can be important for high-level expression of the gene of interest in trans.
[0237] In some embodiments, the self-amplifying platform does not require viral particle propagation (e.g., is not associated with undesired viral particle formation), hi some embodiments, the self-amplifying platform is incapable of forming viral particles.
[0238] In some embodiments, the RNA may contain an internal ribosome entry site (IRES) element. In some embodiments, the RNA does not contain an IRES site, and in particular, in some embodiments, the saRNA does not contain an IRES site. In some such embodiments, translation of the gene of interest and / or replicase is not driven by an IRES element. In some such embodiments, the IRES element is replaced with a 5'-cap. In some such embodiments, the replacement with a 5'-cap does not affect the sequence of the polypeptide encoded by the RNA.
[0239] In some embodiments, the complexes described herein comprise a modRNA, a saRNA, a taRNA, or a uRNA. In some embodiments, the complexes comprise a modRNA. In some embodiments, the complexes comprise a saRNA. In some embodiments, the complexes comprise a taRNA. In some embodiments, the complexes comprise a uRNA.
[0240] How to use The conjugates described herein are useful for the treatment and prevention of the diseases, disorders, and conditions described herein in a subject. In some embodiments, the disclosure provides a method of treating a disease, disorder, or condition in a subject, comprising administering a conjugate described herein to the subject. In some embodiments, the disclosure provides a use of a conjugate described herein for the treatment of a disease, disorder, or condition. In some embodiments, the disease, disorder, or condition is an infectious disease, cancer, an autoimmune disease, or a rare disease.
[0241] In some embodiments, the present disclosure provides a conjugate described herein for use as a medicament.
[0242] In some embodiments, the present disclosure provides a conjugate described herein for use in the treatment and / or prevention of a disease or disorder, wherein the disease or disorder is an infectious disease, cancer, a genetic disorder, an autoimmune disease, or a rare disease.
[0243] In some embodiments, the infectious disease is caused by or associated with a viral pathogen. In some embodiments, the viral pathogen is from a family selected from the families Poxviridae, Rhabdoviridae, Filoviridae, Paramyxoviridae, Hepadnaviridae, Coronaviridae, Caliciviridae, Picornaviridae, Reoviridae, Retroviridae, and Orthomyxoviridae. In some embodiments, the infectious disease is a virus selected from SARS-CoV-2, influenza, Crimean-Congo hemorrhagic fever (CCHF), Ebola virus, Lassa virus, Marburg virus, HIV, Nipah virus, and MERS-CoV.
[0244] In some embodiments, the infectious disease is caused by or associated with a bacterial pathogen. In some embodiments, the bacterial pathogen is Actinomyces israelii, bacillus antracis, Bacteroides fragilis, Bordetella pertussis, Borrelia burgdorferi, Borrelia garinii, Borrelia afzelii, Borrelia recurrentis, Brucella abortus, Brucella canis, Brucella melitensis, Brucella suis, Campolobacter jejuni, Chlamydia pneumoniae, Chlamydia trachomatis, Chlamydophila psittaci, Clostridium botulinum, Clostridium difficile, Clostridium perfringens, Clostridium tetani, Corynebacterium idphteriae, Ehrlichia canis, Ehrlichia chaffeensis, Enterococcus faecalis, Enterococcus faecium, Escherichia coli, Francisella tularensis, Haemophilus influenzae, Helicobacter pylori, Klebsiella pneumoniae, Legionella pneumophila, Leptospira, Listeria monocytogenes, Mycobacterium leprae, Mycobacterium tuberculosis, Mycoplasma pneumoniae, Neisseria gonorrhoeae, Neisseria meningitidis, Pseudomonas aeruginosa, Nocardia asteroids, Rickettsia ricektssii, Salmonella typhi, Salmonella typhimurium, Shigella sonnei, Shigelladysenteriae, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus saprophyticus, Streptococcus agalactiae, Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus viridans, Treponema pallidum, Vibrio cholerae, and Yersinia pestis.
[0245] In some embodiments, the infectious disease is caused by or associated with a parasite, hi some embodiments, the parasite is from a family selected from Plasmodium, Leishmania, Cryptosporidium, Entamoeba, Trypanosomas, Schistosomes, Ascaris, Echinococcus, and Taeniidae.
[0246] In some embodiments, the disease, disorder, or condition is cancer, hi some embodiments, the cancer is selected from bladder cancer, breast cancer, colorectal cancer, renal cancer, lung cancer, lymphoma, melanoma, oral / oropharyngeal cancer, pancreatic cancer, prostate cancer, thyroid cancer, and uterine cancer.
[0247] In some embodiments, the disease, disorder, or condition is a genetic disorder. In some embodiments, the genetic disorder is associated with a gain-of-function or loss-of-function mutation.
[0248] In some embodiments, the disease, disorder, or condition is an autoimmune disease, hi some embodiments, the autoimmune disease is selected from Addison's disease, celiac disease, rheumatoid arthritis, lupus, inflammatory bowel disease, dermatomyositis, multiple sclerosis, diabetes, Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy, psoriasis, pernicious anemia, Graves' disease, Hashimoto's thyroiditis, myasthenia gravis, and Sjogren's syndrome vasculitis.
[0249] In some embodiments, the disease, disorder, or condition is a rare disease. As described herein, a rare disease refers to a life-threatening or chronically debilitating disease that has a very low incidence rate (e.g., less than 1 / 2000 people) and requires a special combination of efforts to address it.
[0250] In some embodiments, the present disclosure provides conjugates that can selectively target specific systems in the body. As used herein, reference to "targeting" a specific system refers to causing increased expression of RNA derived from the cargo in the conjugate in the desired system. For example, in some embodiments, the conjugates described herein can selectively target the lung, liver, spleen, heart, brain, lymph nodes, bladder, kidney, and pancreas. As described herein, a conjugate "selectively targets" an organ if a single target expresses mRNA at 65% or more of the amount expressed in other organs after administration (e.g., 65% or more of the mRNA in the entire body is expressed from a single organ, with the remaining 35% distributed among one or more different organs). In some embodiments, the conjugates described herein selectively target the lung. In some embodiments, the conjugates described herein selectively target the liver. In some embodiments, the conjugates described herein selectively target the spleen. In some embodiments, the conjugates described herein selectively target the heart.
[0251] In some embodiments, the present disclosure provides a method of increasing or causing an increase in expression of RNA in a target in a subject, the method comprising administering to the subject a conjugate described herein, in some embodiments, the target is selected from lung, liver, spleen, heart, brain, lymph node, bladder, kidney, and pancreas.
[0252] Delivery method The present disclosure provides, among other things, a conjugate (e.g., a pharmaceutical composition or pharmaceutical formulation referred to herein) administered to a subject. For example, in some embodiments, the conjugate is administered as monotherapy. In some embodiments, the conjugate is administered as part of a combination therapy. In some embodiments, the concentration of total RNA (e.g., the total concentration of all of the one or more RNA molecules) in a pharmaceutical composition described herein is from about 0.01 mg / mL to about 0.5 mg / mL, or from about 0.05 mg / mL to about 0.1 mg / mL.
[0253] Pharmaceutical compositions, as used herein, may further comprise pharmaceutically acceptable excipients, including any and all solvents, dispersion media, diluents, or other liquid vehicles, dispersing or suspending aids, surface active agents, isotonicity agents, thickening or emulsifying agents, preservatives, solid binders, lubricants, etc., suitable for the particular dosage form desired. Remington's The Science and Practice of Pharmacy, 21st Edition, A.R. Gennaro (Lippincott, Williams & Wilkins, Baltimore, MD, 2006; incorporated herein by reference in its entirety) discloses various excipients used in formulating pharmaceutical compositions and known techniques for their preparation. Except insofar as any conventional excipient vehicle is incompatible with the substance or its derivatives, such as by producing any undesirable biological effect or otherwise interacting in a deleterious manner with any other component(s) of the pharmaceutical composition, its use is contemplated within the scope of the present disclosure.
[0254] In some embodiments, the excipients are approved for human and veterinary use. In some embodiments, the excipients are approved by the U.S. Food and Drug Administration. In some embodiments, the excipients are pharmaceutical grade. In some embodiments, the excipients meet the standards of the United States Pharmacopoeia (USP), the European Pharmacopoeia (EP), the British Pharmacopoeia, and / or the International Pharmacopoeia.
[0255] Pharmaceutically acceptable excipients used in the preparation of pharmaceutical compositions include, but are not limited to, inert diluents, dispersing and / or granulating agents, surface active agents and / or emulsifying agents, disintegrating agents, binders, preservatives, buffers, lubricants, and / or oils. Such excipients may optionally be included in the pharmaceutical preparation. Excipients such as cocoa butter and suppository waxes, coloring agents, coating agents, sweeteners, flavoring agents, and / or perfumes may be present in the composition, according to the discretion of the formulator.
[0256] General considerations in the formulation and / or manufacture of pharmaceutical products can be found, for example, in Remington: The Science and Practice of Pharmacy 21st ed., Lippincott Williams & Wilkins, 2005 (incorporated herein by reference in its entirety).
[0257] In some embodiments, the pharmaceutical compositions provided herein can be prepared using one or more pharmaceutically acceptable carriers or diluents, as well as any other known adjuvants and excipients, such as those found in Remington: The Science and Practice of Pharmacy 21st ed., Lippincott Williams & Wilkins, 2005 (incorporated herein by reference in its entirety).
[0258] The pharmaceutical conjugates and compositions described herein can be administered by any suitable method known in the art. As will be appreciated by those skilled in the art, the route and / or mode of administration may depend on several factors, including, but not limited to, the stability and / or pharmacokinetics and / or pharmacodynamics of the pharmaceutical compositions described herein.
[0259] In some embodiments, the pharmaceutical compositions described herein are formulated for parenteral administration, which typically includes modes of administration other than enteral and topical administration by injection, including, but not limited to, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal, epidural, and intrasternal injection and infusion.
[0260] In some embodiments, the pharmaceutical compositions described herein are formulated for intravenous administration. In some embodiments, pharmaceutically acceptable carriers that may be useful for intravenous administration include sterile aqueous solutions or dispersions and sterile powders for preparing sterile injectable solutions or dispersions.
[0261] In certain embodiments, the pharmaceutical compositions described herein are formulated for subcutaneous (sc) administration. In certain embodiments, the pharmaceutical compositions described herein are formulated for intramuscular (im) administration.
[0262] Therapeutic compositions typically must be sterile and stable under the conditions of manufacture and storage. The compositions can be formulated as solutions, dispersions, powders (e.g., lyophilized powders), microemulsions, lipid nanoparticles, or other ordered structures suitable to high drug concentrations. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyols (e.g., glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants. In many cases, it is preferable to include an isotonic agent, for example, a polyalcohol such as sugar, mannitol, sorbitol, or sodium chloride, in the composition. In some embodiments, prolonged absorption of injectable compositions can be achieved by including an agent that delays absorption, for example, monostearate salts and gelatin.
[0263] Sterile injectable solutions can be prepared by incorporating the active compound in the required amount in the appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by microfiltration sterilization.
[0264] In some embodiments, dispersions are prepared by incorporating the active compound into a sterile vehicle containing a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and freeze-drying (lyophilization) which yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.
[0265] Examples of suitable aqueous and non-aqueous carriers that can be used in the pharmaceutical compositions described herein include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like) and suitable mixtures thereof, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of coating materials such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.
[0266] These compositions may also contain adjuvants such as preservatives, wetting agents, emulsifying agents, and dispersing agents. Prevention of the presence of microorganisms can be ensured both by sterilization procedures and by the inclusion of various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, etc. It may also be desirable to include isotonic agents such as sugars and sodium chloride in the pharmaceutical compositions described herein. In addition, prolonged absorption of injectable pharmaceutical forms can be achieved by including agents that delay absorption, such as aluminum monostearate and gelatin.
[0267] Formulations of the pharmaceutical compositions described herein may be prepared by any method known or hereafter developed in the art of pharmacology. Generally, such preparatory methods include the step of bringing into association the active ingredient(s) with a diluent or other excipient and / or one or more other accessory ingredients, and then, if necessary and / or desired, shaping and / or packaging the product into a desired single- or multi-dosage unit.
[0268] Pharmaceutical compositions according to the present disclosure may be prepared, packaged, and / or sold in bulk, as a single unit dose, and / or as a plurality of single unit doses. As used herein, a "unit dose" is a discrete amount of a pharmaceutical composition comprising a predetermined amount of at least one RNA product produced using the systems and / or methods described herein.
[0269] In some embodiments, the active agent that can be included in the pharmaceutical compositions described herein is or includes a therapeutic agent administered in a combination therapy described herein. The pharmaceutical compositions described herein can be administered in combination therapy, i.e., in conjunction with other agents. In some embodiments, such a therapeutic agent can include an agent that depletes or functionally inactivates regulatory T cells. For example, in some embodiments, the combination therapy can include a provided pharmaceutical composition and at least one immune checkpoint inhibitor.
[0270] In some embodiments, the pharmaceutical compositions described herein may be administered in conjunction with radiation therapy and / or autologous peripheral stem cell or bone marrow transplantation.
[0271] In some embodiments, the pharmaceutical compositions described herein can be frozen to allow for long-term storage.
[0272] Although the description of pharmaceutical compositions provided herein is directed primarily to pharmaceutical compositions suitable for administration to humans, it will be understood by those skilled in the art that such compositions are generally suitable for administration to animals of all kinds. Modifications of pharmaceutical compositions suitable for administration to humans to make them suitable for administration to a variety of animals are well understood, and an ordinarily skilled veterinary pharmacologist can design and / or implement such modifications with no more than routine experimentation, if any.
[0273] Illustrative Embodiments The following numbered embodiments are illustrative, but non-limiting, of certain aspects of the present disclosure:
[0274] Embodiment 1. A conjugate comprising: i) a cationic oligosaccharide comprising one or more cationic moieties linked to a trehalose, sucrose, or gluco-n-oligosaccharide moiety, wherein n is 2 to 6; ii) a surfactant; and iii) one or more additives selected from a sterol, a helper lipid, an immunomodulator, and a targeting molecule.
[0275] Embodiment 2. The surfactant is or comprises a compound comprising an amphiphilic moiety selected from polysorbate, poloxamer, and / or polyalkylene glycol (e.g., polyethylene glycol), poly(2-oxazoline), poly(2-oxazine), polysarcosine, polyvinylpyrrolidone, and poly[N-(2-hydroxypropyl)methacrylamide], wherein the amphiphilic moiety comprises one or more C 12 -C 20 2. The conjugate of embodiment 1, which is bound to an aliphatic group.
[0276] Embodiment 3. The complex of embodiment 1 or 2, wherein the surfactant is or comprises a polysorbate selected from polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80, and combinations thereof.
[0277] Embodiment 4. The complex of any one of embodiments 1 to 3, wherein the molar ratio of the cationic oligosaccharide to the surfactant is from about 1:0.0075 to about 1:3.
[0278] Embodiment 5. The complex of any one of embodiments 1 to 4, wherein the molar ratio of the cationic oligosaccharide to the surfactant is from about 1:0.5 to about 1:1.
[0279] Embodiment 6. The complex of any one of embodiments 1 to 5, wherein the molar ratio of the cationic oligosaccharide to the surfactant is about 1:0.5.
[0280] Embodiment 7. The conjugate of any one of embodiments 1 to 6, further comprising a cargo.
[0281] Embodiment 8. The conjugate of embodiment 7, wherein the cargo is a nucleic acid.
[0282] Embodiment 9. The complex of embodiment 8, wherein the nucleic acid is RNA.
[0283] Embodiment 10. The complex of embodiment 9, wherein the RNA is modRNA, saRNA, taRNA, or uRNA.
[0284] Embodiment 11. The conjugate of any one of embodiments 1 to 10, wherein the conjugate has an N / P ratio of less than 20:1.
[0285] Embodiment 12. The conjugate of any one of embodiments 1 to 11, wherein the conjugate has an N / P ratio of 12:1 or less.
[0286] Embodiment 13. The conjugate of any one of embodiments 1 to 12, wherein the conjugate has an N / P ratio of about 6:1.
[0287] Embodiment 14. The complex of any one of embodiments 1 to 13, wherein the complex has a diameter of about 50 nm to about 150 nm.
[0288] Embodiment 15. A complex according to any one of embodiments 1 to 14, wherein the one or more additives are or comprise a sterol and / or a helper lipid and / or an immunomodulator.
[0289] Embodiment 16. The complex of any one of embodiments 1 to 15, wherein the one or more additives is or comprises a sterol.
[0290] Embodiment 17. The complex of embodiment 16, wherein the sterol is selected from β-sitosterol, stigmasterol, cholesterol, cholecalciferol, ergocalciferol, calcipotriol, botulin, lupeol, ursolic acid, oleanolic acid, cycloartenol, lanosterol, or α-tocopherol.
[0291] Embodiment 18. The complex of any one of embodiments 1 to 17, wherein the molar ratio of the cationic oligosaccharide to the sterol is from about 1:0.25 to about 1:1.
[0292] Embodiment 19. The complex of embodiment 18, wherein the ratio of the cationic oligosaccharide to the sterol is about 1:0.5.
[0293] Embodiment 20. The complex of any one of embodiments 1 to 19, wherein the one or more additives is or comprises a helper lipid.
[0294] Embodiment 21. The helper lipid is selected from the group consisting of phosphatidylcholine, phosphatidylethanolamine, phosphatidylglycerol, phosphatidic acid, phosphatidylserine, and sphingomyelin, more preferably distearoylphosphatidylcholine (DSPC), dioleoylphosphatidylcholine (DOPC), dimyristoylphosphatidylcholine (DMPC), dipentadecanoylphosphatidylcholine, dilauroylphosphatidylcholine, dipalmitoylphosphatidylcholine (DPPC), diarachidylphosphatidylcholine (D ... Dodecylphosphatidylcholine (DAPC), dibehenoylphosphatidylcholine (DBPC), ditricosanoylphosphatidylcholine (DTPC), dilignoceroylphosphatidylcholine (DLPC), palmitoyloleoylphosphatidylcholine (POPC), 1,2-di-O-octadecenyl-sn-glycero-3-phosphocholine (18:0 diether PC), 1-oleoyl-2-cholesterylhemisuccinoyl-sn-glycero-3-phosphocholine (OChemsPC), 1-hexadecyl-sn-glycero-3-phosphocholine (C16 21. The conjugate of any one of embodiments 1 to 20, wherein the phosphatidylethanolamine is selected from the group consisting of phosphatidylethanolamine (Phosphatidylethanolamine), ...
[0295] Embodiment 22. A conjugate according to any one of embodiments 1 to 21, wherein the helper lipid is selected from DSPC and DMPC.
[0296] Embodiment 23. The complex of any one of embodiments 1 to 21, wherein the molar ratio of the cationic oligosaccharide to the helper lipid is from about 1:0.25 to about 1:1.
[0297] Embodiment 24. The complex of any one of embodiments 1 to 23, wherein the molar ratio of the cationic oligosaccharide to the helper lipid is about 1:0.5.
[0298] Embodiment 25. The complex of any one of embodiments 1 to 24, wherein the one or more additives are or include a sterol and a helper lipid.
[0299] Embodiment 26. The complex of any one of embodiments 1 to 25, wherein the molar ratio of the cationic oligosaccharide:the sterol:the helper lipid is from about 1:0.25:0.25 to about 1:1:1.
[0300] Embodiment 27. The complex of embodiment 26, wherein the molar ratio of the cationic oligosaccharide:the sterol:the helper lipid is about 1:0.5:0.5.
[0301] Embodiment 28. The complex of any one of embodiments 1 to 27, wherein the molar ratio of the cationic oligosaccharide:the surfactant:the sterol:the helper lipid is about 1:0.5:0.5:0.5.
[0302] Embodiment 29. The conjugate of any one of embodiments 1 to 28, wherein the one or more additives is or comprises an immunomodulatory agent.
[0303] Embodiment 30. The conjugate of any one of embodiments 1 to 29, wherein the immunomodulatory agent is an immunostimulatory agent or an immunosuppressant.
[0304] Embodiment 31. The conjugate of any one of embodiments 1 to 30, wherein the immunomodulatory agent is a small molecule agonist or antagonist of a TLR or PRR receptor.
[0305] Embodiment 32. The conjugate of any one of embodiments 1 to 31, wherein the immunomodulatory agent is a small molecule downstream inhibitor of NF-κB.
[0306] Embodiment 33. The immunomodulatory agent is sp 2 The conjugate according to any one of embodiments 1 to 32, which is a glycosaminoglycolipid.
[0307] Embodiment 34. The conjugate of any one of embodiments 1 to 33, wherein the immunomodulatory agent is a TLR inhibitor.
[0308] Embodiment 35. The conjugate of embodiment 34, wherein the TLR inhibitor is an inhibitor of TLR2, TLR4, and / or TLR6.
[0309] Embodiment 36. The conjugate of embodiment 35, wherein the TLR inhibitor is an inhibitor of TLR4.
[0310] Embodiment 37. The conjugate of embodiment 13, wherein the inhibitor of TLR4 is TAK-242.
[0311] Embodiment 38. The conjugate of any one of embodiments 1 to 30, wherein the immunomodulator is a terpenoid.
[0312] Embodiment 39. The complex of embodiment 38, wherein the terpenoid is a triterpene.
[0313] Embodiment 40. The complex of embodiment 39, wherein the triterpene is a triterpenoid.
[0314] Embodiment 41. The complex of embodiment 39, wherein the triterpenoid is a synthetic or natural derivative of amylin, betulinic acid, oleanolic acid, sterol, squalene, or ursolic acid.
[0315] Embodiment 42. The conjugate of any one of embodiments 38 to 41, wherein the immunomodulator is a sterol, squalene, oleanolic acid, ursolic acid, betulinic acid, or amylin.
[0316] Embodiment 43. The conjugate of any one of embodiments 38 to 42, wherein the immunomodulator is a glucocorticoid.
[0317] Embodiment 44. The conjugate of embodiment 43, wherein the glucocorticoid is dexamethasone, prednisolone, fluticasone propionate, budesonide, or a pharmaceutically acceptable salt thereof.
[0318] Embodiment 45. The conjugate of embodiment 44, wherein the glucocorticoid is dexamethasone or a pharmaceutically acceptable salt thereof.
[0319] Embodiment 46. The conjugate of any one of embodiments 38 to 45, wherein the conjugate further comprises one or more additional immunomodulatory agents.
[0320] Embodiment 47. The conjugate of embodiment 46, wherein said one or more additional immunomodulatory agents is or comprises a small molecule agonist or antagonist of a TLR or PRR receptor.
[0321] Embodiment 48. The conjugate of embodiment 47, wherein the one or more additional immunomodulatory agents is or comprises TAK-242.
[0322] Embodiment 49. The complex of any one of embodiments 1 to 48, wherein the one or more additives are or include a sterol, a helper lipid, and an immunomodulator.
[0323] Embodiment 50. The conjugate of any one of embodiments 1 to 49, wherein the molar ratio of the cationic oligosaccharide to the immunomodulator is from about 1:0.05 to about 1:0.5.
[0324] Embodiment 51. The conjugate of embodiment 50, wherein the molar ratio of the cationic oligosaccharide to the immunomodulator is about 1:0.5.
[0325] Embodiment 52. The conjugate of any one of embodiments 1 to 51, wherein the one or more additives is or comprises a targeting molecule.
[0326] Embodiment 53. The cationic oligosaccharide is a compound of Formula I: [ka] or a pharmaceutically acceptable salt thereof, wherein: A is A 1 , A 2 , or A 3 and [ka] R 1 and R 2 each independently, in each instance, H, R a , and -C(O)-R a Selected from R 1 or R 2 At least one instance of is not H, Each R a But independently, C1-C 20 Aliphatic, C3-C 20 cycloaliphatic, C5-C6 aryl, 3- to 12-membered heterocyclyl containing 1 to 3 heteroatoms selected from N, O, and S; a But there is one or more R b optionally replaced by Each R b are independently halogen, -N3, -R c , -OR c , -SR c , -NHR c , -C(O)-R c , -OC(O)R c , -NHC(O)R c , -C(O)NHR c , and -NHC(O)NHR c is selected from Each R c are independently optionally substituted C-C 20 Aliphatic, optionally substituted C3-C 20selected from cycloaliphatic, optionally substituted C5-C6 aryl, optionally substituted 3- to 12-membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, and optionally substituted 4- to 12-membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S; X 1 and X 2 are each independently selected from -S-, -SS-, and -NH-; Y 1 and Y 2 each independently represents an optionally substituted C 1-30 an aliphatic group, wherein one or more carbons are optionally and independently -Cy-, -NR Y -, -NR Y C(O)-, -C(O)NR Y -, -NR Y C(O)O-, -OC(O)NR Y -, -NR Y C(O)NR Y -, -NR Y C(S)NR Y -, -C(S)NR Y -, -C(O)NR Y SO2-, -SO2NR Y substituted by -C(O)-, -OC(O)O-, -O-, -C(O)-, -OC(O)-, -C(O)O-, -SO-, or -SO2-; Each R Y are independently H or an optionally substituted C1-C6 aliphatic; each Cy independently represents an optionally substituted C3-C 14 an optionally substituted 5- to 14-membered heterocyclyl ring having 1 to 3 heteroatoms selected from cycloaliphatic, N, O, and S, and an optionally substituted 5- to 14-membered heteroaryl ring having 1 to 3 heteroatoms selected from N, O, and S; Z 1 and Z 2 each independently represents an optionally substituted 5- to 14-membered heterocyclyl ring having 1 to 3 heteroatoms selected from N, O, and S; an optionally substituted 5- to 14-membered heteroaryl ring having 1 to 3 heteroatoms selected from N, O, and S; -N+ (M)3, [ka] is a cationic or ionizable group selected from Each M is independently -C0-C6 aliphatic -R z , or -C0-C6 aliphatic -N + (R z )3, Each R z are independently H, optionally substituted C1-C6 aliphatic, optionally substituted C3-C 20 selected from cycloaliphatic, optionally substituted C5-C6 aryl, optionally substituted 3-12 membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, and optionally substituted 4-12 membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S; or Two or more R's z can be taken together with the atom to which they are attached to form an optionally substituted 3- to 12-membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, or an optionally substituted 4- to 12-membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S; 53. The conjugate of any one of embodiments 1 to 52, wherein p is an integer selected from 1, 2, 3, 4, or 5.
[0327] Embodiment 54. The cationic oligosaccharide is a compound of Formula Ia: [ka] or a pharmaceutically acceptable salt thereof.
[0328] Embodiment 55. The oligosaccharide is a compound of formula Ib: [ka] or a pharmaceutically acceptable salt thereof.
[0329] Embodiment 56. The oligosaccharide is a compound of formula Ic: [ka] or a pharmaceutically acceptable salt thereof.
[0330] Embodiment 57.R 1 and R 2 are each independently R a , and -C(O)-R a Selected from R a But C1-C 20 57. The conjugate of any one of embodiments 53 to 56, which is aliphatic.
[0331] Embodiment 58.R 1 and R 2 are -C(O)-R, respectively. a and R a But C1-C 14 58. The conjugate of any one of embodiments 53 to 57, which is aliphatic.
[0332] Embodiment 59. Each R a But C5-C 10 59. The conjugate of any one of embodiments 53 to 58, which is a straight chain alkyl.
[0333] Embodiment 60.R 1 and R 2 are -C(O)-R, respectively. a and each R a But independently, [ka] 60. The conjugate of any one of embodiments 53 to 59, selected from:
[0334] Embodiment 61.X 1 and X 2 and each is -S-.
[0335] Embodiment 62.Y1 and Y 2 each independently represents an optionally substituted C 1-30 an aliphatic group, where one or more carbons are independently -NR Y C(O)NR Y -, or -NR Y C(S)NR Y 62. The conjugate of any one of embodiments 53 to 61, substituted with -.
[0336] Embodiment 63.R Y is H.
[0337] Embodiment 64.Y 1 and Y 2 is each C1-C4 aliphatic -NHC(S)NH-C1-C4 aliphatic.
[0338] Embodiment 65.Y 1 and Y 2 is each —CH2—CH2—NHC(S)NH—CH2—CH2—
[0339] Embodiment 66.Z 1 and Z 2 are each independently a cationic or ionizable group comprising an optionally substituted 5-14 membered heterocycle having 1-3 heteroatoms selected from N, O, and S.
[0340] Embodiment 67.Z 1 and Z 2 However, each independently, [ka] [ka] 67. The conjugate of any one of embodiments 53 to 66, selected from:
[0341] Embodiment 68.Z1 and Z 2 However, each independently, [ka] 68. The conjugate of embodiment 67, selected from:
[0342] Embodiment 69. The complex of any one of embodiments 53 to 68, wherein the cationic oligosaccharide further comprises one or more suitable counterions.
[0343] Embodiment 70. The conjugate of any one of embodiments 1 to 53, wherein the cationic oligosaccharide is selected from Table 1, or a pharmaceutically acceptable salt thereof.
[0344] Embodiment 71. The conjugate of any one of embodiments 1 to 53, wherein the cationic oligosaccharide is selected from Table 2, or a pharmaceutically acceptable salt thereof.
[0345] Embodiment 72. A method for increasing or causing an increase in expression of RNA in a target in a subject, the method comprising administering to the subject a complex described in any one of embodiments 1 to 71.
[0346] Embodiment 73. The method of embodiment 72, wherein the target is selected from the lung, liver, spleen, heart, brain, lymph nodes, bladder, kidney, and pancreas.
[0347] Embodiment 74. A method of treating a disease, disorder, or condition in a subject, comprising administering to the subject a conjugate of any one of embodiments 1 to 71.
[0348] Embodiment 75. The method of embodiment 74, wherein the disease, disorder, or condition is an infectious disease, cancer, a genetic disorder, an autoimmune disease, or a rare disease.
[0349] Embodiment 76. The method of any one of embodiments 72 to 75, wherein the conjugate is administered intramuscularly.
[0350] Embodiment 77. The method of any one of embodiments 72 to 75, wherein the complex is administered subcutaneously.
[0351] Embodiment 78. A conjugate according to any one of embodiments 1 to 71 for use as a medicament.
[0352] Embodiment 79. The conjugate of any one of embodiments 1 to 71, for use in the treatment and / or prevention of a disease or disorder, wherein the disease or disorder is an infectious disease, cancer, a genetic disorder, an autoimmune disease, or a rare disease.
[0353] The foregoing is a description of certain non-limiting embodiments of the subject matter described herein. Accordingly, it should be understood that the embodiments described herein are merely exemplary of the subject matter reported herein. Reference to details of the illustrated embodiments is not intended to limit the scope of the claims, which themselves recite those features deemed essential.
[0354] The systems and methods of the claimed subject matter are intended to encompass variations and adaptations developed using information from the embodiments described herein. Adaptations, modifications, or both of the systems and methods described herein may be performed by those skilled in the relevant art.
[0355] Throughout the description, when a system is described as having, including, or comprising particular components, or a method is described as having, including, or comprising particular steps, it is further contemplated that there are systems within the inventive subject matter that consist essentially of or consist of the recited components, and that there are methods within the inventive subject matter that consist essentially of or consist of the recited processing steps.
[0356] It should be understood that the order of steps or order for performing certain actions is immaterial so long as any embodiment of the subject matter described herein remains operable. Moreover, two or more steps or actions may be conducted simultaneously.
[0357] Acknowledgments The applicants would like to thank the Consejo Superior de Investigaciones Cientificas and FIUS / UNIVERSITY OF SEVILLE / for their support and contribution to the development of this study. [Example]
[0358] The present teachings include descriptions provided in the examples, which are not intended to limit the scope of any claims. Unless specifically stated in the past tense, inclusion in the examples is not intended to imply that the experiment was actually performed. The following non-limiting examples are provided to further illustrate the present teachings. Those skilled in the art will understand in light of this application that many changes can be made to the specific embodiments provided herein and still obtain the same or similar results without departing from the spirit and scope of the present teachings.
[0359] While the general methods illustrate the synthesis of specific compounds of the present disclosure, it will be understood that the following general methods and others known to those of skill in the art can be applied to all compounds and subclasses and species of each of these compounds as described herein.
[0360] In the examples below, the following abbreviations may be used: aq. (aqueous); ACN (acetonitrile); C29 (TL2-C29); CSA (camphorsulfonic acid); d# (days or number of days, e.g., d0 is day 0; d20 is day 20); DCM (dichloromethane); DEA (diethylamine); Dexa (dexamethasone); DHP (dihydropyran); DMF (N,N-dimethylformamide); DIPEA (N,N-diisopropylethylamine); DMAP (4-dimethylaminopyridine); DMG-PEG (1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol); DMSO (dimethyl sulfoxide); EA (ethyl acetate); ee (enantiomeric excess); equiv. (equivalents); ethanol (EtOH); h (hours or hours); Hex (hexane); HPLC (high performance liquid chromatography); IPA (isopropyl alcohol); K HMDS (potassium bis(trimethylsilyl)amide); LAH (lithium aluminum hydride); LCMS (liquid chromatography-mass spectrometry); LDA (lithium diisopropylamide); LiHMDS (lithium bis(trimethylsilyl)amide); LNP (lipid nanoparticles); MeOH (methanol); min (minutes or minutes); NMR (nuclear magnetic resonance); Pd / C (palladium on carbon); PPhO (triphenylphosphine oxide); PMBC (peripheral blood mononuclear cells); Pt / C (platinum on carbon); rb (round bottom); Rf (retention); rt or RT (room temperature); SM (starting material); TEA (triethylamine); THF (tetrahydrofuran); THP (tetrahydropyran); TLC (thin layer chromatography); TsOH (p-toluenesulfonic acid or tosylic acid); T20 / T40 / T60 (Tween 20 / Tween 40 / Tween 60); and UV (ultraviolet).
[0361] Example 1 - Delivery of modRNA using cationic oligosaccharides Forty-eight female BALB / c mice were divided into 16 study groups. All groups received the same amount of formulated luciferase-encoding saRNA (2 μg) intramuscularly (i.m.) into each leg. In vivo luciferase expression was measured in the administered tissues at six time points (6 hours, days 1, 2, 3, and 6). All groups received modRNA formulated with N / P6. Each group received modRNA formulated with one of the following cationic oligosaccharides: JRL13, JLJB619, JLF42, JLF41, JLF128, JLF142, JLF131, JLF58, JLF96, JLF97, JLF135, JLF94, JLF90, JLF99, JLF82, and JLF138. Formulations were complexed in MBG buffer (final concentration 5% w / v glucose, 10 mM MES, pH 6.1) at a final RNA concentration of 0.1 mg / ml. The mixing ratio of the RNA-containing solution to the cationic oligosaccharide-containing solution was 9:1 (v:v) in all cases. Additives such as Tween 20 / 40 / 60, when present, were mixed with the oligosaccharide in DMSO at the listed molar ratio before complexing with RNA. Formulations were characterized before injection to confirm their hydrodynamic diameter. Figure 1A is a bar graph showing the hydrodynamic diameter of complexes formulated with modRNA and different cationic oligosaccharides at an N / P6 ratio. Figure 1B is a bar graph showing the bioluminescence quantified over the experimental period and normalized to the JLF41-modRNA group.
[0362] Example 2 - Complex containing surfactant This example considers different surfactants with various structures and chemical compositions. All candidates are based on either polyethylene glycol, poly(2-oxazoline), or polysarcosine. All candidates contain aliphatic chains between 6 and 18 carbons in length.
[0363] Nine female BALB / c mice were divided into three study groups. All groups received the same amount of formulated luciferase-encoding modRNA (2 μg) administered intramuscularly into each leg. In vivo luciferase expression was measured in the administered tissues at five time points (6 hours, days 1, 2, 3, and 6). The first group received modRNA formulated exclusively in JLF99, the second group received modRNA formulated in a mixture of JLF99 and Tween 20 (1:0.5 molar ratio), and the third group received modRNA formulated in a mixture of JLF99 and Tween 20 (1:1 molar ratio). All groups received modRNA formulated in N / P6. The formulations were complexed in MBG buffer (final concentration 5% w / v glucose, 10 mM MES, pH 6.1) at a final RNA concentration of 0.1 mg / ml. The mixing ratio of the RNA-containing solution to the cationic oligosaccharide + Tween 20-containing solution was 9:1 (v:v) in all cases. The formulations were characterized prior to injection to confirm their hydrodynamic diameter. Figure 2A is a plot showing the hydrodynamic diameter of complexes formulated in N / P6 but with different surfactants, within surfactant:JLF99 ratios between approximately 0:1 and approximately 0.5:1. C14-pMeOx45 is a monoalkyl (C)-pMeOx45 complex with 45 repeating units of poly(2-methyl-2-oxazoline). 14 ) and C14-pSar23 is a monoalkyl (C14-pSar23) with 23 repeating units of polysarcosine. 14). Figure 2B is a plot showing the hydrodynamic diameter of complexes formulated in N / P6 with either Tween 20 or Tween 40 and surfactant:JLF99 ratios between approximately 0:1 and approximately 0.5:1. Figure 2C is a plot showing the expression of luciferase-encoding modRNA 24 hours after transfection of C2C12 cells with 100 ng of RNA / well of N / P6-formulated modRNA, Tween 20, or Tween 40 at different surfactant:JLF99 ratios. Data here represent three independent experiments (n = 3) technically repeated three times. Figure 2D is a plot showing the expression of luciferase-encoding modRNA 24 hours after transfection of HepG2 cells with 100 ng of RNA / well of N / P6-formulated modRNA, Tween 20, or Tween 40 at different surfactant:JLF99 ratios. Data here represent three independent experiments (n = 3) technically repeated three times. Figure 2E is a bar graph showing the hydrodynamic diameter of complexes formulated at different ratios of JLF99 to detergent. Figure 2F is a bar graph showing the quantified bioluminescence over the entire duration of the experiment, expressed as area under the curve. Figure 2G is a plot showing the quantified bioluminescence in the dorsal axis over approximately 6 days. Figure 2H is an image showing the bioluminescence in the ventral axis 6 hours after modRNA injection in each group.
[0364] Example 3 - Physical Properties of Example Composites In this example, six different cationic oligosaccharides with carbon chains of different lengths were tested in combination with modRNA: JLF81 (C6 aliphatic), JLF154 (C8 aliphatic), JLF99 (C 10 aliphatic), JLF158(C 12 Aliphatic), and JLF170(C 14Aliphatic). Each cationic oligosaccharide and modRNA complex was formed in combination with Tween 20. The cationic oligosaccharide was systematically varied in each formulation, but the molar ratio of cationic oligosaccharide to Tween 20 was constant (1:0.5) for all formulations. All formulations were prepared with N / P6. The formulations were complexed in MBG buffer (final concentration 5% w / v glucose, 10 mM MES, pH 6.1) at a final RNA concentration of 0.1 mg / ml, and the mixing ratio of the RNA-containing solution to the cationic oligosaccharide + Tween 20-containing solution was 9:1 (v:v) in all cases. Figure 3A is a plot showing the hydrodynamic diameter of exemplary complexes. Figure 3B is a bar graph showing the expression of luciferase-encoding modRNA 24 hours after transfection into either C2C12, HepG2, or RAW264.7 cells with 100 ng of RNA / well. Data here represent two independent experiments (n=2) that were technically repeated three times.
[0365] The size of the complexes described in this example was analyzed by a DynaPro PlateReader II using dynamic light scattering (DLS) to calculate the hydrodynamic size of the complexes. Formulations were measured by diluting samples to 0.01 mg / mL RNA in 120 μl of 5% MGB (10 mM MES, pH 6.1, 5% D-glucose) in wells of a 96-well plate. Ten data points were recorded per well, each for 10 seconds.
[0366] Example 4 - Complexes containing helper lipids and / or sterols This example examines the complexation of JLF99 and Tween 20 with specific helper lipids and / or sterols. The JL99 + Tween 20 combination was used at a constant molar ratio of 1:0.5, while different helper lipids or sterols were used at different molar ratios relative to JLF99. All formulations here were prepared with luciferase-encoding modRNA at N / P6. Formulations were complexed in MBG buffer (final concentration of 5% w / v glucose, 10 mM MES, pH 6.1) at a final RNA concentration of 0.1 mg / ml. The mixing ratio of the RNA-containing solution to the cationic oligosaccharide and Tween / sterol / helper lipid-containing solution was 9:1 (v:v) in all cases.
[0367] The formulations in this example provide (1) a combination of JLF99, Tween 20, and cholesterol in a molar ratio of 1:0.5:1 (JLF99:Tween 20:cholesterol), and (2) JLF99, Tween 20, and β-sitosterol in a molar ratio of 1:0.5:1 (JLF99:Tween 20:β-sitosterol). Five formulations contain JLF99, Tween 20, a helper lipid, and β-sitosterol, where the helper lipid in the formulation is DOPE, DOPC, DOPS, DSPC, or DSPE, and in all cases the molar ratio of JLF99:Tween 20:helper lipid:β-sitosterol is 1:0.5:0.5:0.5. Three of the formulations showed a composition of JLF99 + Tween20 + DSPC + sterol, where the sterol was β-sitosterol, stigmasterol, or acetate-α-tocopherol, and in all cases the molar ratio of JLF99:Tween20:DSPC:sterol was 1:0.5:0.5:0.5. Ten formulations showed a combination of JLF99 + Tween20 + helper lipid + β-sitosterol, where the helper lipid was either DSPC or DMPC, and five different molar ratios of JLF99:Tween20:helper lipid:β-sitosterol were 1:0.5:1:0, 1:0.5:0.25:0.75, 1:0.5:0.5:0.5, 1:0.5:0.75:0.25, and 1:0.5:0:1.
[0368] Figure 4A is a bar graph showing the hydrodynamic diameter of complexes formed using either JLF99 + Tween 20 + cholesterol or JLF99 + Tween 20 + β-sitosterol combinations. Figure 4B is a bar graph showing expression of luciferase-encoding modRNA normalized to the JLF99 benchmark at 100 ng of RNA / well in either C2C12, HepG2, or RAW264.7 cells after 24 hours. Figure 4C is a bar graph showing the hydrodynamic diameter of complexes formed using either JLF99 + Tween 20 + cholesterol or JLF99 + Tween 20 + β-sitosterol combinations in a molar ratio of 1:0.5:0.5:0.5 with either DOPE, DOPC, DOPS, DSPC, or DSPE. Figure 4D is a bar graph showing the normalized expression of luciferase-encoding modRNA relative to the JLF99 benchmark 24 h after transfection of either C2C12, HepG2, or RAW264.7 cells with 100 ng of RNA / well of complexes formed in a 1:0.5:0.5:0.5 molar ratio of JLF99 + Tween 20 + β-sitosterol + helper lipids with either DOPE, DOPC, DOPS, DSPC, or DSPE. Data here represent two independent experiments (n = 2) that were technically repeated three times. Figure 4E is a bar graph showing the hydrodynamic diameter of complexes formed in a 1:0.5:0.5:0.5 molar ratio of JLF99 + Tween 20 + sterols + DSPC with either β-sitosterol, stigmasterol, or acetate-α-tocopherol.Figure 4F is a bar graph showing the normalized expression of luciferase-encoding modRNA relative to the JLF99 benchmark 24 hours after transfection of either C2C12, HepG2, or RAW264.7 cells with 100 ng of RNA / well of complexes formed at a 1:0.5:0.5:0.5 molar ratio of JLF99 + Tween 20 + sterol + DSPC, where the sterol was either β-sitosterol, stigmasterol, or acetate-α-tocopherol. Data here represent two independent experiments (n = 2) that were technically repeated three times. Figure 4G is a scatter plot showing the hydrodynamic diameter of complexes formed by combining different molar ratios of JLF99 + Tween 20 + β-sitosterol + helper lipids with either DMPC or DSPC. Figure 4H is a scatter plot showing the expression of luciferase-encoding modRNA 24 hours after transfection of C2C12 cells with 100 ng of RNA / well of complexes formed with different molar ratios of JLF99, Tween 20, β-sitosterol, and helper lipids using either DMPC or DSPC. The data here represent two independent experiments (n = 2) performed technically three times. Figure 4I is a plot showing the expression of luciferase-encoding modRNA 24 hours after transfection of HepG2 cells with 100 ng of RNA / well of complexes formed with different molar ratios of JLF99, Tween 20, β-sitosterol, and helper lipids using either DMPC or DSPC. The data here represent two independent experiments (n = 2) performed technically three times. Figure 4J shows the expression of luciferase-encoding modRNA 24 hours after transfection of RAW647.7 cells with 100 ng of RNA / well of complexes formed at different molar ratios of JLF99, Tween 20, β-sitosterol, and helper lipids using either DMPC or DSPC. Data here represent two independent experiments (n=2) that were technically repeated three times.
[0369] Example 5 - Composites with Exemplary Additives In this example, we investigated the incorporation of β-sitosterol and DSPC into the formulation at different molar ratios relative to JLF99, while maintaining a constant JLF99:Tween 20 molar ratio. Twelve female BALB / c mice were divided into four study groups. All groups received the same amount of formulated luciferase-encoding modRNA (2 μg) administered intramuscularly into each leg. In vivo luciferase expression was measured in the administered tissues at five time points (6 hours, days 1, 2, 3, and 6). The first group received modRNA formulated exclusively in JLF99, the second group received modRNA formulated in a mixture of JLF99, Tween20, β-sitosterol, and DSPC (1:0.5:1:0 molar ratio), the third group received modRNA formulated in a mixture of JLF99, Tween20, β-sitosterol, and DSPC (1:0.5:0.5:0.5 molar ratio), and the fourth group received modRNA formulated in a mixture of JLF99, Tween20, β-sitosterol, and DSPC (1:0.5:0:1 molar ratio). All groups received modRNA formulated in N / P6. The formulations were complexed in MBG buffer (final concentration 5% w / v glucose, 10 mM MES, pH 6.1) at a final RNA concentration of 0.1 mg / ml. The mixing ratio of the RNA-containing solution to the cationic oligosaccharide (+ Tween 20 + β-sitosterol + DSPC)-containing solution was 9:1 (v:v) in all cases. The formulations were characterized before injection to confirm their hydrodynamic diameter. Figure 5A is a bar graph showing the hydrodynamic diameter of different complexes formulated at N / P 6. Figure 5B is a bar graph showing the quantified bioluminescence over the entire duration of the experiment, expressed as area under the curve. Figure 5C is a plot showing the quantified dorsal bioluminescence over the entire duration of the experiment. Figure 5D is an image of the ventral bioluminescence measured 6 hours after injection.
[0370] Example 6 - Analysis of composites containing specific additives Six female BALB / c mice were divided into two study groups. All groups received the same amount of formulated luciferase-encoding modRNA (2 μg) administered intramuscularly into each leg. Six hours after injection, in vivo luciferase expression was measured in the administered tissues. The first group received modRNA formulated exclusively in JLF99 + Tween 20 (1:0.5 molar ratio), while the second group received modRNA formulated in a mixture of JLF99 + Tween 20 + β-sitosterol + DSPC (1:0.5:0.5:0.5 molar ratio). All groups received modRNA formulated in N / P6. The formulations were complexed in MBG buffer (final concentration 5% w / v glucose, 10 mM MES, pH 6.1) at a final RNA concentration of 0.1 mg / ml. The mixing ratio of the RNA-containing solution to the cationic oligosaccharides + Tween 20 + β-sitosterol + DSPC-containing solution was 9:1 (v:v) in all cases. The formulations were characterized before injection to confirm their hydrodynamic diameter. Figure 6A is a bar graph showing the hydrodynamic diameter of different complexes formulated with N / P6. Figure 6B is a bar graph showing the quantified dorsal bioluminescence in the region of interest (muscle) 6 hours after injection. Figure 6C is a bar graph showing the quantified ventral bioluminescence in the region of interest (liver) 6 hours after injection. Figure 6D is an image of the ventral bioluminescence measured 6 hours after injection.
[0371] Example 7 - Conjugates containing immunomodulators This example provides a complex containing a third component that can either enable a specific immune response (e.g., Th1, Th2, or Th1 / Th2 response) or, alternatively, inhibit the immune response to the protein expressed from the delivered RNA, thereby avoiding proinflammatory signals that may hinder the therapeutic efficacy of RNA therapy. In this experiment, the immunostimulatory molecule MGC-VI-150 was used in combination with JLF99 + Tween 20 to formulate luciferase-encoding modRNA. Six female BALB / c mice were divided into two study groups. All groups received the same amount of formulated luciferase-encoding modRNA (2 μg) administered intravenously into each leg. In vivo luciferase expression in the administered tissues was measured at five time points (6 hours, days 1, 2, 3, and 6). Nine days after injection, the mice were euthanized and their spleens were removed to quantify the T cell response to the luciferase peptide. The first group received modRNA formulated exclusively in JLF99 + Tween 20 (1:0.5 molar ratio), while the second group received modRNA formulated in a mixture of JLF99 + Tween 20 + MGC-VI-150 (1:0.5:0.1 molar ratio). All groups received modRNA formulated with N / P6. The formulations were complexed in MBG buffer (final concentration 5% w / v glucose, 10 mM MES, pH 6.1) at a final RNA concentration of 0.1 mg / ml. The mixing ratio of the RNA-containing solution to the cationic oligosaccharide + Tween 20 + MGC-VI-150-containing solution was 9:1 (v:v) in all cases. The formulations were characterized prior to injection to confirm their hydrodynamic diameter. Figure 7A is a bar graph showing the hydrodynamic diameter of different complexes formulated with N / P6. Figures 7B and 7C are plots and bar graphs, respectively, showing quantified dorsal bioluminescence in the region of interest (muscle) over the course of the experiment as area under the curve, and Figure 7D is a bar graph showing quantified spot numbers in the ELISpot readout, reflecting T cell responses to luciferase peptide or an irrelevant peptide (AH1).
[0372] Example 8 - Conjugates containing immunomodulators This example provides a complex containing an immunomodulator that can inhibit the immune response to proteins expressed from RNA delivery, thereby avoiding pro-inflammatory signals that may hinder the therapeutic efficacy of RNA therapy. In this experiment, two different immunoinhibitory molecules, TAK-242 (a TLR4 inhibitor) and dexamethasone (a broad-spectrum immunosuppressant), were used in combination with cationic oligosaccharides and Tween 40 to formulate luciferase-encoding modRNA.
[0373] Example 8a - Analysis of pro-inflammatory cytokines using formulations containing cationic oligosaccharides and TLR4 inhibitors In the first part of this example, the secretion of proinflammatory cytokines in human peripheral blood mononuclear cells (hPBMCs) was evaluated for two different cationic oligosaccharides: JLF99 and JLF605. In total, four formulations were tested: the first formulation contained JLF99 and Tween 40 (1:0.5 molar ratio), the second formulation contained JLF99, Tween 40, and TAK-242 (1:0.5:0.5 molar ratio), the third formulation contained JLF605 and Tween 40 (1:0.5 molar ratio), and the fourth formulation contained JLF605, Tween 40, and TAK-242 (1:0.5:0.5 molar ratio). All groups received modRNA (encoding firefly luciferase) formulated with N / P6. The formulations were complexed in MBG buffer (final concentration 5% w / v glucose, 10 mM MES, pH 6.1) at a final RNA concentration of 0.15 mg / ml, and the mixing ratio of the RNA-containing solution to the cationic oligosaccharide + Tween 40 (+ TAK-242, optional)-containing solution was 9:1 (v:v) in all cases. 5 IL-6, TNF-α, IL-1β, and IFN-γ secretion 24 hours after transfection of hPMBCs was assessed in the supernatant using the MSD kit standard protocol.
[0374] Figure 8A is a scatter plot showing quantified IL-6 secretion in hPBMCs upon exposure to different doses of test formulations, Figure 8B is a scatter plot showing quantified TNF-α secretion in hPBMCs upon exposure to different doses of test formulations, Figure 8C is a scatter plot showing quantified IL-1β secretion in hPBMCs upon exposure to different doses of test formulations, and Figure 8D is a scatter plot showing quantified IFN-γ secretion in hPBMCs upon exposure to different doses of test formulations.
[0375] Example 8b - Analysis of pro-inflammatory cytokines and chemokines using formulations containing cationic oligosaccharides and TLR4 inhibitors, optionally with dexamethasone In the second part of the experiment, to further understand the requirements for a non-inflammatory formulation, we evaluated the secretion of both proinflammatory cytokines and chemokines in hPBMCs and luciferase expression in human primary hepatocytes in the presence of a combination of dexamethasone and TAK-242. Three formulations were tested: one containing JLF218 and Tween 40 (1:0.5 molar ratio), one containing JLF218, Tween 40, and dexamethasone (1:0.5:0.5 molar ratio), and one containing JLF218, Tween 40, dexamethasone, and TAK-242 (1:0.5:0.5:0.5 molar ratio). All groups received modRNA (encoding firefly luciferase) formulated with N / P6. The formulations were complexed in MBG buffer (final concentration 5% w / v glucose, 10 mM MES, pH 6.1) at a final RNA concentration of 0.15 mg / ml, and the mixing ratio of the RNA-containing solution to the cationic oligosaccharide + Tween 40 (+ dexamethasone + TAK-242, optional)-containing solution was 9:1 (v:v) in all cases. 5 IL-6, TNF-α, IL-1β, IFN-γ, MIP-1β, IP-10, and MCP-1 secretion were assessed in the supernatant 24 hours after transfection of hPMBCs using the MSD kit standard protocol. Primary human hepatocytes were transfected with 0.3 μg of modRNA and luciferase expression was assessed over the course of 6 days.
[0376] Figure 8E is a scatter plot showing quantified IL-6 secretion in hPBMCs upon exposure to different doses of test formulation. Figure 8F is a scatter plot showing quantified TNF-α secretion in hPBMCs upon exposure to different doses of test formulation. Figure 8G is a scatter plot showing quantified IL-1β secretion in hPBMCs upon exposure to different doses of test formulation. Figure 8H is a scatter plot showing quantified IFN-γ secretion in hPBMCs upon exposure to different doses of test formulation. Figure 81 is a scatter plot showing quantified MIP-1β secretion in hPBMCs upon exposure to different doses of test formulation. Figure 8J is a scatter plot showing quantified IP-10 secretion in hPBMCs upon exposure to different doses of test formulation. Figure 8K is a scatter plot showing quantified MCP-1 secretion in hPBMCs upon exposure to different doses of test formulation. Figure 8L is a plot showing normalized expression of luciferase-encoding modRNA at different time points (6 hours, day 2, day 6) after transfection of primary human hepatocytes with 0.3 μg of modRNA complexed with JLF218 + Tween 40 + dexamethasone + TAK-242 versus JLF218 + Tween 40 + dexamethasone.
[0377] Example 9 - Modulation of T cell responses This example provides a complex containing a third component that can enhance cellular immune responses without significantly affecting humoral responses. In this example, the immunostimulatory molecule MGC-103 was used in combination with JLF99+Tween 40 to formulate a luciferase-encoding modRNA. Twenty female BALB / c mice were divided into four study groups. One group received buffer alone as a negative control, and three groups received 1 μg of formulated modRNA encoding the hemagglutinin (HA) protein of influenza strain California / 7 / 2009 administered im in one leg in a prime / boost schedule (day 0 / day 28). The first group received modRNA formulated exclusively in a mixture of JLF99 and Tween 40 (1:0.5 molar ratio), the second group's modRNA was formulated in a mixture of JLF99, Tween 40, and MGC-103 (1:0.5:0.1 molar ratio), and the third group's modRNA was formulated in a mixture of JLF99, Tween 40, and MGC-103 (1:0.5:0.25 molar ratio). All groups received modRNA formulated in N / P6. The formulations were complexed in MBG buffer (final concentration 5% w / v glucose, 10 mM MES, pH 6.1) at a final RNA concentration of 0.1 mg / ml. The mixing ratio of the RNA-containing solution to the cationic oligosaccharides + Tween 40 (and optionally MGC-103)-containing solution was 9:1 (v:v) in all cases. The formulations were characterized prior to injection to confirm their hydrodynamic diameter. Animals underwent noninvasive serological monitoring at different time points (days 0, 14, 21, 28, and 49) over a 49-day period, and spleens were harvested at the end of the experiment to quantify CD4 / CD8 T cell responses to influenza HA peptides. Anti-influenza HA antibodies in serum were quantified by enzyme-linked immunosorbent assay (ELISA). CD4 / CD8 T cell responses were quantified by IFN-ELISPOT of splenocytes. Figure 9A is a bar graph showing the hydrodynamic diameter of different conjugates formulated with N / P6. Figure 9B is a scatter plot showing the serological levels of specific IgG against HA at different time points over the course of the experiment (days 0, 14, 28, and 49).FIG. 9C is a plot showing the quantified spot numbers in the IFN-ELISPOT readout, reflecting the CD4 / CD8 T cell response to the HA peptide pool.
[0378] Example 10 - Conjugates containing TLR4 inhibitors in combination with dexamethasone This example provides a complex containing a third component that can inhibit immune responses to proteins expressed from delivered RNA and avoid pro-inflammatory signals that can hinder the therapeutic efficacy of RNA therapy. In this experiment, luciferase-encoding modRNA was formulated using the TLR4 inhibitor molecule, TAK-242, alone or in combination with the broad-spectrum immunosuppressant, dexamethasone, in combination with the cationic oligosaccharides described herein plus Tween 40.
[0379] In the first part of the experiment, the secretion of pro-inflammatory cytokines in hPBMCs was evaluated for two different cationic oligosaccharides: JLF218 and PRX093, and different combinations including TAK-242 and / or dexamethasone were tested. In total, five formulations were tested: one containing JLF218 and Tween 40 (1:0.5 molar ratio), one containing JLF218, Tween 40, and TAK-242 (1:0.5:0.5 molar ratio), one containing JLF218, Tween 40, TAK-242, and dexamethasone (1:0.5:0.5:0.5 molar ratio), one containing PRX093 and Tween 40 (1:0.5 molar ratio), and one containing PRX093, Tween 40, TAK-242, and dexamethasone (1:0.5:0.5:0.5 molar ratio). All groups received N / P6-formulated modRNA (encoding firefly luciferase). The formulations were complexed in MBG buffer (final concentration 5% w / v glucose, 10 mM MES, pH 6.1) at a final RNA concentration of 0.15 mg / ml, and the mixing ratio of the RNA-containing solution to the cationic oligosaccharide + Tween 40 (+ TAK-242 + dexamethasone, optional)-containing solution was 9:1 (v:v) in all cases. 5IL-6, TNF-α, IL-1β, IFN-γ, MIP-1β, IP-10, and MCP-1 secretion were assessed in the supernatant 24 hours after transfection of hPMBCs using the MSD kit standard protocol. Primary human hepatocytes were transfected with varying doses of modRNA, ranging from 0.01 to 1 μg, and luciferase expression was assessed over the course of 6 days.
[0380] Figure 10A is a scatter plot showing quantified IL-6 secretion in hPBMCs upon exposure to different doses of test formulation. Figure 10B is a scatter plot showing quantified TNF-α secretion in hPBMCs upon exposure to different doses of test formulation. Figure 10C is a scatter plot showing quantified IL-1β secretion in hPBMCs upon exposure to different doses of test formulation. Figure 10D is a scatter plot showing quantified IFN-γ secretion in hPBMCs upon exposure to different doses of test formulation. Figure 10E is a scatter plot showing quantified MCP-1 secretion in hPBMCs upon exposure to different doses of test formulation. Figure 10F is a scatter plot showing quantified MIP-1β secretion in hPBMCs upon exposure to different doses of test formulation. Figure 10G is a scatter plot showing quantified IP-10 secretion in hPBMCs upon exposure to different doses of test formulation. FIG. 10H is a bar graph showing cumulative luciferase expression in the dose range of 0.01 to 1 μg for both test groups over the course of 6 days post-transfection.
[0381] In the second part of the experiment, expression of luciferase-encoding modRNA was evaluated in combination with various cationic oligonucleotides in the presence of dexamethasone and TAK-242. Six formulations were tested in total, each containing one of JLF218, JLF244, PRX093, JLF301, JLF245, or JLF608 in combination with Tween 40, dexamethasone, and TAK-242 at a molar ratio of 1:0.5:0.5:0.5. All groups received modRNA (encoding firefly luciferase) formulated with N / P6. The formulations were complexed in MBG buffer (final concentration 5% w / v glucose, 10 mM MES, pH 6.1) at a final RNA concentration of 0.15 mg / ml. The mixing ratio of the RNA-containing solution to the cationic oligonucleotide + Tween 40 (+ dexamethasone + TAK-242, optional)-containing solution was 9:1 (v:v) in all cases. Primary human hepatocytes were transfected with varying doses of modRNA from 0.01 to 1 μg, and luciferase expression was assessed over the course of 6 days. Figure 10I is a bar graph showing cumulative luciferase expression in the dose range of 0.01 to 1 μg for all test groups at different time points over the course of the experiment (24 h, 48 h, 144 h).
[0382] This example shows that the incorporation of TAK-242 results in a reduction of proinflammatory cytokines (Figures 10A-10D), while the incorporation of dexamethasone has only a minor effect on TNFα secretion (Figure 10B). The addition of dexamethasone has an improved effect on the secretion of proinflammatory chemokines compared to TAK-242 alone (Figures 10E-10G).
[0383] Example 11 - Synthesis Example This example provides certain exemplary methods for the synthesis of the cationic oligosaccharides described herein. Exemplary methods for preparing the cationic oligosaccharides of the present disclosure are provided in EP21382958.3, which is incorporated herein by reference in its entirety.
[0384] Unless otherwise specified, all reagents and solvents used in the preparations disclosed in the following examples were purchased from commercial sources and used without further purification. Thin layer chromatography (TLC) was performed on silica gel 60F. 254 Analysis was performed on Merck-coated aluminum sheets by visualization with UV light (λ 254 nm) and charring with 10% ethanolic H2SO4, 0.1% ethanolic ninhydrin, and heating at 100 °C. Column chromatography was performed on Silice 60 ACC Chromagel (SDS 70-200 and 35-70 μm). The structures of all compounds described herein, including synthetic intermediates and precursors, are 1 H and 13 The results were confirmed by C nuclear magnetic resonance (NMR) and mass spectrometry (MS). NMR experiments were performed at 300 (75.5) and 500 (125.7, 202) MHz using a Bruker 300 ADVANCE and 500 DRX. 1D TOCSY, 2D COSY, HMQC, and HSQC experiments were used to assist in NMR assignments. Mass spectra (high-resolution mass spectra) were performed on a Bruker Daltonics Esquire 6000™ (LTQ-Orbitrap XL ETD). Samples were introduced via a solid probe heated to 30-280°C. ESI was used as the ionization source (electrospray ionization) with methanol as the solvent. Samples were introduced by direct infusion using a Cole-Parmer syringe at a flow rate of 2 μl / min. Ions were scanned between 300 and 3000 Da at a scan rate of 13000 Da / s with unit resolution using resonant ejection at multipole resonance at one-third of the radio frequency (Ω = 781.25 kHz).
[0385] method This example provides synthetic methods and schemes for preparing the compounds described herein. References to compound numbers in this Example 11 are intended to refer to the corresponding structures in Schemes 1-5.
[0386] Scheme 1 illustrates the synthesis of compounds of formula I, where A is A 1 and R 1 and R 2 are both -C(O)-R a and X 1 and X 2 are both -S- and Y 1 and Y 2 are both -(CH2)2- and Z 1 and Z 2 is NH3 + (Compound 4T in Scheme 1). Scheme 1 also shows general routes (Routes A1, A2, B1, and B2) that can be implemented for the synthesis of compounds of Formula I, where A is A 1 and R 1 and R 2 are both -C(O)-R a and X 1 and X 2 are both -S- and Y 1 and Y 2 are both -(CH2)2-NHC(S)NH-(CH2)2-, and Z 1 and Z 2 is identical (compound 6T in Scheme 1): [ka]
[0387] Scheme 2 illustrates the synthesis of compounds of formula I, where A is A 2 and R 1 and R 2 are both -C(O)--R a and X 1 and X 2 are both -S- and Y 1 and Y 2 are both -(CH2)2- and Z 1 and Z 2 is NH3 + (Compound 4S in Scheme 2). Scheme 2 also shows general routes (Routes A1 and A2) that can be implemented for the synthesis of compounds of formula I, where A is A 2and R 1 and R 2 are both -(C=O)R a and X 1 and X 2 are both -S- and Y 1 and Y 2 are both -(CH2)2-NHC(S)NH-(CH2)2-, and Z 1 and Z 2 are identical: [ka]
[0388] Scheme 3 illustrates the synthesis of compounds of formula I, where A is A 1 and R 1 and R 2 are both -C(O)R a and X 1 and X 2 are both -S- and Y 1 and Y 2 are both -(CH2)2- and Z 1 and Z 2 is -N(CH3)H2 + (Compound 8T in Scheme 3) or -N(CH3)2H + (compound 9T in Scheme 3): [ka]
[0389] Scheme 4 illustrates the synthesis of compounds of formula I, where A is A 3 and R 1 is -C(O)-R a and R 2 is -C(O)-R a or methyl, and X 1 and X 2 are both -S- and Y 1 and Y 2 are both -(CH2)2- and Z 1 and Z 2 is NH3 +and p is 1 (compound 4M in Scheme 4). Scheme 4 also shows general routes (route A1, A2, B1, and B2) that can be implemented for the synthesis of compounds of formula I, where A is A 3 and R 1 is -C(O)-R a and R 2 is -(C=O)R a or methyl, and X 1 and X 2 are both -S- and Y 1 and Y 2 are both -(CH2)2-NHC(S)NH-(CH2)2-, and Z 1 and Z 2 are identical: [ka]
[0390] In some embodiments, R 1 and R 2 are both -C(O)-R a The synthesis of compounds of formula I, wherein: [ka]
[0391] In an exemplary embodiment, the synthesis of a compound of Formula I according to Scheme 1 or 2 involves the addition of a cationic head group Z 1 and Z 2 In a reaction step leading to the installation of: [ka] [ka] [ka]
[0392] material In some exemplary embodiments, the following precursors used in the synthesis of certain compounds described herein were prepared according to known methods.
[0393] 6,6'-Diiodo-6,6'-dideoxy-α,α'-trehalose (1T) was prepared from commercially available reagents according to the procedure described in JM Garcia Fernandez, C. Ortiz Mellet, JL Jimenez Blanco, J. Fuentes Mota, A. Gadelle, A. Coste-Sarguet, J. Defaye, Carbohydr. Res. 1995, 268, 57-71.
[0394] 6,6'-Diiodo-6,6'-dideoxy-sucrose (1S) was prepared from commercially available reagents according to literature procedures. See J.M. Garcia Fernandez, A. Gadelle, J. Defaye, Carbohydr. Res. 1994, 265, 249-269.
[0395] Methyl 6,6'-diiodo-6,6'-dideoxy-2,3,2',3',4'-penta-O-acetyl-β-maltoside (1M) was prepared from commercially available reagents according to the procedure described in the literature. G.O. Aspinall, R.C. Carpenter, L. Khondo, Carbohydr. Res. 1987, 165, 281-298.
[0396] As used herein, an arrow followed by a code in parentheses, e.g., "(→ code)" indicates the lipophilic tail (R in compounds of Formula I) provided by the aforementioned reagent during synthesis. 1 and R 2 substituent) or cationic head group (Z in compounds of formula I) 1 and Z 2 For example, "hexanoic anhydride (→L1)" is intended to refer to the moiety L1 attached to the compound via the use of hexanoic anhydride, as set forth in the table above.
[0397] Hexanoic anhydride (CAS#2051-49-2, →L1) and octanoyl (CAS#111-64-8, →L2), decanoyl (CAS#112-13-0, →L3), 2-ethylhexanoyl (CAS#39053-77-5, →L3.1), 4-ethyloctanoyl (CAS#16493-81-5, →L3.2), lauroyl (CAS#112-16-3, →L4), myristoyl (CAS#112-64-1, →L5), stearoyl (CAS#112-76-5, →L7), and oleoyl (CAS#112-77-6, →L7.1) chlorides were purchased from commercial sources.
[0398] 2-(N-tert-butoxycarbonylamino)ethanethiol (CAS#67385-09-5, C1SH), 2-(N,N-dimethylamino)ethyl isothiocyanate (CAS#7097-89-4, →C3), 2-(4-methylpiperazin-1-yl)ethanamine (CAS#934-98-5, →C7), 2-(4-isopropylpiperazin-1-yl)ethanamine (CAS#132740-59-1, →C7.1), tert-butyl 4 -(2-Aminoethyl)piperazine-1-carboxylate (CAS#192130-34-0, →C8), 2-morpholinoethanamine (CAS#2038-03-1, →C9), 2-morpholinoethyl isothiocyanate (CAS#2038-03-1, →C9), 1-(2-aminoethyl)piperidine (CAS#63224-35-1, →C9.1), 2-(1H-imidazol-1-yl)ethanamine (CAS#5739-10-6, →C10) ), 2-(1H-imidazol-2-yl)ethanamine (CAS#19225-96-8, →C10.1), 2-(1H-imidazol-4-yl)ethan-1-amine (CAS#51-45-6, →C10.2), 2,2'-(piperazine-1,4-diyl)diethanamine (CAS#6531-38-0, →C14), tert-butyl(2-aminoethyl)(ethyl)carbamate (CAS#105628-63-5, →C15), N,N-diethanamine Ethylethylenediamine (CAS#100-36-7, →C16), 1,4-bis-Boc-1,4,7-triazaheptane (CAS#120131-72-8, →C18), 1-(2-aminoethyl)pyrrolidine (CAS#7154-73-6, →C47.1), N-(2-aminoethyl)-1,4-oxazepane (CAS#878155-50-1, →C48), 1-(2-aminoethyl)homopiperidine (CAS#51388-00-2, →C48).1), tert-butyl N-(2-aminoethyl)-N-(2-hydroxyethyl)carbamate (CAS#364056-56-4, →OH1), N,N-bis(2-hydroxyethyl)ethylenediamine (CAS#3197-06-6, →OH5), 3,3'-((2-aminoethyl)azanediyl)bis(propan-1-ol) (CAS#50331-68-5, →OH6), 4,4'-((2-aminoethyl)azanediyl)bis(butan-1-ol) (CAS#197966-97-5, →OH7), 2-((2-aminoethyl)amino)-2-(hydroxymethyl)propane-1,3-diol ( CAS#1211477-35-8, → OH10), 2-(4-(2-aminoethyl)piperazin-1-yl)ethanol (CAS#20542-08-9, → OH12), 1-(2-aminoethyl)piperidin-4-one (CAS#1196887-97-4, → C54), N-(2-aminoethyl)-4-piperidinol (CAS#129999-60-6, → C59), [1-(2-amino-ethyl)-piperidin-3-yl]-methanol (CAS#857637-03-7, → C59.1), 2-(4-methoxy-piperidin-1-yl)-ethylamine (CAS#911300-69-1, → C59.2), 2-(4,4-difluoropiperidin-1-yl)ethanamine (CAS#605659-03-8, →C60), 4-(2-aminoethyl)-thiomorpholine (CAS#53515-36-9, →C61), 4-(2-aminoethyl)thiomorpholine-1,1-dioxide (CAS#89937-52-0, →C63), 1-[4-(2-aminoethyl)piperazin-1-yl]ethenone (CAS#148716-35-2, →C66), 4-(2-aminoethyl)piperazin-2-one (CAS#145625-71-4 , → C68), 1-(2-aminoethyl)piperidine-4-carboxamide (CAS#443897-95-8, → C69), [1-(2-aminoethyl)piperidin-4-yl]methanol dihydrochloride (CAS#1311315-83-9, → C70), 2-[N-methyl-N-(tert-butoxycarbonyl)amino]ethanethiol (CAS#134464-53-2, C2SH), and 2-(N,N-dimethylamino)ethanethiol (CAS#108-02-1, C3SH) were purchased from commercial sources.
[0399] 2-(N-tert-butoxycarbonylamino)ethyl isothiocyanate (→C1), D. M. Kneeland, K. Ariga, V. M. Lynch, C.Y. Huang, E. V. Anslyn, J. Am. Chem. Soc. 1993, 115, 10042-10055. 2-(N-methyl-N-tert-butoxycarbonylamino)ethyl isothiocyanate (→C2), T. Kim, Y.-J. Kim, I.-H. Ha n, D. Lee, J. Ham, K.S. Kan, J.W. Lee, Bioorg.Med.Chem.Lett. 2015, 25, 62-66. 2-(N,N,N-trimethylamino)ethyl isothiocyanate (→C4), Y.-J. Ghang, J.J. Lloyd, M.P. Moehlig, J.K. Arguelles, M. Mettry, X. Zhang, R.R. Julian, Q. Cheng, R.J. Hooley, Langmuir 2014,30,10160-10166. 2-(2-Aminoethyl)-1,3-di-(tert-butoxycarbonyl)guanidine (→C11), S.M. Hickey, T.D. Ashton, J.M. White, J. Li, R.L. Nation, H.Y. Yu, A.G. Elliott, M.S. Butler, J.X. Huang, M.A. Crooper, F.M. Pfeffer, RSC Adv. 2015,5,28582-28596. N,N-Bis[2-(tert-butoxycarbonylamino)ethyl]ethylenediamine (→C43) was prepared according to the procedure described in Y. Wu, A. Kaur, E. Fowler, M. M. Wiedmann, R. Young, W. R. J. D. Galloway, L. Olsen, H. F. Score, A. Chattopadhyay, T. T.-L. Kwan, W. Xu, S. J. Walsh, P. de Andrade, M. Janecek, S. Arumugam, L. S. Itzhaki, Y. Heng Lau, D. R. Spring, ACS Chem. Biol. 2019, 14, 526-533. N,N-Bis(2-acetamidoethyl)ethylenediamine (→C45) was prepared according to the procedure described in L. Liu, M. Rozenman, R. Breslow, J. Am. Chem. Soc. 2002, 124, 12660-12661.
[0400] N I ,N I -Dimethyl-N II N-tert-butoxycarbonyl-diethylenetriamine (→C12), N-(3-hydroxypropyl)-N-(tert-butoxycarbonyl)ethylenediamine (→OH2), and N-(4-hydroxybutyl)-N-(tert-butoxycarbonyl)ethylenediamine (→OH3) were obtained from commercially available N I ,N I They were synthesized from -dimethyl-diethylenetriamine, N-(3-hydroxypropyl)ethylenediamine, and N-(4-hydroxybutyl)ethylenediamine, respectively, by sequential primary amine trifluoroacetylation with ethyl trifluoroacetate, carbamoylation of the remaining amino group with BocO, and base-promoted trifluoroacetide hydrolysis.
[0401] N-(2-aminoethyl)-1,3-oxazolidine (CAS#67626-78-2, →C47) was synthesized from commercially available N-(2-hydroxyethyl)-1,3-oxazolidine (CAS#20073-50-1) by sequential hydroxylmesylation using mesyl chloride, displacement with sodium azide, and final catalytic hydrogenation using H-Pd / C.
[0402] 4-(2-Aminoethyl)-thiomorpholine-1-oxide (→C62) was synthesized by sequential primary amine carbamoylation with BocO, thioether oxidation with m-chloroperbenzoic acid, and final acid-promoted carbamate cleavage.
[0403] N I -(tert-butoxycarbonylmethyl)-N II -(2-Isothiocyanatoethyl)-ethylenediamine (→C5) was synthesized from commercially available diethylenetriamine according to the following scheme (Scheme 5). [ka]
[0404] The synthetic intermediates 2T, 2S, 2M, 3T, 3S, and 3M in the reaction sequences shown in Schemes 1, 2, and 4 were prepared as described below:
[0405] 6,6'-Bis[2-(tert-butoxycarbonylamino)ethylthio]-α,α'-trehalose (2T). To a mixture of diiodo-trehalose 1T (14.3 g, 25.44 mmol) and CsCO (23.45 g, 71.23 mmol) in anhydrous DMF (150 mL) under N was added a solution of 2-(N-tert-butoxycarbonylamino)ethanethiol (CSH, 13.6 mL, 76.32 mmol) in anhydrous DMF (100 mL) under N. The reaction mixture was stirred overnight at room temperature, and the solid remaining in suspension was decanted and filtered. The solvent was then removed under reduced pressure, and the resulting residue was triturated with EtO (500 mL) to generate a sticky solid. The residue was filtered, triturated with EtOH (250 mL), and the remaining solid was filtered again. The solvent was finally evaporated to dryness to give analytically pure compound 2T in essentially quantitative yield (16.8 g). 26 H 48 N2O 13 S2. Molecular weight: 660.26. ESI-MS (m / z) 705.51 ([M+HCO2] - ).
[0406] 6,6'-Bis[2-(tert-butoxycarbonylamino)ethylthio]sucrose (2S). To a mixture of diiodo-sucrose 1S (1.07 g, 1.9 mmol) and CsCO (1.75 g, 5.33 mmol) in anhydrous DMF (30 mL) under a N atmosphere, 2-(tert-butoxycarbonylamino)ethyl mercaptan (1.0 mL, 5.7 mmol) was added. The reaction mixture was stirred overnight at room temperature. The solvent was then removed under reduced pressure, and the resulting residue was triturated with EtO (100 mL) to generate a sticky solid. The residue was filtered, triturated with EtOH (50 mL), and the remaining solid was filtered again. The solvent was finally evaporated to dryness to give analytically pure compound 2S in essentially quantitative yield (1.25 g). Chemical formula: C26H48N2O13S2. Molecular weight: 660.26. ESI-MS (m / z) 705.56 ([M+HCO2]-).
[0407] Methyl 6,6'-bis[2-(tert-butoxycarbonylamino)ethylthio]-β-maltoside (2M). To a mixture of methyl 6,6'-dideoxy-6,6'-diiodo-β-maltoside 1M (1.20 g, 1.5 mmol) and CsCO (1.38 g, 4.20 mmol) in anhydrous DMF (40 mL) under a N atmosphere, 2-(tert-butoxycarbonylamino)ethyl mercaptan (CSH, 0.80 mL, 4.50 mmol) was added. The reaction mixture was stirred overnight at room temperature. The reaction mixture was diluted with a 1:1 EtO-toluene mixture (200 mL) and extracted with water (2 × 100 mL). The organic phase was dried over NaSO, filtered, and concentrated to dryness. The resulting residue was chromatographed using a 1:1 EtOAc-petroleum ether mixture as eluent to give the per-O-acetylated intermediate in 90% yield (1.20 g). Acetate removal was achieved by treatment with NaOMe (0.67 mmol, 36 mg) in MeOH (25 mL) for 1 h, followed by Amberlite IR120 (H + ) Quantitative purification was achieved by neutralizing with ion exchange resin, filtering, and evaporating to dryness. Chemical formula: C 27 H 20 N2O 13S2. Molecular weight: 674.82. ESI-MS (m / z) 719.50 ([M+HCO2] - ).
[0408] General procedure for the complete hydroxyl acylation of 2T, 2S, and 2M to give intermediates 3T, 3S, and 3M. To a solution of the corresponding acylating agent (listed in the lipid reagent list above → L1–L7.1, 2T and 2S are 46 mmol, 2M is 38 mmol) in anhydrous DMF (20 mL) at 0 °C under an inert N atmosphere, a solution of 2T, 2S, or 2M (5.1 mmol) and DMAP (2T and 2S are 92 mmol, 2M is 76 mmol) in anhydrous DMF (100 mL) was added dropwise over 10 min. The reaction mixture was allowed to warm to room temperature over 2 h and further stirred overnight. The reaction was then diluted with a 1:1 water-DCM mixture (400 mL). The organic layer was decanted and further washed with water (100 mL), 2N H2SO4 (2 x 100 mL), saturated NaHCO3 (100 mL), and water (100 mL), dried over MgSO4 or Na2SO4, filtered, and evaporated under reduced pressure. The resulting syrupy residue was purified by column chromatography using the eluent indicated in each case to give the R 1000 (R 1000) as defined by codes L1 to L7.1 in the lipid reagent list above. a The corresponding 3T, 3S, or 3M reaction intermediates bearing the substituents were obtained. [Table 6]
[0409] General procedure for the hydrolysis of the tert-butoxycarbonyl group in reaction intermediates 3T (→ 4T), 3S (→ 4S), and 3M (→ 4M). To a solution of 3T, 3S, or 3M (1 mmol) in DCM (10 mL) was added trifluoroacetic acid (TFA, 10 mL) at room temperature. The reaction mixture was stirred at room temperature for 1 hour, and then the solvent was evaporated under reduced pressure. Traces of acid were removed by repeated coevaporation with water. The resulting residue was lyophilized from 10 mM HCl to give the corresponding diamines 4T, 4S, and 4M as hydrochloride salts in quantitative yield. In some preferred embodiments, the following compounds of Formula I, characterized by the structure 4T, were synthesized according to Scheme 2 using the procedure described above: JLF19, JLF150, JLF20, JLF155, JLF23, and JLF46.
[0410] In some preferred embodiments, the following compounds of formula I characterized by structure 4S were synthesized according to Scheme 1 following the procedures described above: JLF50, JLF62.
[0411] General Procedure for the Synthesis of Diisothiocyanate Reaction Intermediates 5T, 5S, and 5M in Schemes 1, 2, and 4: To a solution of 4T, 4S, or 4M (1 mmol) in a heterogeneous mixture of water and DCM (1:1 mL), CaCO3 (0.48 g, 4.8 mmol), and Cl2CS (0.22 mL, 2.4 mmol) was added sequentially. The mixture was vigorously stirred at room temperature for 1 hour, then transferred to a decantation funnel and diluted with water and DCM (1:1, 100 mL). The organic layer was decanted, washed with water (50 mL) and saturated aqueous NaHCO3 (50 mL), dried over MgSO4 or Na2SO4, filtered, and evaporated under reduced pressure to give the R2000 series, as defined by the codes in the Lipid Reagents List. a The target diisothiocyanate reaction intermediates 5T, 5S, or 5M bearing the substituents were obtained:
[0412] Compound 5T-L1: Yield 99%. Chemical formula: C 54 H 88 N2O 15 S4. MW:1133.54. ESI-MS (m / z) 1155.58 ([M+Na] +).
[0413] Compound 5T-L3): Yield 90%. Chemical formula:C 78 H 136 N2O 15 S4. MW:1470.19. ESI-MS (m / z) 1514.87 ([M+HCO2] - ).
[0414] Compound 5T-L3.1: Yield 78%. Chemical formula:C 78 H 136 N2O 15 S4. MW:1470.19. ESI-MS (m / z) 1513.88 ([M+HCO2] - ).
[0415] Compound 5T-L3.2: Yield 94%. Chemical formula:C 78 H 136 N2O 15 S4. MW:1470.19. ESI-MS (m / z) 1487.22 ([M+NH4] + ) Compound 5S-L1: Yield 99%. Chemical formula:C 54 H 88 N2O 15 S4. MW:1133.54. ESI-MS (m / z) 1155.58 ([M+Na] + ).
[0416] Compound 5S-L3: Yield 90%. Chemical formula:C 78 H 136 N2O 15 S4. MW:1470.19. ESI-MS (m / z) 1514.87 ([M+HCO2] - ).
[0417] Compound 5M-L3: Yield 93%. Chemical formula:C 69 H 120 N2O 15 S4. MW:1329.96. ESI-MS (m / z) 1375.09 ([M+HCO2] - ).
[0418] General procedure for the synthesis of compounds of formula I according to Routes A1, A2, B1, and B2 of Schemes 1, 2, and 4.
[0419] Route A1 (Scheme 1, 2, or 4): To a solution of the corresponding diamine dihydrochloride (4T, 4S, or 4M, 0.1 mmol) in DCM (10 mL) and triethylamine (EtN, 0.3 mmol, 41 μL) was added the corresponding isothiocyanate reagent SCN-(CH)-Z in DCM (5 mL). a -PG 1 A solution of 4T, 4S, or 4M was added over time. The reaction mixture was stirred at room temperature for 16 hours, monitoring the pH to ensure it remained basic (if the pH was found to be below neutral, it should be readjusted to slightly basic (approximately pH 8) by adding aliquots of EtN). Once the reaction was complete (TLC showed the complete disappearance of the starting material 4T, 4S, or 4M, and a higher R f After 2 min, the reaction mixture was concentrated to dryness, and the crude material was purified by column chromatography using the indicated eluent. The resulting intermediate with a Boc-protected amino group was then treated with a 1:1 DCM-TFA mixture (10 mL) at room temperature for 1 h, followed by evaporation of the solvent under reduced pressure. Traces of TFA were removed by coevaporation with toluene (3 × 10 mL). Lyophilization from 10 mM HCl afforded the target product 6T, 6S, or 6M in the indicated yield in each case.
[0420] In some embodiments, the following compounds of formula I characterized by structure 6T were synthesized according to Scheme 1, Route A1: JLF31, JLF32, JLF33, JLF35, JLF43, JLF58, JLF78, JLJB617, JLJB618, JLJB619.
[0421] In some embodiments, the following compounds of formula I, characterized by structure 6S, were synthesized according to Scheme 2, Route A1: JLF59, JLF60, JLF68, JLF69, JLF76, JLF77
[0422] Route A2 (Scheme 1, 2, or 4): Similarly to Route A1, Route A2 involves the reaction of compounds of structure 4T, 4S, or 4M with the isothiocyanate reagent SCN-(CH)-Z using a similar protocol. 1 This refers to a coupling reaction with 6T. Upon completion of the reaction, the reaction mixture was transferred to a decantation funnel and partitioned between DCM and 0.1 N aqueous HCl (1:1, 20 mL). The organic layer was decanted, dried over MgSO or NaSO, filtered, and evaporated under reduced pressure. In these cases, column chromatography purification was performed. The resulting products were lyophilized from 10 mM HCl to give the target products 6T, 6S, or 6M in the yields indicated in each case.
[0423] In some embodiments, the following compounds of formula I characterized by structure 6T were synthesized according to Scheme 1, route A2: JLF25, JLF26, JLF29, JLF30, JLF41, JLF42, JLF154, JLF158, JLF170, JLJB604, JLJB605.
[0424] In some embodiments, the following compounds of formula I, characterized by structure 6S, were synthesized according to Scheme 2, route A2: JLF54, JLF55, JLF66, JLF67.
[0425] Route B1 (Scheme 1, 2, or 4): To a solution of the corresponding diisothiocyanate reaction intermediate 5T, 5S, or 5M (1 mmol) in DCM (10 mL) is added the corresponding amine reagent HN-(CH)-Z in DCM (5 mL). a -PG 1 (0.3 mmol) was added. The reaction mixture was stirred at room temperature for 16 hours while monitoring the pH to ensure it remained basic. Once the reaction was complete (TLC showed complete disappearance of the starting material 5T, 5S, or 5M, and a lower R fAfter 2 min, the reaction mixture was concentrated to dryness, and the crude material was purified by column chromatography using the indicated eluent. The resulting intermediate was further treated with a 1:1 DCM-TFA mixture (10 mL) at room temperature for 1 h, followed by evaporation of the solvent under reduced pressure, coevaporation of traces of acidic material with toluene (3 × 10 mL), and lyophilization from 10 mM HCl to give the target products 6T, 6S, or 6M in the indicated yields in each case.
[0426] In some embodiments, the following compounds of formula I characterized by structure 6T were synthesized according to Scheme 1, Route B1: JLF93, JLF94, JLF96, JLF97, JLF98, JLF102, JLF103, JLF111, JLF115, JLF120, JLF121, JLF139, JLF141, JLF200, JLF201, JLF220, PER20.
[0427] Route B2: Similarly to Route B1, Route B2 involves the reaction of compounds of structure 5T, 5S, or 5M with the amine reagent H2N-(CH2)2-Z using a similar protocol. 1 This refers to a coupling reaction with 6T. Upon reaction completion, the reaction mixture was transferred to a decantation funnel and partitioned between DCM and 0.1 N aqueous HCl (1:1, 20 mL). The organic layer was decanted, dried over MgSO or NaSO, filtered, and evaporated under reduced pressure. In these cases, column chromatography purification was not necessary. The resulting products were lyophilized from 10 mM HCl to give the target products 6T, 6S, or 6M in the indicated yields.
[0428] In some embodiments, the following compounds of formula I characterized by structure 6T were synthesized according to Scheme 1, Route B2: JLF81, JLF82, JLF87, JLF90, JLF95, JLF99, JLF106, JLF108, JLF110, JLF111, JLF125, JLF128, JLF130, JLF131, JLF134, JLF135, JLF138, JLF142, JLF163, JLF164, JLF165, JLF190, JLF197, JLF223, JLF234, JLF237, JLF238, JLF244, JLF245 , JLF248, JLF301, JLF601, JLF602, JLF604, JLF605, JLF606, JLF607, JLF608, PRX051, NC117, NC118.
[0429] In some embodiments, the following compounds of formula I characterized by structure 6S were synthesized according to Scheme 2, route B2: JLF218, PRX052, PRX093, PRX094, PRX096.
[0430] In some embodiments, the following compounds of formula I characterized by structure 6M were synthesized according to Scheme 4, route B2: JMB500, JMB501, JMB503.
[0431] General procedure for the synthesis of compounds of formula I according to Scheme 3, Routes C1 and C2.
[0432] The diiodotrehalose derivative 1T was per-O-acylated according to a procedure similar to the general procedure for the complete hydroxyl acylation of 2T and 2S to give the above-mentioned intermediates 3T and 3S. The resulting crude product was subjected to column chromatography purification (1:10 EtOAc-petroleum ether) to give intermediate 7T in 67% yield.
[0433] In a preferred embodiment, R a The diiodo reactive intermediate 7T, whose substituents are defined by the code L1 (7T-L1), was prepared according to this procedure.
[0434] Route C1: To a mixture of 7T (0.1 mmol) and CsCO (91 mg, 0.28 mmol) in anhydrous DMF (3 mL) under a N atmosphere, 2-[N-methyl-N-(tert-butoxycarbonyl)amino]ethathiol (CSH, 52 μL, 0.3 mmol) was added, and the reaction mixture was stirred at room temperature overnight. The solvent was then removed under reduced pressure, and the resulting residue was purified by column chromatography (1:6 EtOAc-petroleum ether). The resulting intermediate was treated with a 1:1 DCM-TFA mixture (4 mL) at room temperature for 1 h. The solvent was evaporated under reduced pressure, and traces of acid were repeatedly coevaporated with water. The residue was lyophilized from 10 mM HCl to give 8T in 60% yield.
[0435] In a preferred embodiment, the following compound of formula I, characterized by structure 8T, was synthesized according to Scheme 3, route C1: JLF40.
[0436] Route C2: Similar to Route C1, Route C2 represents the coupling reaction between 7T and 2-(N,N-dimethylamino)ethanethiol (C3SH) following a similar protocol. Upon completion of the reaction, the reaction mixture was transferred to a decantation funnel and partitioned between DCM and 0.1 N aqueous HCl (1:1, 20 mL). The organic layer was decanted, dried over MgSO4 or Na2SO4, filtered, and evaporated under reduced pressure. In this case, column chromatography purification was not necessary. The resulting product was lyophilized from 10 mM HCl to give compound 8T in 82% yield.
[0437] In a preferred embodiment, the following compound of formula I, characterized by structure 8T, was synthesized according to Scheme 3, route C2: JLF48.
[0438] Example 11a - Compound JLF19 It was synthesized from compound 3T-L7 according to Scheme 1 (steps 3T-4T) in quantitative yield. Chemical formula: C 124 H 238 Cl2N2O 15 S2. Molecular weight: 2132.29 ESI-MS (m / z) 1031.08 ([M-2Cl]2+ ).
[0439] Example 11b - Compound JLF20 It was synthesized from compound 3T-L5 according to Scheme 1 (steps 3T-4T) in quantitative yield. Chemical formula: C 100 H 190 Cl2N2O 15 S2. Molecular weight: 1795.64 ESI-MS (m / z) 1723.23 ([M-2HCl+H] + ), 862.20 ([M-2Cl] 2+ ).
[0440] Example 11c - Compound JLF23 It was synthesized from compound 3T-L3 according to Scheme 1 (steps 3T-4T) in quantitative yield. Chemical formula: C 76 H 142 Cl2N2O 15 S2. Molecular weight: 1458.99 ESI-MS (m / z) 1385.93 ([M-2HCl+H] + ), 693.98 ([M-2Cl] 2+ ).
[0441] Example 11d - Compound JLF25 Compound 4T-L5 was synthesized from the corresponding isothiocyanate reagent (code C3) according to Scheme 1, Route A2 (steps 4T-6T). Yield: 72%. Chemical formula: C 110 H 210 Cl2N6O 15 S4. Molecular weight: 2056.06 ESI-MS (m / z) 992.56 ([M-2Cl] 2+ ).
[0442] Example 11e - Compound JLF26 Compound 4T-L5 was synthesized from the corresponding isothiocyanate reagent (code C4) according to Scheme 1, Route A2 (steps 4T-6T). Yield: 76%. Chemical formula: C 112 H 214 I2N6O 15 S4. Molecular weight: 2267.02 ESI-MS (m / z) 1006.49 ([M-2I]2+ ).
[0443] Example 11f - Compound JLF29 Compound 4T-L7 was synthesized from the corresponding isothiocyanate reagent (code C3) according to Scheme 1, Route A2 (steps 4T-6T). Yield: 77%. Chemical formula: C 132 H 254 Cl2N6O 15 S4. Molecular weight: 2264.65 ESI-MS (m / z) 1160.74 ([M-2Cl] 2+ ).
[0444] Example 11g - Compound JLF30 Compound 4T-L7 was synthesized from the corresponding isothiocyanate reagent (code C4) according to Scheme 1, Route A2 (steps 4T-6T). Yield: 87%. Chemical formula: C 134 H 258 I2N6O 15 S4. Molecular weight: 2575.61 ESI-MS (m / z) 1174.68 ([M-2I] 2+ ).
[0445] Example 11h - Compound JLF31 Compound 4T-L5 was synthesized from the corresponding isothiocyanate reagent (code C2) according to Scheme 1, Route A1 (steps 4T-6T). Yield: 91%. Chemical formula: C 108 H 206 Cl2N6O 15 S4. Molecular weight: 2028.00 ESI-MS (m / z) 978.06 ([M-2Cl] 2+ .
[0446] Example 11i - Compound JLF32 Compound 4T-L7 was synthesized from the corresponding isothiocyanate reagent (code C1) according to Scheme 1, Route A1 (steps 4T-6T). Yield: 66%. Chemical formula: C 128 H 246 Cl2N6O 15 S4. Molecular weight: 2308.54 ESI-MS (m / z) 1132.20 ([M-2Cl] 2+).
[0447] Example 11j - Compound JLF33 Compound 4T-L7 was synthesized from the corresponding isothiocyanate reagent (code C2) according to Scheme 1, Route A1 (steps 4T-6T). Yield: 86%. Chemical formula: C 130 H 250 Cl2N6O 15 S4. Molecular weight: 2336.60 ESI-MS (m / z) 1146.25 ([M-2Cl] 2+ ).
[0448] Example 11k - Compound JLF35 Compound 4T-L1 was synthesized from the corresponding isothiocyanate reagent (code C5) according to Scheme 1, Route A1 (steps 4T-6T). Yield: 89%. Chemical formula: C 66 H 122 Cl4N8O 19 S4. Molecular weight: 1601.78 ESI-MS (m / z) 728.30 ([M-2HCl-2Cl] 2+ ).
[0449] Example 111 - Compound JLF40 Synthesized from precursor 7T-L1 and HS-(CH)NMe(CSH) according to Scheme 3, Route C2 (steps 7T-8T). Yield: 82%. Chemical formula: C 56 H 102 Cl2N2O 15 S2. Molecular weight: 1178.45 ESI-MS (m / z) 1105.68 ([M-HCl-Cl] + ), 553.47 ([M-2Cl] 2+ ).
[0450] Example 11m - Compound JLF41 This compound was synthesized from compound 4T-L3 and the corresponding isothiocyanate reagent (code C3) according to Scheme 1, Route A2 (steps 4T-6T). Yield: 55%. Chemical formula: C 86 H 162 Cl2N6O 15S4. Molecular weight: 1719.41 ESI-MS (m / z) 1645.95 ([M-HCl-Cl] + ), 824.06 ([M-2Cl] 2+ ).
[0451] Example 11n - Compound JLF42 This compound was synthesized from compound 4T-L3 and the corresponding isothiocyanate reagent (code C4) according to Scheme 1, Route A2 (steps 4T-6T). Yield: 57%. Chemical formula: C 88 H 166 I2N6O 15 S4. Molecular weight: 1930.37 ESI-MS (m / z) 838.06 ([M-2I] 2+ ).
[0452] Example 11o - Compound JLF43 This compound was synthesized from compound 4T-L3 and the corresponding isothiocyanate reagent (code C2) according to Scheme 1, Route A1 (steps 4T-6T). Yield: 52%. Chemical formula: C 84 H 158 Cl2N6O 15 S4. Molecular weight: 1691.36 ESI-MS (m / z) 810.09 ([M-2Cl] 2+ ).
[0453] Example 11p - Compound JLF46 It was synthesized from compound 3T-L7.1 according to Scheme 1 (steps 3T-4T) in quantitative yield. Chemical formula: C 124 H 226 Cl2N2O 15 S2. Molecular weight:2021.19 ESI-MS (m / z) 1024.38 ([M-2Cl] 2+ ).
[0454] Example 11q - Compound JLF48 Synthesized from precursor 7T-L1 and HS-(CH2)2N(Boc)Me(C2SH) according to Scheme 3, Route C1 (steps 7T-8T). Yield: 60%. Chemical formula: C 54 H 98 Cl2N2O 15S2. Molecular weight: 1150.40 ESI-MS (m / z) 1077.63 ([M-HCl-Cl] + ), 536.44 ([M-2Cl] 2+ ).
[0455] Example 11r - Compound JLF50 It was synthesized from compound 3S-L1 according to Scheme 2 (steps 3S-4S) in quantitative yield. Chemical formula: C 52 H 94 Cl2N2O 15 S2. Molecular weight: 1122.34 ESI-MS (m / z) 1049.63 ([M-HCl-Cl] + ), 525.44 ([M-2Cl] 2+ ).
[0456] Example 11s - Compound JLF54 This compound was synthesized from compound 4S-L1 and the corresponding isothiocyanate reagent (code C3) according to Scheme 2, Route A2 (steps 4S-6S). Yield: 59%. Chemical formula: C 62 H 114 Cl2N6O 15 S4. Molecular weight: 1382.76 ESI-MS (m / z) 1309.71 ([M-HCl-Cl] + ), 655.57 ([M-2Cl] 2+ ).
[0457] Example 11t - Compound JLF55 This compound was synthesized from compound 4S-L1 and the corresponding isothiocyanate reagent (code C4) according to Scheme 2, Route A2 (steps 4S-6S). Yield: 59%. Chemical formula: C 64 H 118 I2N6O 15 S4. Molecular weight: 1593.72 ESI-MS (m / z) 1338.63 ([M-HI-I] + ), 1338.63 ([M-HI-Me3NI] + ), 669.80 ([M-2I] 2+ ), 639.99 ([MI-Me3NI] 2+ ).
[0458] Example 11u - Compound JLF58 This compound was synthesized from compound 4S-L1 and the corresponding isothiocyanate reagent (code OH1) according to Scheme 1, Route A1 (steps 4T-6T). Yield: 69%. Chemical formula: C 62 H 114 Cl2N6O 17 S4. Molecular weight: 1414.76 ESI-MS (m / z) 1341.70 ([M-HCl-Cl] + ), 671.61 ([M-2Cl] 2+ ).
[0459] Example 11v - Compound JLF59 This compound was synthesized from compound 4S-L1 and the corresponding isothiocyanate reagent (code C1) according to Scheme 2, Route A1 (steps 4S-6S). Yield: 62%. Chemical formula: C 58 H 106 Cl2N6O 15 S4. Molecular weight: 1326.65 ESI-MS (m / z) 1253.69 ([M-HCl-Cl] + ), 627.59 ([M-2Cl] 2+ ).
[0460] Example 11w - Compound JLF60 This compound was synthesized from compound 4S-L1 and the corresponding isothiocyanate reagent (code C2) according to Scheme 2, Route A1 (steps 4S-6S). Yield: 49%. Chemical formula: C 60 H 110 Cl2N6O 15 S4. Molecular weight: 1354.71 ESI-MS (m / z) 1284.69 ([M-HCl-Cl] + ), 641.59 ([M-2Cl] 2+ ).
[0461] Example 11x - Compound JLF62 It was synthesized from compound 3S-L3 according to Scheme 2 (steps 3S-4S) in quantitative yield. Chemical formula: C 76 H 142 Cl2N2O 15S2. Molecular weight: 1458.99 ESI-MS (m / z) 1385.98 ([M-2HCl+H] + ), 693.95 ([M-2Cl] 2+ ).
[0462] Example 11y - Compound JLF66 This compound was synthesized from compound 4S-L3 and the corresponding isothiocyanate reagent (code C3) according to Scheme 2, Route A2 (steps 4S-6S). Yield: 81%. Chemical formula: C 86 H 162 Cl2N6O 15 S4. Molecular weight: 1719.41 ESI-MS (m / z) 1646.99 ([M-HCl-Cl] + ), 824.14 ([M-2Cl] 2+ ).
[0463] Example 11z - Compound JLF67 This compound was synthesized from compound 4S-L3 and the corresponding isothiocyanate reagent (code C4) according to Scheme 2, Route A2 (steps 4S-6S). Yield: 85%. Chemical formula: C 88 H 166 I2N6O 15 S4. Molecular weight: 1930.37 ESI-MS (m / z) 1615.91 ([M-HI-I] + ), 838.21 ([M-2I] 2+ ).
[0464] Example 11aa - Compound JLF68 This compound was synthesized from compound 4S-L3 and the corresponding isothiocyanate reagent (code C1) according to Scheme 2, Route A1 (steps 4S-6S). Yield: 57%. Chemical formula: C 82 H 154 Cl2N6O 15 S4. Molecular weight: 1663.30 ESI-MS (m / z) 1590.90 ([M-HCl-Cl] + ), 796.06 ([M-2Cl] 2+ ).
[0465] Example 11ab - Compound JLF69 According to Scheme 2, Route A1 (steps 4S-6S), compound 4S-L3 was synthesized from the corresponding isothiocyanate reagent (code C2). Yield: 73%. It was synthesized according to Route A1 by coupling compounds 4S-L3 and C2. Overall yield (2 steps) from 4S-L3 was 73%. Chemical formula: C 84 H 158 Cl2N6O 15 S4. Molecular weight: 1691.36 ESI-MS (m / z) 1618.92 ([M-HCl-Cl] + ), 810.09 ([M-2Cl] 2+ ).
[0466] Example 11ac - Compound JLF76 This compound was synthesized from compound 4S-L1 and the corresponding isothiocyanate reagent (code C5) according to Scheme 2, Route A1 (steps 4S-6S). Yield: 66%. Chemical formula: C 66 H 122 Cl4N8O 19 S4. Molecular weight: 1601.78 ESI-MS (m / z) 1454.66 ([M-4HCl-H] - ).
[0467] Example 11ad - Compound JLF77 This compound was synthesized from compound 4S-L3 and the corresponding isothiocyanate reagent (code C5) according to Scheme 2, Route A1 (steps 4S-6S). Yield: 62%. Chemical formula: C 90 H 170 Cl4N8O 19 S4. Molecular weight: 1938.43 ESI-MS (m / z) 897.20 ([M-2HCl-2Cl] 2+ ).
[0468] Example 11ae - Compound JLF78 This compound was synthesized from compound 4T-L3 and the corresponding isothiocyanate reagent (code C5) according to Scheme 1, Route A1 (steps 4T-6T). Yield: 68%. Chemical formula: C 90 H 170 Cl4N8O 19S4. Molecular weight: 1938.43 ESI-MS (m / z) 897.20 ([M-2HCl-2Cl] 2+ ).
[0469] Example 11af - Compound JLF81 This compound was synthesized from the diisothiocyanate precursor 5T-L1 and the corresponding amine reagent (code C9) according to Scheme 1, Route B2 (steps 5T-6T). Yield: 86%. Chemical formula: C 66 H 118 Cl2N6O 17 S4. Molecular weight: 1466.84 ESI-MS (m / z) 1393.77 ([M-HCl-Cl] + ), 697.87 ([M-2Cl] 2+ ).
[0470] Example 11ag - Compound JLF82 This compound was synthesized from the diisothiocyanate precursor 5T-L1 and the corresponding amine reagent (code C7) according to Scheme 1, Route B2 (steps 5T-6T). Yield: 66%. Chemical formula: C 68 H 126 Cl4N8O 15 S4. Molecular weight: 1565.84 ESI-MS (m / z) 1419.81 ([M-3HCl-Cl] + ), 710.90 ([M-2HCl-2Cl] 2+ ), 1418.96 ([M-4HCl-H] - ).
[0471] Example 11ah - Compound JLF87 This compound was synthesized from the diisothiocyanate precursor 5T-L1 and the corresponding amine reagent (code C10) according to Scheme 1, Route B2 (steps 5T-6T). Yield: 89%. Chemical formula: C 64 H 108 Cl2N8O 15 S4. Molecular weight: 1428.75 ESI-MS (m / z) 1355.67 ([M-HCl-Cl] + ), 678.77 ([M-2Cl] 2+ ).
[0472] Example 11ai - Compound JLF90 This compound was synthesized from the diisothiocyanate precursor 5T-L1 and the corresponding amine reagent (code C10.2) according to Scheme 1, Route B2 (steps 5T-6T). Yield: 73%. Chemical formula: C 64 H 108 Cl2N8O 15 S4. Molecular weight: 1428.75 ESI-MS (m / z) 1355.68 ([M-HCl-Cl] + ), 678.77 ([M-2Cl] 2+ ), 1354.61 ([M-2HCl-H] - ).
[0473] Example 11aj - Compound JLF93 This compound was synthesized from the diisothiocyanate precursor 5T-L1 and the corresponding amine reagent (code C8) according to Scheme 1, Route B2 (steps 5T-6T). Yield: 81%. Chemical formula: C 66 H 122 Cl4N8O 15 S4. Molecular weight: 1537.78 ESI-MS (m / z) 1391.74 ([M-3HCl-Cl] + ), 696.90 ([M-2Cl] 2+ ), 647.65 ([M-Hexanoyl-2Cl] 2+ ), 1390.84 ([M-4HCl-H] - ).
[0474] Example 11ak - Compound JLF94 This compound was synthesized from the diisothiocyanate precursor 5T-L1 and the corresponding amine reagent (code C11) according to Scheme 1, Route B1 (steps 5T-6T). Yield: 95%. Chemical formula: C 60 H 110 Cl2N 10 O 15 S4. Molecular weight: 1410.74 ESI-MS (m / z) 1337.68 ([M-HCl-Cl] + ), 669.73 ([M-2Cl] 2+ ), 1336.62 ([M-2HCl-H] - ).
[0475] Example 11a1 - Compound JLF95 This compound was synthesized from the diisothiocyanate precursor 5T-L1 and the corresponding amine reagent (code C10.1) according to Scheme 1, Route B2 (steps 5T-6T). Yield: 42%. Chemical formula: C 64 H 108 Cl2N8O 15 S4. Molecular weight: 1428.75 ESI-MS (m / z) 1355.65 ([M-HCl-Cl] + ), 678.79 ([M-2Cl] 2+ ), 1354.62 ([M-2HCl-H] - ).
[0476] Example 11am - Compound JLF96 This compound was synthesized from the diisothiocyanate precursor 5T-L1 and the corresponding amine reagent (code OH2) according to Scheme 1, Route B1 (steps 5T-6T). Yield: 97%. Chemical formula: C 64 H 118 Cl2N6O 17 S4. Molecular weight: 1442.81 ESI-MS (m / z) 1369.76 ([M-HCl-Cl] + ), 685.79 ([M-2Cl] 2+ ).
[0477] Example 11an - Compound JLF97 This compound was synthesized from the diisothiocyanate precursor 5T-L1 and the corresponding amine reagent (code OH3) according to Scheme 1, Route B1 (steps 5T-6T). Yield: 34%. Chemical formula: C 66 H 122 Cl2N6O 17 S4. Molecular weight: 1470.87 ESI-MS (m / z) 1397.78 ([M-HCl-Cl] + ), 699.81 ([M-2Cl] 2+ ).
[0478] Example 11ao - Compound JLF98 This compound was synthesized from the diisothiocyanate precursor 5T-L3 and the corresponding amine reagent (code C11) according to Scheme 1, Route B1 (steps 5T-6T). Yield: 99%. Chemical formula: C 84 H 158 Cl2N 10 O 15 S4. Molecular weight: 1747.38 ESI-MS (m / z) 838.07 ([M-2Cl] 2+ ).
[0479] Example 11ap - Compound JLF99 This compound was synthesized from the diisothiocyanate precursor 5T-L3 and the corresponding amine reagent (code C9) according to Scheme 1, Route B2 (steps 5T-6T). Yield: 45%. Chemical formula: C 90 H 166 Cl2N6O 17 S4. Molecular weight: 1803.48 ESI-MS (m / z) 1731.03 ([M-HCl-Cl] + ), 866.19 ([M-2Cl] 2+ ).
[0480] Example 11aq - Compound JLF102 This compound was synthesized from the diisothiocyanate precursor 5T-L1 and the corresponding amine reagent (code C18) according to Scheme 1, Route B1 (steps 5T-6T). Yield: 94%. Chemical formula: C 62 H 118 Cl4N8O 15 S4. Molecular weight: 1485.71 ESI-MS (m / z) 1339.69 ([M-HCl-Cl] + ), 670.54 ([M-2Cl] 2+ ), 1338.93 ([M-2HCl-H] - ).
[0481] Example 11ar-Compound JLF103 This compound was synthesized from the diisothiocyanate precursor 5T-L3 and the corresponding amine reagent (code C18) according to Scheme 1, Route B1 (steps 5T-6T). Yield: 62%. Chemical formula: C 86 H 166 Cl4N8O15 S4. Molecular weight: 1822.36 ESI-MS (m / z) 1677.15 ([M-3HCl-Cl] + ), 839.10 ([M-2HCl-2Cl] 2+ ).
[0482] Example 11a - Compound JLF106 This compound was synthesized from the diisothiocyanate precursor 5T-L1 and the corresponding amine reagent (code C14) according to Scheme 1, Route B2 (steps 5T-6T). Yield: 94%. Chemical formula: C 62 H 110 Cl2N6O 15 S4. Molecular weight: 1378.73 ESI-MS (m / z) 1305.94 ([M-HCl-Cl] + ), 653.86 ([M-2Cl] 2+ ), 1350.66 ([M-2HCl+HCO2] - ).
[0483] Example 11 at-Compound JLF108 This compound was synthesized from the diisothiocyanate precursor 5T-L3 and the corresponding amine reagent (code C7) according to Scheme 1, Route B2 (steps 5T-6T). Yield: 78%. Chemical formula: C 92 H 174 Cl4N8O 15 S4. Molecular weight: 1902.49 ESI-MS (m / z) 1757.06 ([M-3HCl-Cl] + ), 879.22 ([M-2HCl-2Cl] 2+ ), 1755.25 ([M-4HCl-H] - ).
[0484] Example 11au-Compound JLF110 This compound was synthesized from the diisothiocyanate precursor 5T-L3 and the corresponding amine reagent (code C10) according to Scheme 1, Route B2 (steps 5T-6T). Yield: 72%. Chemical formula: C 88 H 156 Cl2N8O 15S4. Molecular weight: 1765.40 ESI-MS (m / z) 1691.98 ([M-HCl-Cl] + ), 847.16 ([M-2Cl] 2+ ).
[0485] Example 11av - Compound JLF111 This compound was synthesized from the diisothiocyanate precursor 5T-L3 and the corresponding amine reagent (code C10.2) according to Scheme 1, Route B2 (steps 5T-6T). Yield: 49%. This compound was synthesized via Route B1 by coupling compounds 5T-L3 and C10.2. Overall yield (2 steps) from 5T-L3 was 49%. Chemical formula: C 88 H 156 Cl2N8O 15 S4. Molecular weight: 1765.70 ESI-MS (m / z) 1692.93 ([M-HCl-Cl] + ), 847.13 ([M-2Cl] 2+ ), 1691.14 ([M-2HCl-H] - ).
[0486] Example 11aw - Compound JLF115 This compound was synthesized from the diisothiocyanate precursor 5T-L3 and the corresponding amine reagent (code C8) according to Scheme 1, Route B1 (steps 5T-6T). Yield: 68%. Chemical formula: C 90 H 170 Cl4N8O 15 S4. Molecular weight: 1874.43 ESI-MS (m / z) 1571.05 ([M-3HCl-Cl] + ), 865.23 ([M-2HCl-2Cl] 2+ ).
[0487] Example 11ax - Compound JLF120 This compound was synthesized from the diisothiocyanate precursor 5T-L1 and the corresponding amine reagent (code C43) according to Scheme 1, Route B1 (steps 5T-6T). Yield: 88%. Chemical formula: C 66 H 130 Cl6N 10 O 15 S 10. Molecular weight: 1644.76 ESI-MS (m / z) 1426.74 ([M-5HCl-Cl] + ), 713.56 ([M-4HCl-2Cl] 2+ ), 1424.65 ([M-6HCl-H] - ).
[0488] Example 11ay - Compound JLF121. This compound was synthesized from the diisothiocyanate precursor 5T-L3 and the corresponding amine reagent (code C43) according to Scheme 1, Route B1 (steps 5T-6T). Yield: 55%. This compound was synthesized via Route B1 by coupling compounds 5T-L3 and C43. Overall yield (2 steps) from 5T-L3 was 55%. Chemical formula: C 90 H 178 Cl6N 10 O 15 S 10 . Molecular weight: 1981.41 ESI-MS (m / z) 1763.11 ([M-5HCl-Cl] + ), 882.20 ([M-4HCl-2Cl] 2+ ), 1761.32 ([M-6HCl-H] - ).
[0489] Example 11az - Compound JLF125 This compound was synthesized from the diisothiocyanate precursor 5T-L1 and the corresponding amine reagent (code C16) according to Scheme 1, Route B2 (steps 5T-6T). Yield: 60%. Chemical formula: C 66 H 122 Cl2N6O 15 S4. Molecular weight: 1438.87 ESI-MS (m / z) 1365.77 ([M-HCl-Cl] + ), 683.99 ([M-2Cl] 2+ ), 1364.81 ([M-2HCl-H] - ).
[0490] Example 11ba - Compound JLF128 This compound was synthesized from the diisothiocyanate precursor 5T-L3 and the corresponding amine reagent (code C18) according to Scheme 1, Route B2 (steps 5T-6T). Yield: 76%. This compound was synthesized via Route B2 by coupling compounds 5T-L3 and C18. Yield: 76% from 5T-L3. Chemical formula: C 90 H 170 Cl2N6O 15 S4. Molecular weight: 1775.52 ESI-MS (m / z) 1703.07 ([M-HCl-Cl] + ), 852.21 ([M-2Cl] 2+ ), 1701.28 ([M-2HCl-H] - ).
[0491] Example 11bb - Compound JLF130 This compound was synthesized from the diisothiocyanate precursor 5T-L1 and the corresponding amine reagent (code OH12) according to Scheme 1, Route B2 (steps 5T-6T). Yield: 71%. Chemical formula: C 70 H 130 Cl4N8O 17 S4. Molecular weight: 1625.89 ESI-MS (m / z) 1479.81 ([M-3HCl-Cl] + ), 740.95 ([M-2HCl-2Cl] 2+ ), 1478.81 ([M-4HCl-H] - ).
[0492] Example 11bc - Compound JLF131 This compound was synthesized from the diisothiocyanate precursor 5T-L3 and the corresponding amine reagent (code C46) according to Scheme 1, Route B2 (steps 5T-6T). Yield: 40%. Chemical formula: C 98 H 182 Cl2N 10 O 19 S4. Molecular weight: 2003.73 ESI-MS (m / z) 1931.17 ([M-HCl-Cl] + ), 966.35 ([M-2Cl] 2+ ), 1929.40 ([M-2HCl-H] - ), 1965.40 ([M-HCl-H]- ).
[0493] Example 11bd - Compound JLF134 This compound was synthesized from the diisothiocyanate precursor 5T-L1 and the corresponding amine reagent (code OH5) according to Scheme 1, Route B2 (steps 5T-6T). Yield: 74%. Chemical formula: C 66 H 122 Cl2N6O 19 S4. Molecular weight: 1502.87 ESI-MS (m / z) 1429.97 ([M-HCl-Cl] + ), 715.89 ([M-2Cl] 2+ ), 1428.72 ([M-2HCl-H] - ).
[0494] Example 11be - Compound JLF135 This compound was synthesized from the diisothiocyanate precursor 5T-L1 and the corresponding amine reagent (code OH10) according to Scheme 1, Route B2 (steps 5T-6T). Yield: 61%. Chemical formula: C 66 H 122 Cl2N6O 21 S4. Molecular weight: 1534.86 ESI-MS (m / z) 1461.79 ([M-HCl-Cl] + ), 731.90 ([M-2Cl] 2+ ), 1460.71 ([M-2HCl-H] - ).
[0495] Example 11bf - Compound JLF138 This compound was synthesized from the diisothiocyanate precursor 5T-L1 and the corresponding amine reagent (code C7.1) according to Scheme 1, Route B2 (steps 5T-6T). Yield: 90%. Chemical formula: C 72 H 134 Cl4N6O 15 S4. Molecular weight: 1621.95 ESI-MS (m / z) 1475.94 ([M-3HCl-Cl] + ), 739.04 ([M-2HCl-2Cl] 2+ ), 1475.01 ([M-4HCl-H] - ).
[0496] Example 11bg - Compound JLF139 This compound was synthesized from the diisothiocyanate precursor 5T-L1 and the corresponding amine reagent (code C15) according to Scheme 1, Route B1 (steps 5T-6T). Yield: 99%. Chemical formula: C 62 H 114 Cl2N6O 15 S4. Molecular weight: 1382.76 ESI-MS (m / z) 1309.84 ([M-HCl-Cl] + ), 655.88 ([M-2Cl] 2+ ), 1308.96 ([M-2HCl-H] - ).
[0497] Example 11bh - Compound JLF141 This compound was synthesized from the diisothiocyanate precursor 5T-L1 and the corresponding amine reagent (code C12) according to Scheme 1, Route B1 (steps 5T-6T). Yield: 78%. Chemical formula: C 66 H 126 Cl4N8O 15 S4. Molecular weight: 1541.82 ESI-MS (m / z) 1395.90 ([M-3HCl-Cl] + ), 698.68 ([M-2HCl-2Cl] 2+ ), 1394.92 ([M-4HCl-H] - ).
[0498] Example 11bi-compound JLF142 This compound was synthesized from the diisothiocyanate precursor 5T-L3 and the corresponding amine reagent (code OH5) according to Scheme 1, Route B2 (steps 5T-6T). Yield: 39%. Chemical formula: C 66 H 126 Cl4N8O 15 S4. Molecular weight: 1541.82 ESI-MS (m / z) 1767.15 ([M-3HCl-Cl] + ), 884.24 ([M-2HCl-2Cl] 2+ ), 1765.37 ([M-4HCl-H] - ).
[0499] Example 11bj - Compound JLF150 It was synthesized from precursor 3T-L2 according to Scheme 1 (steps 3T-4T) in quantitative yield. Chemical formula: C 64 H 118 Cl2N2O 15 S4. Molecular weight: 1290.67. ESI-MS (m / z) 1217.91 ([M-HCl-Cl] + ), 609.45 ([M-2Cl] 2+ ).
[0500] Example 11bk - Compound JLF154 Compound 4T-L2 was synthesized from the corresponding isothiocyanate reagent (code C9) according to Scheme 1, Route A2 (steps 4T-6T). Yield: 72%. Chemical formula: C 78 H 142 Cl2N6O 17 S4. Molecular weight: 1635.16. ESI-MS (m / z) 1561.98 ([M-HCl-Cl] + ), 781.99 ([M-2Cl] 2+ ).
[0501] Example 11bl - Compound JLF155 It was synthesized from the diamine precursor 3T-L4 according to Scheme 1 (steps 3T-4T) in quantitative yield. Chemical formula: C 88 H 166 Cl2N2O 15 S4. Molecular weight: 1627.32. ESI-MS (m / z) 1555.21 ([M-HCl-Cl] + ), 778.15 ([M-2Cl] 2+ ).
[0502] Example 11bm - Compound JLF158 Compound 4T-L4 was synthesized from the corresponding isothiocyanate reagent (code C9) according to Scheme 1, Route A2 (steps 4T-6T). Yield: 61%. Chemical formula: C 102 H 190 Cl2N6O 17S4. Molecular weight: 1971.81. ESI-MS (m / z) 950.19 ([M-2Cl] 2+ ).
[0503] Example 11bn - Compound JLF163 This compound was synthesized from the diisothiocyanate precursor 5T-L1 and the corresponding amine reagent (code C30) according to Scheme 1, Route B2 (steps 4T-6T). Yield: 87%. Chemical formula: C 68 H 110 Cl2N6O 15 S4. Molecular weight: 1450.80. ESI-MS (m / z) 1377.69 ([M-HCl-Cl] + ), 689.41 ([M-2Cl] 2+ ).
[0504] Example 11 bo-Compound JLF164 This compound was synthesized from the diisothiocyanate precursor 5T-L1 and the corresponding amine reagent (code C9.1) according to Scheme 1, Route B2 (steps 4T-6T). Yield: 99%. Chemical formula: C 68 H 122 Cl2N6O 15 S4. Molecular weight: 1462.89. ESI-MS (m / z) 1389.81 ([M-HCl-Cl] + ), 695.45 ([M-2Cl] 2+ ).
[0505] Example 11bp - Compound JLF165 This compound was synthesized from the diisothiocyanate precursor 5T-L1 and the corresponding amine reagent (code OH6) according to Scheme 1, Route B2 (steps 4T-6T). Yield: 72%. Chemical formula: C 70 H 132 Cl2N6O 17 S4. Molecular weight: 1558.79. ESI-MS (m / z) 1485.80 ([M-HCl-Cl] + ), 743.90 ([M-2Cl] 2+ ).
[0506] Example 11bq - Compound JLF170 This compound was synthesized from the diisothiocyanate precursor 5T-L3 and the corresponding amine reagent (code C9) according to Scheme 1, Route B2 (steps 4T-6T). Yield: 86%. Chemical formula: C 114 H 214 Cl2N6O 17 S4. Molecular weight: 2140.13. ESI-MS (m / z) 2106.80 ([M-HCl-Cl] + ), 1034.29 ([M-2Cl] 2+ ).
[0507] Example 11br-Compound JLF200 This compound was synthesized from the diisothiocyanate precursor 5T-L1 and the corresponding amine reagent (code C52) according to Scheme 1, Route B1 (steps 4T-6T). Yield: 68%. Chemical formula: C 62 H 114 Cl2N6O 15 S4. Molecular weight: 1382.76. ESI-MS (m / z) 1309.80 ([M-HCl-Cl] + ), 655.44 ([M-2Cl] 2+ ).
[0508] Example 11bs - Compound JLF201 This compound was synthesized from the diisothiocyanate precursor 5T-L1 and the corresponding amine reagent (code C53) according to Scheme 1, Route B1 (steps 4T-6T). Yield: 70%. Chemical formula: C 60 H 110 Cl2N6O 15 S4. Molecular weight: 1354.71. ESI-MS (m / z) 1281.7 ([M-HCl-Cl] + ), 641.42 ([M-2Cl] 2+ ).
[0509] Example 11bt-Compound JLF218 This compound was synthesized from compound 4S-L3 and the corresponding isothiocyanate reagent (code C9) according to Scheme 1, Route A2 (steps 4T-6T). Yield: 56%. Chemical formula: C 90 H 166 Cl2N6O 17S4. Molecular weight: 1803.48. ESI-MS (m / z) 1731.08 ([M-HCl-Cl] + ), 866.11 ([M-2Cl] 2+ ).
[0510] Example 11bu-Compound JLF220 This compound was synthesized from the diisothiocyanate precursor 5T-L1 and the corresponding amine reagent (code C65) according to Scheme 1, Route B1 (steps 4T-6T). Yield: 79%. Chemical formula: C 62 H 114 Cl2N 10 O 15 S4. Molecular weight: 1438.79. ESI-MS (m / z) 1365.77 ([M-HCl-Cl] + ), 683.45 ([M-2Cl] 2+ ).
[0511] Example 11bv - Compound JLF223 This compound was synthesized from the diisothiocyanate precursor 5T-L1 and the corresponding amine reagent (code OH7) according to Scheme 1, Route B1 (steps 4T-6T). Yield: 75%. Chemical formula: C 74 H 138 Cl2N6O 19 S4. Molecular weight: 1615.08. ESI-MS (m / z) 1541.90 ([M-HCl-Cl] + ), 771.97 ([M-2Cl] 2+ ).
[0512] Example 11bw - Compound JLF234 This compound was synthesized from the diisothiocyanate precursor 5T-L3 and the corresponding amine reagent (code C70) according to Scheme 1, Route B1 (steps 4T-6T). Yield: 51%. Chemical formula: C 94 H 174 Cl2N6O 17 S4. Molecular weight: 1859.59. ESI-MS (m / z) 1787.35 ([M-HCl-Cl] + ), 894.28 ([M-2Cl] 2+ ).
[0513] Example 11bx - Compound JLF237 This compound was synthesized from the diisothiocyanate precursor 5T-L3 and the corresponding amine reagent (code C26) according to Scheme 1, Route B1 (steps 4T-6T). Yield: 23%. Chemical formula: C 88 H 160 Cl2N 16 O 15 S4. Molecular weight: 1881.49. ESI-MS (m / z) 905.17 ([M-2Cl] 2+ ).
[0514] Example 11bx - Compound JLF238 This compound was synthesized from the diisothiocyanate precursor 5T-L3 and the corresponding amine reagent (code C59.2) according to Scheme 1, Route B1 (steps 4T-6T). Yield: 66%. Chemical formula: C 94 H 174 Cl2N6O 17 S4. Molecular weight: 1859.59. ESI-MS (m / z) 894.19 ([M-2Cl] 2+ ).
[0515] Example 11 by-compound JLF244 This compound was synthesized from the diisothiocyanate precursor 5T-L3 and the corresponding amine reagent (code C63) according to Scheme 1, Route B1 (steps 4T-6T). Yield: 66%. Chemical formula: C 94 H 172 Cl2N8O 17 S4. Molecular weight: 1885.59. ESI-MS (m / z) 1813.12 ([M-HCl-Cl] + ), 907.18 ([M-2Cl] 2+ ).
[0516] Example 11bz - Compound JLF245 This compound was synthesized from the diisothiocyanate precursor 5T-L3 and the corresponding amine reagent (code C68) according to Scheme 1, Route B1 (steps 4T-6T). Yield: 60%. Chemical formula: C 90 H 164 Cl2N8O 17S4. Molecular weight: 1829.48. ESI-MS (m / z) 1757.08 ([M-HCl-Cl] + ), 879.15 ([M-2Cl] 2+ ).
[0517] Example 11ca - Compound JLF248 This compound was synthesized from the diisothiocyanate precursor 5T-L3 and the corresponding amine reagent (code C59.1) according to Scheme 1, Route B1 (steps 4T-6T). Yield: 58%. Chemical formula: C 94 H 174 Cl2N6O 17 S4. Molecular weight: 1859.59. ESI-MS (m / z) 1786.13 ([M-HCl-Cl] + ), 894.17 ([M-2Cl] 2+ ).
[0518] Example 11cb - Compound JLF301 This compound was synthesized from the diisothiocyanate precursor 5T-L3 and the corresponding amine reagent (code C66) according to Scheme 1, Route B1 (steps 4T-6T). Yield: 77%. Chemical formula: C 94 H 172 Cl2N8O 17 S4. Molecular weight: 1885.59. ESI-MS (m / z) 1812.25 ([M-HCl-Cl] + ), 907.19 ([M-2Cl] 2+ ).
[0519] Example 11cc - Compound JLJB604 Compound 4T-L1 was synthesized from the corresponding isothiocyanate reagent (code C3) according to Scheme 1, Route A2 (steps 4T-6T). Yield: 69%. Chemical formula: C 62 H 114 Cl2N6O 15 S4. Molecular weight: 1382.76 ESI-MS (m / z) 1309.62 ([M-HCl-Cl] + ), 655.53 ([M-2Cl] 2+ ).
[0520] Example 11cd - Compound JLJB605 Compound 4T-L1 was synthesized from the corresponding isothiocyanate reagent (code C4) according to Scheme 1, Route A2 (steps 4T-6T). Yield: 94%. Chemical formula: C 64 H 118 I2N6O 15 S4. Molecular weight: 1593.72 ESI-MS (m / z) 1278.58 ([MI-Me3NI] + ), 669.80 ([M-2I] 2+ ), 1382.20 ([M-2HI+Cl] - ), 1323.49 ([M-HI-Me3NI+HCO2] + ).
[0521] Example 11ce - Compound JLJB617 This compound was synthesized from compound 4T-L3 and the corresponding isothiocyanate reagent (code C1) according to Scheme 1, Route A1 (steps 4T-6T). Yield: 21%. Chemical formula: C 82 H 154 Cl2N6O 15 S4. Molecular weight: 1663.30 ESI-MS (m / z) 795.97 ([M-2Cl] 2+ ).
[0522] Example 11cf - Compound JLJB618 Compound 4T-L5 was synthesized from the corresponding isothiocyanate reagent (code C1) according to Scheme 1, Route A1 (steps 4T-6T). Yield: 50%. Chemical formula: C 106 H 202 Cl2N6O 15 S4. Molecular weight: 1999.95 ESI-MS (m / z) 1927.39 ([M-HCl-Cl] + ), 964.29 ([M-2Cl] 2+ ).
[0523] Example 11cg - Compound JLJB619 Compound 4T-L1 was synthesized from the corresponding isothiocyanate reagent (code C2) according to Scheme 1, Route A2 (steps 4T-6T). Yield: 52%. Chemical formula: C 60 H 110 Cl2N6O 15 S4. Molecular weight: 1354.71 ESI-MS (m / z) 1281.40 ([M-HCl-Cl] + ), 641.22 ([M-2Cl] 2+ ).
[0524] Example 11ch - Compound PER20 This compound was synthesized from the diisothiocyanate precursor 5T-L3 and the corresponding amine reagent (code OH1) according to Scheme 1, Route B1 (steps 5T-6T). Yield: 59%. Chemical formula: C 86 H 162 Cl2N6O 17 S4. Molecular weight: 1751.41 ESI-MS (m / z) 840.14 ([M-2Cl] 2+ ).
[0525] Example 11ci - Compound JLF190 This compound was synthesized from the diisothiocyanate precursor 5T-L3 and the corresponding amine reagent (code C9.1) according to Scheme 1, Route B1 (steps 5T-6T). Yield: 87%. Chemical formula: C 92 H 170 Cl2N6O 15 S4. Molecular weight: 1799.54. ESI-MS (m / z) 1727.11 ([M-HCl-Cl] + ), 864.11 ([M-2Cl] 2+ ).
[0526] Example 11cj - Compound JLF601 This compound was synthesized from the diisothiocyanate precursor 5T-L3 and the corresponding amine reagent (code C47) according to Scheme 1, Route B1 (steps 5T-6T). Yield: 10%. Chemical formula: C 88 H 160 NO 17 S4. Molecular weight: 1702.51. ESI-MS (m / z) 1701.11 ([MH]- ).
[0527] Example 11ck-Compound JLF602 This compound was synthesized from the diisothiocyanate precursor 5T-L3 and the corresponding amine reagent (code C48) according to Scheme 1, Route B1 (steps 5T-6T). Yield: 84%. Chemical formula: C 92 H 170 Cl2N6O 17 S4. Molecular weight: 1831.54. ESI-MS (m / z) 880.17 ([M-2Cl] 2+ ).
[0528] Example 11 cl-Compound JLF604 This compound was synthesized from the diisothiocyanate precursor 5T-L3 and the corresponding amine reagent (code C54) according to Scheme 1, Route B1 (steps 5T-6T). Yield: 24%. Chemical formula: C 92 H 166 Cl2N6O 17 S4. Molecular weight: 1827.51. ESI-MS (m / z) 1773.11 ([M-HCl-Cl+H2O] + ), 896.21 ([M-2Cl+2H2O] 2+ ).
[0529] Example 11cm-Compound JLF605 This compound was synthesized from the diisothiocyanate precursor 5T-L3 and the corresponding amine reagent (code C59) according to Scheme 1, Route B1 (steps 5T-6T). Yield: 58%. Chemical formula: C 92 H 166 Cl2N6O 17 S4. Molecular weight: 1831.54. ESI-MS (m / z) 1759.10 ([M-HCl-Cl] + ), 880.15 ([M-2Cl] 2+ ).
[0530] Example 11cn - Compound JLF606 This compound was synthesized from the diisothiocyanate precursor 5T-L3 and the corresponding amine reagent (code C60) according to Scheme 1, Route B1 (steps 5T-6T). Yield: 90%. Chemical formula: C 92 H 166 Cl2F4N6O 15 S4. Molecular weight: 1871.50. ESI-MS (m / z) 1799.06 ([M-HCl-Cl] + ), 900.11 ([M-2Cl] 2+ ).
[0531] Example 11 co-compound JLF607 This compound was synthesized from the diisothiocyanate precursor 5T-L3 and the corresponding amine reagent (code C61) according to Scheme 1, Route B1 (steps 5T-6T). Yield: 85%. Chemical formula: C 90 H 166 Cl2N6O 15 S6. Molecular weight: 1835.51. ESI-MS (m / z) 1762.30 ([M-HCl-Cl] + ), 881.65 ([M-2Cl] 2+ ).
[0532] Example 11cp-Compound JLF608 This compound was synthesized from the diisothiocyanate precursor 5T-L3 and the corresponding amine reagent (code C62) according to Scheme 1, Route B1 (steps 5T-6T). Yield: 51%. Chemical formula: C 90 H 166 Cl2N6O 15 S6. Molecular weight: 1867.60. ESI-MS (m / z) 1795.05 ([M-HCl-Cl] + ), 898.12 ([M-2Cl] 2+ ).
[0533] Example 11cq - Compound JLF197 This compound was synthesized from the diisothiocyanate precursor 5T-L3 and the corresponding amine reagent (code C63) according to Scheme 1, Route B1 (steps 5T-6T). Yield: 95%. Chemical formula: C 90 H 166 Cl2N6O 19S6. Molecular weight: 1899.60. ESI-MS (m / z) 1827.02 ([M-2Cl] 2+ ).
[0534] Example 11cr-Compound PRX051 This compound was synthesized from the diisothiocyanate precursor 5T-L3 and the corresponding amine reagent (code C48.1) according to Scheme 1, Route B1 (steps 5T-6T). Yield: 86%. Chemical formula: C 92 H 170 Cl2N6O 17 S4. Molecular weight: 1827.59. ESI-MS (m / z) 1755.18 ([M-HCl-Cl] + ), 878.18 ([M-2Cl] 2+ ).
[0535] Example 11cs - Compound PRX052 This compound was synthesized from the diisothiocyanate precursor 5T-L3 and the corresponding amine reagent (code C47.1) according to Scheme 1, Route B1 (steps 5T-6T). Yield: 90%. Chemical formula: C 90 H 166 Cl2N6O 15 S4. Molecular weight: 1771.49. ESI-MS (m / z) 1699.11 ([M-HCl-Cl] + ), 850.12 ([M-2Cl] 2+ ).
[0536] Example 11ct - Compound PRX093 This compound was synthesized from the diisothiocyanate precursor 5S-L3 and the corresponding amine reagent (code C10) according to Scheme 1, Route B1 (steps 5T-6T). Yield: 88%. Chemical formula: C 90 H 166 Cl2N6O 15 S4. Molecular weight: 1765.40. ESI-MS (m / z) 1692.15 ([M-HCl-Cl] + ), 847.10 ([M-2Cl] 2+ ).
[0537] Example 11cu-Compound PRX094 This compound was synthesized from the diisothiocyanate precursor 5S-L3 and the corresponding amine reagent (code C59) according to Scheme 1, Route B1 (steps 5T-6T). Yield: 76%. Chemical formula: C 90 H 166 Cl2N6O 15 S4. Molecular weight: 1831.54. ESI-MS (m / z) 1759.23 ([M-HCl-Cl] + ), 880.18 ([M-2Cl] 2+ ).
[0538] Example 11cv - Compound PRX096 This compound was synthesized from the diisothiocyanate precursor 5S-L3 and the corresponding amine reagent (code C66) according to Scheme 1, Route B1 (steps 5T-6T). Yield: 63%. Chemical formula: C 90 H 166 Cl2N6O 15 S4. Molecular weight: 1885.59. ESI-MS (m / z) 1812.23 ([M-HCl-Cl] + ), 907.22 ([M-2Cl] 2+ ).
[0539] Example 11cw - Compound NC117 This compound was synthesized from the diisothiocyanate precursor 5S-L3.1 and the corresponding amine reagent (code C9) according to Scheme 1, Route B2 (steps 5T-6T). Yield: 76%. Chemical formula: C 90 H 166 Cl2N6O 17 S4. Molecular weight: 1803.48. ESI-MS (m / z) 1731.20 ([M-HCl-Cl] + ), 866.17 ([M-2Cl] 2+ ).
[0540] Example 11cx - Compound NC118 This compound was synthesized from the diisothiocyanate precursor 5S-L3.2 and the corresponding amine reagent (code C9) according to Scheme 1, Route B2 (steps 5T-6T). Yield: 65%. Chemical formula: C 90 H 166 Cl2N6O 17S4. Molecular weight: 1803.48. ESI-MS (m / z) 1731.21 ([M-HCl-Cl] + ), 866.18 ([M-2Cl] 2+ ).
[0541] Example 11 cy-Compound JMB500 This compound was synthesized from the diisothiocyanate precursor 5M-L3 and the corresponding amine reagent (code C9) according to Scheme 4, Route B2 (steps 5M-6M). Yield: 91%. Chemical formula: C 81 H 150 Cl2N6O 16 S4. Molecular weight: 1663.26. ESI-MS (m / z) 1591.13 ([M-HCl-Cl] + ), 796.10 ([M-2Cl] 2+ ).
[0542] Example 11cz - Compound JMB501 This compound was synthesized from the diisothiocyanate precursor 5M-L3 and the corresponding amine reagent (code C10.1) according to Scheme 4, Route B2 (steps 5M-6M). Yield: 89%. Chemical formula: C 79 H 140 Cl2N6O 16 S4. Molecular weight: 1625.17. ESI-MS (m / z) 1552.16 ([M-HCl-Cl] + ), 777.06 ([M-2Cl] 2+ ).
[0543] Example 11da - Compound JMB503 This compound was synthesized from the diisothiocyanate precursor 5M-L3 and the corresponding amine reagent (code C59) according to Scheme 4, Route B2 (steps 5M-6M). Yield: 95%. Chemical formula: C 83 H 154 Cl2N6O 16 S4. Molecular weight: 1691.31. ESI-MS (m / z) 1619.17 ([M-HCl-Cl] + ), 810.13 ([M-2Cl] 2+ ).
[0544] Example 12 - Additional synthetic examples This example provides synthetic methods and schemes for preparing the compounds described herein. References to compound numbers in this Example 12 are intended to refer to the corresponding structures in Schemes 1a or 2a.
[0545] Scheme 1a illustrates the synthesis of compounds of formula I, where A is A 1 and R 1 and R 2 are both -C(O)-R a and Y 1 and Y 2 are both -(CH2)2- and Z 1 and Z 2 is NH3 + (Compounds ssJRL13 and PRX022 in Scheme 1a). Scheme 1a also shows general routes (Routes A1, A2, B1, and B2) that can be implemented for the synthesis of compounds of Formula I, where A is A 1 and R 1 and R 2 are both -C(O)-R a and Y 1 and Y 2 are both -(CH2)2-NHC(S)NH-(CH2)2-, and Z 1 and Z 2 is identical (compound 8T in Scheme 1a): [ka]
[0546] Scheme 2a illustrates the synthesis of compounds of formula I, where A is A 2 and R 1 and R 2 are both -C(O)-R a and Y 1 and Y 2 are both -(CH2)2- and Z 1 and Z 2 is NH3 +(Compound PRX104 in Scheme 2a). Scheme 1a also shows general routes (Routes A1, A2, B1, and B2) that can be implemented for the synthesis of compounds of Formula I, where A is A 2 and R 1 and R 2 are both -C(O)-R a and Y 1 and Y 2 are both -(CH2)2-NHC(S)NH-(CH2)2-, and Z 1 and Z 2 are identical (compound 8S in Scheme 2a): [ka]
[0547] In some embodiments, R 1 and R 2 are both -C(O)-R a The synthesis of compounds of formula I, wherein: [ka]
[0548] In some embodiments, the synthesis of compounds of Formula I according to Scheme 1a includes the step of preparing a cationic moiety Z 1 and Z 2 The reaction steps leading to the installation of involved the following isothiocyanate or amine reagents: [ka]
[0549] In some embodiments, the following precursors used in the synthesis of certain compounds described herein were prepared according to known methods:
[0550] 6,6'-diiodo-6,6'-dideoxy-α,α'-trehalose (1T) was prepared according to a literature procedure. See JM Garcia Fernandez, et al., Carbohydr. Res. 1995, 268, 57-71.
[0551] 6,6'-Dithio-6,6'-di-S-acetyl-α,α'-trehalose (2T). Compound 2T was synthesized using a procedure similar to that described by Bong. See D. Bong, et al., Chem. Commun. 2011, 47, 2853-2855. In this example, potassium thioacetate was replaced with equimolar amounts of triethylamine and thioacetic acid, which were added sequentially (in that order) to the reaction mixture.
[0552] 6,6'-Dithio-α,α'-trehalose (3T). Compound 3T was quantitatively obtained by treating compound 2 with sodium methoxide according to the procedure described by D. Bong et al., Chem. Commun. 2011, 47, 2853-2855.
[0553] 6,6'-Diiodo-6,6'-dideoxy-sucrose (1S). Compound 1S was prepared from commercially available reagents according to literature procedures. See JM Garcia Fernandez, et al., Carbohydr. Res. 1994, 265, 249-269.
[0554] 6,6'-Di(mercaptoacetyl)-2,3,4,1',3',4'-hexa-O-acetylsucrose (2S). Compound 2S was obtained by sequentially treating compound 1S with acetic anhydride and thioacetic acid, adapting a literature procedure. See W. J. Lee, et al., J. Am. Chem. Soc. 1993, 115, 1860-1869.
[0555] As used herein, an arrow followed by a code in parentheses, e.g., "(→ code)" indicates the lipophilic tail (R in compounds of Formula I) provided by the aforementioned reagent during synthesis. 1 and R 2 substituent) or cationic moiety (Z in compounds of formula I 1 and Z 2 For example, "hexanoyl chloride (→L1)" is intended to refer to the moiety L1 attached to the compound via the use of hexanoyl chloride, as set forth in the table above.
[0556] Hexanoyl (CAS#2051-49-2, →L1) and decanoyl (CAS#112-13-0, →L3) chlorides were purchased from commercial sources.
[0557] 2-(N-tert-butoxycarbonylamino)ethanethiol (CAS#67385-09-5), 2-morpholinoethanamine (CAS#2038-03-1, →C9), 2-morpholinoethyl isothiocyanate (CAS#2038-03-1, →C9), and 2-(2-aminoethyl)-1,3-di-(tert-butoxycarbonyl)guanidine (CAS#203258-44-0, →C11) were purchased from commercial sources.
[0558] 2-(N-tert-butoxycarbonylamino)ethyl isothiocyanate (→C1) was prepared according to the procedure described in D. M. Kneeland, et al., J. Am. Chem. Soc. 1993, 115, 10042-10055.
[0559] N-(4-Hydroxybutyl)-N-(tert-butoxycarbonyl)ethylenediamine (→OH) was synthesized from commercially available N-(4-hydroxybupyl)ethylenediamine by sequential primary amine trifluoroacetylation with ethyl trifluoroacetate, carbamoylation of the remaining amino group with BocO, and base-promoted trifluoroacetide hydrolysis.
[0560] The synthetic intermediates 4, 5T, 5S, 6T-L1, 6T-L3, 6S-L3, diamines ssJRL9, PRX017, PRX104, and diisothiocyanates 7T-L1, 7T-L3, and 7S-L3 in the reaction sequences shown in Schemes 1a and 2a were prepared as described below:
[0561] 2-(tert-Butoxycarbonylamino)ethyl methoxycarbonyl disulfide (4). The asymmetric disulfide 4 was synthesized by adapting the procedure described by Pilkington for cysteine. See L.I. Pilkington, et al., Chem. Commun. 2019, 55, 8868-8871. Briefly, a solution of commercially available 2-(tert-butoxycarbonylamino)ethanethiol (or Boc-protected cysteamine, Boc-Cyst, 1.09 g, 6.16 mmol) in fresh deoxygenated dioxane (20 mL) was treated with methoxycarbonylsulfanyl chloride (0.78 g, 0.55 mL, 6.16 mmol) at 0 °C under a N atmosphere. The reaction mixture was allowed to warm to room temperature and stirred for 16 h. The mixture was then diluted with DCM (50 mL) and washed with water (50 mL). The organic layer was decanted, dried (MgSO4), filtered and concentrated to dryness to give a colorless oil 4 (yield 1.07 g, 65%), the purity of which was confirmed by TLC, 1 H and 13 The product was confirmed by C NMR and MS. Compound 4 was used in the next step without further purification.
[0562] TLC (1:5 EtOAc-petroleum ether) 0.50
[0563] 1 H NMR (400 MHz, CDCl3) δ 5.39 (bs, 1 H, NH), 3.92 (s, 3 H, OMe), 3.40 (q, 2 H, 3 J H,H 5.8 Hz, CH2NH), 2.89 (t, 2 H, CH2S), 1.47 (s, 9 H, CMe3).
[0564] 13 C NMR (100.6 MHz, CDCl3) δ 178.5 (CO thiocarbonate), 155.8 (CO carbamate), 79.5 (CMe3), 67.1 (OMe), 39.5 (CH2S), 38.3 (CH2N), 28.4 (CMe3) ESI-MS (m / z) 290.18 ([M+Na] + ).
[0565] 6,6'-Bis-(2-(tert-butoxycarbonylamino)ethyldithio)-α,α'-trehalose (5). To a solution of disulfide 4 (0.48 g, 1.82 mmol) in freshly degassed MeOH (10 mL) at 0 °C was added a solution of dithiol 3T (0.28 g, 0.76 mmol) in MeOH (5 mL) dropwise over a period of 1 h. The reaction was stirred at 0 °C for an additional 1 h, and then the solvent was evaporated under reduced pressure. The resulting syrupy residue was purified by column chromatography (20:1 EtOAc-EtOH → 45:5:3 EtOAc-EtOH-water) to give 5T. Yield 0.39 g (71%).
[0566] TLC(45:5:3 EtOAc-EtOH-water) 0.46
[0567] 1 H NMR (400 MHz, MeOD) δ 5.17 (d, 2 H, J 1,2 3.8 Hz, H-1), 3.97 (ddd, 2 H, J 4,5 3.8 Hz, J 5,6a 2.1 Hz, J 5,6b 8.6 Hz, H-5), 3.79 (t, 2 H, J 2,3 = J 3,4 = 9.3 Hz, H-3), 3.52 (dd, 2 H, H-2), 3.38 (m, 4 H, CH2N), 3.29 (dd, 2 H, J 6a,6b13.6 Hz, H-6a), 3.23 (dd, 2 H, H-4), 2.94 (dd, 2 H, H-6b), 2.83 (m, 4 H, CH2S), 1.46 (s, 18 H, CMe3).
[0568] 13 C NMR (100.6 MHz, MeOD) δ156.9 (CO), 93.0 (C-1), 78.9 (CMe3), 73.4 (C-4), 73.1 (C-3), 71.8 (C-2), 71.2 (C-5), 43.2 (C-6), 39.4 (CH2N), 37.6 (CH2S), 37.4 (CMe3).
[0569] ESI-MS (m / z) 1471.71 ([2M+Na] + ), 747.49 ([M+Na] + ).
[0570] 6,6'-Bis(tert-butoxycarbonylaminoethyldithio)-sucrose (5S). To a solution of dithioacetate 2S (1.00 g, 1.41 mmol) in MeOH (20 mL) degassed at room temperature, NaOMe (76 mg, 1.41 mmol) was added, and the solution was stirred at room temperature for 45 min. The reaction mixture was then cooled to 0 °C, and a solution of disulfide 4 (0.90 g, 3.38 mmol) in freshly degassed MeOH (10 mL) was added. The reaction was further stirred at 0 °C for 1 h and concentrated to dryness. The resulting syrupy residue was purified by column chromatography with gradient elution (20:1 EtOAc-EtOH → 45:5:3 EtOAc-EtOH-water) to give compound 5S. A 68% yield (0.70 g) was obtained.
[0571] TLC (45:5:3 EtOAc-EtOH-water) 0.45.
[0572] 1 H NMR (400 MHz, MeOD) δ 5.39 (d, 1 H, J 1,2 3.8 Hz, H-1 glc), 4.08 (m, 2 H, H-3,4 fru ), 4.02 (m, 1 H, H-5 glc ), 4.01 (m, 1 H, H-5 fru ), 3.72 (t, 1 H, J 2,3 = J 3,4 9.3 Hz, H-3 glc ), 3.62 (s, 2 H, H-1 fru ), 3.46 (dd, 1 H, H-2 glc ), 3.37 (m, 4H, CH2NHBoc), 3.27 (m, 2 H, H-6 glc , H-6a fru ), 3.25 (dd, 1 H, J 4,5 9.3 Hz, H-4 glc ), 3.12 (dd, 1 H, J 5,6b 3.8 Hz, J 6a,6b 13.6 Hz, H-6b fru ), 2.99 (dd, 1 H, J 5,6b 7.5 Hz, J 6a,6b 13.4 Hz, H-6b glc ), 2.81 (m, 4H, CH2S), 1.46 (bs, 18 H, CMe3).
[0573] 13 C NMR (100.6 MHz, MeOD) δ156.9 (CO), 103.9 (C-2 fru ), 91.9 (C-1 glc ), 80.4 (C-5 fru ), 78.9 (CMe3), 77.9, 78.1 (C-3,4 fru ), 73.0, 72.9 (C-3,4 glc ), 71.9 (C-2 glc ), 71.2 (C-5 glc ), 62.8 (C-1 fru ), 42.6, 42.5 (C-6), 39.5, 39.4 (CH2NHBoc), 37.6, 37.4 (CH2S), 27.5 (CMe3).
[0574] ESI-MS (m / z) 725.25 ([M+H] + ).
[0575] General procedure for the complete hydroxyl acylation of 5T and 5S. In a typical experiment, a solution of derivative 5T or 5S (0.18 g, 0.25 mmol) and DMAP (0.55 g, 4.51 mmol) in DMF (10 mL) under N2 atmosphere was added dropwise over 30 min to a solution of the corresponding acyl chloride (2.26 mmol) in DMF (mL) under N2 at 0 °C. The reaction mixture was allowed to warm to room temperature over 2 h and further stirred overnight. The reaction mixture was then diluted with a diethyl ether-toluene mixture (1:1, 100 mL) and subsequently washed with water (2 × 50 mL) and aqueous 1N HCl (50 mL). The organic layer was dried over MgSO4, filtered, and concentrated under reduced pressure. The syrupy residue was purified by column chromatography using the eluent indicated in each case to give the R 1 or R 2 derivative defined by the code L1 or L3 in the lipid reagent list above. a The corresponding 6T or 6S reaction intermediates bearing the substituents were obtained.
[0576] 6,6'-Bis[2-(tert-butox...
Claims
1. A complex comprising: i) a cationic oligosaccharide comprising one or more cationic moieties linked to a trehalose, sucrose, or gluco-n-oligosaccharide moiety, wherein n is 2 to 6; ii) a surfactant; and iii) one or more additives selected from sterols, helper lipids, immunomodulators, and targeting molecules.
2. The surfactant is or comprises a compound comprising an amphiphilic moiety selected from polysorbates, poloxamers, and / or polyalkylene glycols (e.g., polyethylene glycol), poly(2-oxazolines), poly(2-oxazines), polysarcosines, polyvinylpyrrolidones, and poly[N-(2-hydroxypropyl)methacrylamides], wherein the amphiphilic moiety comprises one or more C 12 -C 20 The conjugate of claim 1 which is linked to an aliphatic group.
3. 3. The complex of claim 1 or 2, wherein the surfactant is or comprises a polysorbate selected from polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80, and combinations thereof.
4. The complex of any one of claims 1 to 3, wherein the molar ratio of said cationic oligosaccharide to said surfactant is from about 1:0.0075 to about 1:
3.
5. The complex of any one of claims 1 to 4, wherein the molar ratio of said cationic oligosaccharide to said surfactant is from about 1:0.5 to about 1:
1.
6. The complex of any one of claims 1 to 5, wherein the molar ratio of said cationic oligosaccharide to said surfactant is about 1:0.
5.
7. The complex of any one of claims 1 to 6, further comprising a cargo.
8. The complex of claim 7 , wherein the cargo is a nucleic acid.
9. The complex of claim 8 , wherein the nucleic acid is RNA.
10. The complex of claim 9, wherein the RNA is modRNA, saRNA, taRNA, or uRNA.
11. The complex of any one of claims 1 to 10, wherein the complex has an N / P ratio of less than 20:
1.
12. The complex of any one of claims 1 to 11, wherein the complex has an N / P ratio of 12:1 or less.
13. The complex of any one of claims 1 to 12, wherein the complex has an N / P ratio of about 6:
1.
14. The complex of any one of claims 1 to 13, wherein the complex has a diameter of about 50 nm to about 150 nm.
15. The complex according to any one of claims 1 to 14, wherein the one or more additives are or comprise a sterol and / or a helper lipid and / or an immunomodulatory agent.
16. 16. The complex of any one of claims 1 to 15, wherein the one or more additives is or comprises a sterol.
17. 17. The complex of claim 16, wherein the sterol is selected from β-sitosterol, stigmasterol, cholesterol, cholecalciferol, ergocalciferol, calcipotriol, botulin, lupeol, ursolic acid, oleanolic acid, cycloartenol, lanosterol, or α-tocopherol.
18. 18. The complex of any one of claims 1 to 17, wherein the molar ratio of said cationic oligosaccharide to said sterol is from about 1:0.25 to about 1:
1.
19. 20. The complex of claim 18, wherein the ratio of said cationic oligosaccharide to said sterol is about 1:0.
5.
20. The complex of any one of claims 1 to 19, wherein the one or more additives are or comprise a helper lipid.
21. The helper lipid is selected from the group consisting of phosphatidylcholine, phosphatidylethanolamine, phosphatidylglycerol, phosphatidic acid, phosphatidylserine, and sphingomyelin, and more preferably from the group consisting of distearoylphosphatidylcholine (DSPC), dioleoylphosphatidylcholine (DOPC), dimyristoylphosphatidylcholine (DMPC), dipentadecanoylphosphatidylcholine, dilauroylphosphatidylcholine, dipalmitoylphosphatidylcholine (DPPC), diarachidoylphosphatidylcholine (DPC), ... phosphatidylcholine (DAPC), dibehenoyl phosphatidylcholine (DBPC), ditricosanoyl phosphatidylcholine (DTPC), dilignoceroyl phosphatidylcholine (DLPC), palmitoyloleoyl phosphatidylcholine (POPC), 1,2-di-O-octadecenyl-sn-glycero-3-phosphocholine (18:0 diether PC), 1-oleoyl-2-cholesterylhemisuccinoyl-sn-glycero-3-phosphocholine (OChemsPC), 1-hexadecyl-sn-glycero-3-phosphocholine (C16 21. The complex of any one of claims 1 to 20, wherein the complex is selected from the group consisting of: Lyso PC), dioleoylphosphatidylethanolamine (DOPE), distearoyl-phosphatidylethanolamine (DSPE), dipalmitoyl-phosphatidylethanolamine (DPPE), dimyristoyl-phosphatidylethanolamine (DMPE), dilauroyl-phosphatidylethanolamine (DLPE), diphytanoyl-phosphatidylethanolamine (DPyPE), and combinations thereof.
22. The complex according to any one of claims 1 to 21, wherein the helper lipid is selected from DSPC and DMPC.
23. 22. The complex of any one of claims 1 to 21, wherein the molar ratio of said cationic oligosaccharide to said helper lipid is from about 1:0.25 to about 1:
1.
24. 24. The complex of any one of claims 1 to 23, wherein the molar ratio of said cationic oligosaccharide to said helper lipid is about 1:0.
5.
25. 25. The complex of any one of claims 1 to 24, wherein the one or more additives are or comprise a sterol and a helper lipid.
26. 26. The complex of any one of claims 1 to 25, wherein the molar ratio of the cationic oligosaccharide:the sterol:the helper lipid is from about 1:0.25:0.25 to about 1:1:
1.
27. 27. The complex of claim 26, wherein the molar ratio of the cationic oligosaccharide:the sterol:the helper lipid is about 1:0.5:0.
5.
28. 28. The complex according to any one of claims 1 to 27, wherein the molar ratio of the cationic oligosaccharide:the surfactant:the sterol:the helper lipid is about 1:0.5:0.5:0.
5.
29. 29. The conjugate of any one of claims 1 to 28, wherein the one or more additives is or comprises an immunomodulatory agent.
30. The conjugate of any one of claims 1 to 29, wherein the immunomodulatory agent is an immunostimulant or an immunosuppressant.
31. The conjugate of any one of claims 1 to 30, wherein the immunomodulatory agent is a small molecule agonist or antagonist of a TLR or PRR receptor.
32. The conjugate of any one of claims 1 to 31, wherein the immunomodulatory agent is a small molecule downstream inhibitor of NF-κβ.
33. The immunomodulatory agent is 2 The complex according to any one of claims 1 to 32, which is an iminoglycolipid.
34. The conjugate of any one of claims 1 to 33, wherein the immunomodulatory agent is a TLR inhibitor.
35. 35. The conjugate of claim 34, wherein the TLR inhibitor is an inhibitor of TLR2, TLR4, and / or TLR6.
36. 36. The conjugate of claim 35, wherein the TLR inhibitor is an inhibitor of TLR4.
37. The conjugate of claim 13, wherein the inhibitor of TLR4 is TAK-242.
38. 31. The complex of any one of claims 1 to 30, wherein the immunomodulatory agent is a terpenoid.
39. 39. The complex of claim 38, wherein the terpenoid is a triterpene.
40. 40. The complex of claim 39, wherein the triterpene is a triterpenoid.
41. 40. The complex of claim 39, wherein the triterpenoid is a synthetic or natural derivative of amylin, betulinic acid, oleanolic acid, sterol, squalene, or ursolic acid.
42. 42. The complex of any one of claims 38 to 41, wherein the immunomodulatory agent is a sterol, squalene, oleanolic acid, ursolic acid, betulinic acid, or amylin.
43. The conjugate of any one of claims 38 to 42, wherein the immunomodulatory agent is a glucocorticoid.
44. 44. The conjugate of claim 43, wherein the glucocorticoid is dexamethasone, prednisolone, fluticasone propionate, budesonide, or a pharma- ceutically acceptable salt thereof.
45. 45. The conjugate of claim 44, wherein the glucocorticoid is dexamethasone or a pharma- ceutically acceptable salt thereof.
46. The conjugate of any one of claims 38 to 45, wherein the conjugate further comprises one or more additional immunomodulatory agents.
47. 47. The conjugate of claim 46, wherein the one or more additional immunomodulatory agents are or comprise small molecule agonists or antagonists of a TLR or PRR receptor.
48. 48. The conjugate of claim 47, wherein the one or more additional immunomodulatory agents is or comprises TAK-242.
49. 49. The complex of any one of claims 1 to 48, wherein the one or more additives are or include a sterol, a helper lipid, and an immunomodulatory agent.
50. 50. The conjugate of any one of claims 1 to 49, wherein the molar ratio of said cationic oligosaccharide to said immunomodulatory agent is from about 1:0.05 to about 1:0.
5.
51. 51. The conjugate of claim 50, wherein the molar ratio of said cationic oligosaccharide to said immunomodulatory agent is about 1:0.
5.
52. 52. The complex of any one of claims 1 to 51, wherein the one or more additives are or comprise a targeting molecule.
53. The cationic oligosaccharide is a compound of formula I: 【Chemistry 1】 or a pharma- ceutically acceptable salt thereof, A is A 1 , A 2 , or A 3 and 【Chemistry 2】 R 1 and R 2 each independently at each instance is H, R a and -C(O)-R a is selected from R 1 Or R 2 At least one instance of is not H, Each R a But independently, C 1 -C 20 aliphatic, C 3 -C 20 cycloaliphatic, C 5 -C 6 aryl, 3- to 12-membered heterocyclyl containing 1 to 3 heteroatoms selected from N, O, and S; a But one or more R b optionally replaced by Each R b are independently halogen, -N 3 , -R c , -OR c , -SR c , -NHR c , -C(O)-R c , -OC(O)R c , -NHC(O)R c , -C(O)NHR c and -NHC(O)NHR c is selected from Each R c is independently an optionally substituted C 1 -C 20 Aliphatic, optionally substituted C 3 -C 20 Cycloaliphatic, optionally substituted C 5 -C 6 aryl, optionally substituted 3- to 12-membered heterocyclyl containing 1 to 3 heteroatoms selected from N, O, and S, and optionally substituted 4- to 12-membered heteroaryl containing 1 to 3 heteroatoms selected from N, O, and S; X 1 and X 2 are each independently selected from -S-, -S-S-, and -NH-; Y 1 and Y 2 each independently represents an optionally substituted C 1-30 an aliphatic group, one or more of the carbons of which are optionally and independently -Cy-, -NR Y --, --NR Y C(O)-, -C(O)NR Y --, --NR Y C(O)O-, -OC(O)NR Y --, --NR Y C(O)NR Y --, --NR Y C(S)NR Y -, -C(S)NR Y --, --C(O)NR Y SO 2 -, -SO 2 N.R. Y C(O)-, -OC(O)O-, -O-, -C(O)-, -OC(O)-, -C(O)O-, -SO-, or -SO 2 - is replaced by Each R Y are independently H or optionally substituted C 1 -C 6 It is aliphatic, Each Cy is independently an optionally substituted C 3 -C 14 cycloaliphatic, optionally substituted 5-14 membered heterocyclyl rings having 1-3 heteroatoms selected from N, O, and S, and optionally substituted 5-14 membered heteroaryl rings having 1-3 heteroatoms selected from N, O, and S; Z 1 and Z 2 are each independently an optionally substituted 5- to 14-membered heterocyclyl ring having 1 to 3 heteroatoms selected from N, O, and S; an optionally substituted 5- to 14-membered heteroaryl ring having 1 to 3 heteroatoms selected from N, O, and S; + (M) 3 , 【Chemistry 3】 is a cationic or ionizable group selected from Each M is independently -C 0 -C 6 Aliphatic-R z , or -C 0 -C 6 Aliphatic-N + (R z ) 3 and Each R z are independently H, optionally substituted C 1 -C 6 Aliphatic, optionally substituted C 3 -C 20 Cycloaliphatic, optionally substituted C 5 -C 6 aryl, optionally substituted 3- to 12-membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, and optionally substituted 4- to 12-membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S; or Two or more R's z can be taken together with the atom to which they are attached to form an optionally substituted 3- to 12-membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, or an optionally substituted 4- to 12-membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S; 53. The conjugate of any one of claims 1 to 52, wherein p is an integer selected from 1, 2, 3, 4, or 5.
54. The cationic oligosaccharide is a compound of formula Ia: 【Chemistry 4】 or a pharma- ceutically acceptable salt thereof.
55. The oligosaccharide is a compound of formula Ib, 【Chemistry 5】 or a pharma- ceutically acceptable salt thereof.
56. The oligosaccharide is a compound of formula Ic, 【Chemistry 6】 or a pharma- ceutically acceptable salt thereof.
57. R 1 and R 2 Each independently represents R a and -C(O)-R a is selected from R a But, C 1 -C 20 The complex of any one of claims 53 to 56, which is aliphatic.
58. R 1 and R 2 are each -C(O)-R a and R a But, C 1 -C 14 58. The conjugate of any one of claims 53 to 57, which is aliphatic.
59. Each R a But, C 5 -C 10 59. The conjugate of any one of claims 53 to 58, which is a straight chain alkyl.
60. R 1 and R 2 are each -C(O)-R a and each R a But independently, 【Chemistry 7】 The complex according to any one of claims 53 to 59, selected from:
61. X 1 and X 2 The conjugate of any one of claims 53 to 60, wherein each is -S-.
62. Y 1 and Y 2 each independently represents an optionally substituted C 1-30 an aliphatic group, one or more carbons of which are independently -NR Y C(O)NR Y - or -NR Y C(S)NR Y The conjugate of any one of claims 53 to 61, substituted with -.
63. R Y is H.
64. Y 1 and Y 2 However, each 1 -C 4 Aliphatic-NHC(S)NH-C 1 -C 4 The complex of any one of claims 53 to 63, which is aliphatic.
65. Y 1 and Y 2 are each -CH 2 -CH 2 -NHC(S)NH-CH 2 -CH 2 -. The complex of claim 64.
66. Z 1 and Z 2 is each independently a cationic or ionizable group comprising an optionally substituted 5-14 membered heterocycle having 1-3 heteroatoms selected from N, O, and S.
67. Z 1 and Z 2 However, each independently, 【Chemistry 8】 【Chemistry 9】 The complex according to any one of claims 53 to 66, selected from:
68. Z 1 and Z 2 However, each independently, 【Chemistry 10】 68. The complex of claim 67, selected from:
69. 69. The complex of any one of claims 53 to 68, wherein the cationic oligosaccharide further comprises one or more suitable counter ions.
70. 54. The complex of any one of claims 1 to 53, wherein the cationic oligosaccharide is selected from Table 1, or a pharma- ceutically acceptable salt thereof.
71. 54. The complex of any one of claims 1 to 53, wherein the cationic oligosaccharide is selected from Table 2, or a pharma- ceutically acceptable salt thereof.
72. 72. A method for increasing or causing an increase in expression of RNA in a target in a subject, the method comprising administering to the subject a complex according to any one of claims 1 to 71.
73. 73. The method of claim 72, wherein the target is selected from the lung, liver, spleen, heart, brain, lymph nodes, bladder, kidney, and pancreas.
74. 72. A method of treating a disease, disorder, or condition in a subject, comprising administering to the subject a conjugate according to any one of claims 1 to 71.
75. 75. The method of claim 74, wherein the disease, disorder, or condition is an infectious disease, cancer, a genetic disorder, an autoimmune disease, or a rare disease.
76. 76. The method of any one of claims 72 to 75, wherein the complex is administered intramuscularly.
77. The method of any one of claims 72 to 75, wherein the complex is administered subcutaneously.
78. A conjugate according to any one of claims 1 to 71 for use as a medicament.
79. 72. The conjugate of any one of claims 1 to 71 for use in the treatment and / or prevention of a disease or disorder, wherein said disease or disorder is an infectious disease, a cancer, a genetic disorder, an autoimmune disease, or a rare disease.
Citation Information
Cited By
Oligosaccharide Compounds and Complexes
JP2024543247A
